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The second decade of the twenty-first century has witnessed a surging interest 
in personalized medicine with the concomitant promise to enable more precise 
diagnosis and treatment of disease and illness, based upon an individual’s unique 
genetic makeup.
In this book, my goal is to contribute to a growing body of literature on per-
sonalized medicine by tracing and analyzing how this field has blossomed in Asia. 
In so doing, I aim to illustrate how various social and economic forces shape the 
co-production of science and social order in global contexts. This book shows 
that there are inextricable transnational linkages between developing and devel-
oped countries and also provides a theoretically guided and empirically grounded 
understanding of the formation and usage of particular racial and ethnic human 
taxonomies in local, national and transnational settings.
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When the mapping of the human genome was completed in 2003, the nota-
ble conclusion was that humans across the globe are 99.9 percent the same at 
the DNA level. However, in the last decade, two remarkable developments have 
ensued. First, human molecular genetics has generated a focus on personalized 
medicine (PM; also known as precision medicine or stratified medicine), with the 
promise and claim to use the analysis of an individual’s unique genetic makeup to 
enable more precise diagnosis and treatment of diseases and illnesses around the 
globe. Second, there is increasing “molecularization of race,” such that human 
taxonomies that the Human Genome Project had declared null and void are re-
inscribed via the DNA (Duster, 2006a; Fullwiley, 2007). In this book, I further 
explore and document the tensions and contradictions in these two develop-
ments and delineate how they have become dangerously intertwined.
To begin with, the European Science Foundation (ESF) published a com-
prehensive report, “Personalised Medicine for the European Citizen: Towards 
More Precise Medicine for the Diagnosis, Treatment and Prevention of Disease 
(iPM),” in December 2012.1 In the United States, PriceWaterhouseCoopers esti-
mated that the personalized medicine market was worth about $232 billion in 
2009 and would exceed $450 billion by 2015.2 In January 2015, the President 
of the United States announced that he is setting aside more than $200 million 
for scientists to pursue “precision medicine.” Similarly, applications of genomics 
that enable personalized health interventions have expanded in the Asia-Pacific 
region.3 Indeed, Ozdemir et al. (2011:1) note that Asia-Pacific is a “new frontier 
for post-genomics medicine.” For instance, it was reported in Nature News that 
China is expected to announce its precision medicine initiative in March 2016, 
and analysts predict that the cost would be more expensive than the $210 million 
initiative in the United States (Cyranoski, 2016).
Personalized medicine and population-based  
research and development
According to the Personalized Medicine Coalition (2014):
In a time of unprecedented scientific breakthroughs and technological 
advancements, personalized health care has the capacity to detect the onset of 
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disease at its earliest stages, pre-empt the progression of disease, and, at the 
same time, increase the efficiency of the health care system by improving 
quality, accessibility, and affordability.
In the 10 years since the completion of the Human Genome Project 
(HGP), advances in genome technology have led to an exponential decrease 
in sequencing costs (more than 16,000-fold). Patients have benefited from 
major biological insights and medical advances, including the develop-
ment of more than 100 drugs whose labels now include pharmacogenomic 
information.
There is, however, a palpable tension between the rhetoric of “individualized” 
medical intervention, based on DNA analysis of an individual’s unique genetic 
makeup, and large-scale genome variation studies that attempt to assess drug 
responses and disease susceptibility of specific “populations.” As Hinterberger 
(2012a:74) puts it, “while contemporary genomic research promises personalized 
medicine (or measures of risk) targeted at the level of the individual, it is primarily 
the comparison of groups and populations that drives human genome research.” 
Moreover, amid the excitement concerning personal genomics and “personalized 
medicine,” Lee (2003:385) suggests that “in the absence of cost-effective, ubiq-
uitous genome scanning tests, it may be more accurate to describe the next wave 
of genomic medicine as population-based rather than one focused on individual 
differences.” In other words, once we reject the scenario of blockbuster drugs 
(i.e. the same drug for everybody with the same illness), the issue becomes pop-
ulation-targeted drugs. The key question is, what is a population? The primary 
concerns are how to target a population correctly, how to ensure that a drug goes 
to the population that is most likely to respond positively, and how to avoid giving 
drugs to the population that is likely to respond negatively.
In these pages, I offer an explanation for how dominant social actors and insti-
tutions involved in the creation, development, and implementation of promised 
personalized medicine think about “population” in Asia and beyond, particularly 
in relation to cancer prevention and treatment. Drugs like Herceptin and Gleevec 
for treatment of breast cancer and chronic myeloid leukemia, respectively, are 
evidence of targeted therapies that pave the way toward personalized treat-
ment. Moreover, the cost of sequencing an individual’s genome has decreased 
to approximately US$1000, which is a small fraction of the initial cost of about 
$3 billion in 2003 (Hayden, 2014). While this book primarily discusses PM for 
cancer, the issues identified might be relevant for the development of personal-
ized medicine for other diseases as well.
What is a population? Race and genetics  
in North America
A key question of contemporary human molecular genetics involves determining 
what constitutes an appropriate reference population for the purposes of drug 
development and disease prevention. The boundary-making of such populations 
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raises both theoretical and empirical questions to be examined in specific social 
contexts. In line with this concern, a significant body of research, carried out 
primarily in North American contexts, has shed light on social forces that shape 
the construction of various population categories within the realm of human 
genetic/genome knowledge production (Duster, 2003, 2006a, 2006b; Fullwi-
ley 2007; Hinterberger, 2010, 2012b; Fujimura and Rajagopalan, 2011). These 
studies are of seminal importance because they demonstrate, empirically, that the 
deployment of seemingly neutral human genome sequencing technology is nec-
essarily a social and cultural phenomenon. Amid the projected high market value 
and enthusiasm for personalized medicine, Kato, Kano, and Shirai (2010) point 
out, correctly, that “while determining genomic sequence data is becoming faster 
and more accurate, interpretation of the clinical significance of genomic infor-
mation is dependent on a science that is still immature and potentially change-
able over time” [emphasis in original]. This is because the interpretation of the 
genetic code itself (as well as the act of genotyping using particular categories 
and criteria) is a human endeavor and, thus, an inevitable function of the lived 
experiences, beliefs, and values of the interpreters, as well as the institutional and 
structural constraints they face.
For example, the National Institutes of Health (NIH), one of the largest funders 
of medical research in the United States, requires all of the projects that it funds 
to gather information on the race and ethnicity of their subjects using categories 
set forth by the White House Office of Management and Budget (OMB) – the 
same categories used by all federal agencies, including the US census. However, 
in the book Inclusion: The Politics of Difference in Medical Research, US soci-
ologist Steven Epstein (2007) demonstrates that attention paid to gender, race 
and ethnicity, and age differences in biomedical research is less a function of the 
“natural” differences of these groups than of successful political mobilization 
efforts by advocacy groups, experts, and members of US Congress. Such efforts 
have culminated in the rise of a new “inclusion-and-difference” policy regime in 
the United States. In other words, the axis of difference for biomedical research is 
significantly determined by politics. Moreover, Fullwiley (2007) shows that one 
of the unintended consequences of such a policy regime is the “molecularization 
of race” in pharmacological laboratory settings – that is, “through practices of 
recruiting, organizing, storing, and comparing human DNA by US race catego-
ries mandated by the Office of Management and Budget and the National Insti-
tutes of Health, US racial distinction is conserved in the laboratory (Fullwiley, 
2007:22).”
This book attempts to contribute to this growing body of literature by tracing 
and analyzing prominent genetic and genomic projects related to personalized 
medicine as they have unfolded in Asia. While various social actors, including 
patients, can participate in “the molecular biopolitics of life itself ” (Rose, 2006), 
the playing field is not level. Here, I will take a closer look at the fuller realm of 
claims-making about genome-based personalized medicine by dominant social 
actors including scientists, physicians, pharmaceutical companies, and state 
authorities. In so doing, I hope to illustrate specific political, economic, cultural, 
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and social forces shaping the co-production of science and social order in trans-
national settings. As Clancey, Graham, Bishop, and Fischer (2013:3) point out, 
“ ‘race and ethnicity’ issues [have been] discussed largely in terms of Europe, 
the Americas, and Africa; the potentially very significant and interesting relation-
ships between biotechnology and society in this half of the world [i.e. Asia] have 
been comparatively under-researched.” I offer an explanation of how populations 
become ethnically and racially labeled in the contexts of a globalized genome 
science and pharmaceutical industry, as well as in national public health poli-
cies. Moreover, I draw on literature in the social sciences to illustrate the actual 
histories of the formation of ethnic categories in these contexts. Finally, drawing 
on extensive interview data with physicians, I highlight the problems of translat-
ing such knowledge regarding the distribution of a particular genetic marker or 
allelic frequencies among ethnic and racial groups at the level of everyday clinical 
practices and the implications for potential discrimination at the societal level.
Personalized medicine, pharmacogenomics,  
and pharmacoethnicity
The idea underlying the field of inquiry known as pharmacogenomics is that drug 
response is personal and genetics plays a part in that response. As Xie and Frueh 
(2005:325) succinctly put it: “the goal of personalized medicine is to maximize 
the likelihood of therapeutic efficacy and to minimize the risk of drug toxicity for 
an individual patient. One of the major contributors to this concept is pharma-
cogenomics.” According to the US National Library of Medicine:4
Pharmacogenomics is the study of how genes affect a person’s response to 
drugs. This relatively new field combines pharmacology (the science of drugs) 
and genomics (the study of genes and their functions) to develop effective, 
safe medications and doses that will be tailored to a person’s genetic makeup.
As such, pharmacogenomics promises to help identify relevant genetic infor-
mation that will make prescribing drugs safer and more effective and potentially 
save the health care industry millions of dollars. Indeed, Allen Roses of Glaxo-
SmithKline asserts that “more than 90 percent of drugs only work in 30–50 per-
cent of people” (BBC News, 2003). It is reported that less than 60 percent of 
patients respond to drugs prescribed via the “trial and error” method in the 
United States (Aspinall and Hamermesh, 2007). This raises the question: who 
might be in the 30–50 percent?
The authors of a 1999 Science article with the practical title “Pharmacogenom-
ics: Translating Functional Genomics into Rational Therapies” predicted the 
explosion of industry interest in using genomic strategies to discover new drug 
targets (Evans and Relling, 1999:487–491). They acknowledged that devel-
oping medications for every member of a population was a “pharmacological 
long shot” and recommended, instead, developing drugs “targeted for specific, 
but genetically identifiable, subgroups of the population.” They note that “all 
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pharmacogenetic polymorphisms studied to date differ in frequency among ethnic 
and racial groups” and concluded that this “marked racial and ethnic diversity” in 
drug-metabolizing enzymes “dictates that race be considered in studies aimed at 
discovering whether specific genotypes or phenotypes are associated with disease 
risk or drug toxicity” (Evans and Relling, 1999:487–491). Similarly, “[p]har-
macoethnicity, or ethnic diversity in drug response or toxicity,” O’Donnell and 
Dolan (2009:4808) write, “results from the combined interaction of many fac-
tors, principally differences in environment, local practice habits and regulatory 
control differences, drug-drug interaction differences, and genetic differences.”
Such a complex array of contributing factors, however, easily gets lost when 
there is an almost exclusive focus on searching for genetic factors – which is the 
mandate of pharmacogenomic pharmacoethnicity studies – that may or may not 
explain observed differences across racially and/or ethnically designated popula-
tion groups. Moreover, as Wailoo (2011) has argued, “the story of cancer and the 
color line therefore becomes the story of cancer’s transformation and of raciali-
zation,” which he defines as “the processes by which scientists used the disease 
to create narratives of difference” (p. 181). Finally, as will be shown in the fol-
lowing pages, some medical geneticists and oncologists mentioned the problems 
in attributing the causes of cancer to either genetics or race/ethnicity – and they 
further pointed out that, in some studies, race and ethnicity are actually used as 
a statistical proxy for environmental exposures and dietary contributory factors 
to cancer.
Nevertheless, the way forward for the study of pharmacoethnicity in cancer 
therapeutics proposed by O’Donnell and Dolan (2009:4810) provides clues to 
its appeal to non-Western countries as they try to attract foreign investments 
and develop knowledge-based economies. O’Donnell and Dolan (2009:4808) 
provide several suggestions for putting the notion of pharmacoethnicity into 
action, including, but not limited to, the following two components: 1) interna-
tional collaboration and repeat trials in multiple different countries so that diverse 
populations can be utilized for clinical trials concerning pharmacoethnicity, and 
2) studying ethnic populations enriched for the phenotype of interest. Thus, the 
concept of pharmacoethnicity encourages the active search for potentially “drug-
gable” or drug-actionable genetic markers and the determination of their fre-
quencies among populations categorized by ethnicity, with an end point of an 
identifiable pharmaceutical market.
The approval of BiDil by the US FDA as the first “ethnic” drug to treat heart 
failure in self-identified African Americans is a case in point. BiDil was seen to be 
a significant step toward personalized medicine (Stein, 2005). Yet, upon closer 
inspection, BiDil is not a pharmacogenomic drug. It is a combination of two 
generic drugs, hydralazine and isosorbide dinitrate, intended to treat all people 
suffering from heart failure. Both drugs have been used to treat heart failure in 
people of all races (U.S. Food and Drug Administration, 2005). Race was the 
key factor that ensured the success of BiDil even though there were no concrete 
trials or research conducted to prove its superior efficacy for African Americans 
compared to other races (Roberts, 2011; Kahn, 2013).
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Why Asia?
There are several reasons to pay special attention to the development of postgenomic 
medicine in Asia. First, cancer is an increasing burden, particularly in developing 
countries. As the International Agency for Research on Cancer (IARC) has stated:
In 2012, the worldwide burden of cancer rose to an estimated 14 million 
new cases per year, a figure expected to rise to 22 million annually within 
the next two decades. Over the same period, cancer deaths are predicted to 
rise from an estimated 8.2 million annually to 13 million per year. Develop-
ing countries are disproportionately affected by the increasing numbers of 
cancers. More than 60 percent of the world’s total cases occur in Africa, 
Asia, and Central and South America, and these regions account for about 
70 percent of the world’s cancer deaths.
(International Agency for Research on Cancer, 2014)
Second, in June 2000, President Bill Clinton (United States), Prime Minister 
Tony Blair (United Kingdom), and two molecular geneticists who had led pub-
lic and private sector human genome projects announced the first mapping and 
sequencing draft of the human genome. However, “Asians must be aware that there 
should be three players,” Ryoji Noyori, the 2001 Nobel Prize winner in Chemis-
try, notes, “America, Europe and Asia” (Nature, 2007). As we shall see, molecular 
geneticists and medical researchers in Asia are contending that Asia is a key player.
Third, I suggest that we will advance our understanding of the fluidity and 
complexity of the categories of ethnicity and race when we examine how “other-
ing” is done when the “self ” is “Asian.” That is, historically, the “Asian” has been 
defined through a “Western”-centric lens and has been seen and treated as the 
non-Western “other.” This book seeks to understand what happens if and when 
the producers of knowledge for genome-based medicine are primarily located in 
Asia. At the same time, the arguments advanced in this book might have implica-
tions for the “Asians” in the United States as well. The US Census Bureau pro-
jected that “between 2013 and 2050, the Asian population (one race) is expected 
to increase 115 percent to 34.3 million,” making it the fastest growing minority 
group in the US (Pew Research Center, 2008).
Time, space, and the emergent other
Many social scientists have explored the concept of “othering” or “the other,” 
which is said to have been coined by philosopher Georg Wilhelm Friedrich Hegel. 
Berenson (1982) believes that the determining factor of one’s self-consciousness 
lies in whether one has recognition for the “being of the Other.” Edward Said 
further popularized the concept in Orientalism, which spurred the development 
of postcolonial theory. Said explains the “other” in the following manner:
The construction of identity – for identity, whether of Orient or Occident, 
France or Britain, while obviously a repository of distinct collective experiences, 
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is finally a construction – involves establishing opposites and “others” whose 
actuality is always subject to the continuous interpretation and re-interpreta-
tion of their differences from “us”. Each age and society re-creates its “Oth-
ers”. Far from a static thing then, identity of self or of “other” is a much 
worked-over historical, social, intellectual, and political process that takes 
place as a contest involving individuals and institutions in all societies.
(Said, 2003:333)
Moreover, Said writes, “the Orient was almost a European invention, and had 
been since antiquity a place of romance, exotic beings, haunting memories and 
landscapes, remarkable experiences” (1978:1). The essentialist boundary between 
the Orient and the Occident has been, that is, the result of human fabrication rather 
than nature. What might be the purpose for these categories?
Said argues that Orientalism, orchestrated by the Western powers, serves as a 
“regime of knowledge” or “ideological suppositions, images and fantasies about 
a currently important and politically urgent region of the world called the ‘Ori-
ent’ ” (Said, 1978). In Western discourse, thus, the East is constructed as the 
inferior other. For instance, Lee (1999:ix) writes about perceptions of Asians in 
United States:
“Orientals are rugs, not people,” says my student, summing up Asian 
American history. As she knows, it is the common experience of all Asian 
Americans – recent immigrant or fourth-generation American born, univer-
sity professor or garment worker – to be asked by other Americans, “Where 
do you come from?” My student knows that the question, while often benign, 
is never completely innocent. “Oakland” or “Oshkosh” is never the accept-
able answer, and its rejection reveals at once that the question is not about 
hometowns. The repeated question always implies, ‘You couldn’t be from 
here.’ It equates the Asian with alien.
This viewpoint concerning the discursive practices of domination by the West 
on the East is not without its critics. These man-made categories suggest an onto-
logical instability (Bhabha, 1994). Indeed, it should be emphasized that Bhabha 
(1994) sees beyond the sole domination of Western ideology and points to the 
involvement of the alienated Oriental Self in the construction, reinforcement, 
and circulation of Orientalist discourse. In other words, it should be emphasized 
that the othered takes part in the othering process.
More recently, Mountz defines the term “other” as both a noun and a verb. 
As a noun, the “other” always constitutes the outside and is therefore “a person 
or group of people who are different from oneself.” As a verb, “other means to 
distinguish, label, categorize, name, identify, place and exclude those who do not 
fit a societal norm” (Mountz, 2009:328).
One may then raise the questions of who gets to define whom, what fits into 
the “us” and “other,” and what purpose does this distinction serve in this mil-
lennium, which is significantly characterized by the rise of data-driven genomic 
science and medicine? Castell proposes that our identity construction within this 
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network society is intertwined with questions like “how, from what, by whom 
and for what?” (Castell, 2004:7). In this regard, there is an emphasis not only on 
power being enmeshed within our self-conception and conception of the “other,” 
but also on the location of the power. Once outside of the socio-geographic 
realms where the definition of “other” originates, the term loses its meaning 
(Chatterjee, 2012). In short, othering may be a tool within an age-old toolbox 
of discrimination and exclusion, but its effective use is contingent on spatial and 
temporal contexts.
Genomics in Asia and the unfolding  
dynamics of othering
One prominent example of othering, which has been occurring for centuries, is 
the dichotomy of “West versus non-West/Asian.” European explorers imagined 
themselves as superior to all of the peoples they encountered, such that these 
people have been “othered” by European imperialism and colonialism (Hud-
son, 1996). In Asia, as elsewhere, othering was a key component of colonial 
administration; artificial boundaries based on “real or imagined attributes such 
as language, customs, religion and indigenousness” were created to meet the 
exigencies of daily rule (Spaan, von Naerssen and Kohl, 2002:163). For instance, 
“the colonial economy marked the origin of the Malaysian multi-ethnic society” 
(Spaan, von Naerssen and Kohl, 2002:163); that is, members of each “race” had 
certain characteristics or mannerisms that made them “suitable” to work in cer-
tain occupations. Later on, the advent of the nation-state necessitated the forma-
tion of the “native” and the “other” (Rabinowitz, 2010).
While othering processes have been studied in health care settings pertaining 
to interactions between health care providers and minority patients, these studies 
have been conducted mostly in advanced developed countries, and such processes 
have not been examined in terms of genomic science and its relation to personal-
ized medicine. As alluded to above, however, the genomic revolution is taking 
hold in Asia; thus, we can raise the question: how are the ‘self’ and ‘other’ defined 
and constructed when the actors ‘defining the situation’ are located in Asia?
Drawing on primary interview data with more than thirty top geneticists and 
medical oncologists in Japan, Korea, Hong Kong, Taiwan, and Singapore,5 as well 
as published documents used as secondary sources, I illustrate how the empirical 
phenomenon of the making and unmaking of “Asian” DNA can be best understood 
as responses to being othered, and, as such, these responses unfold in different con-
texts. We will examine both a project primarily concerned with migration patterns 
(the HUGO Pan-Asian Single Nucleotide Polymorphism Consortium)6 and one 
focused on disease treatment (the IRESSA Pan-Asia Study).7 The former is suitable 
for investigation not only because it is the first inter-Asian genomics collaboration, 
but also because it is seen as laying the foundation for postgenomic medicine in 
Asia (Ozdemir et al., 2011), while the latter facilitated the marketing of the EGFR 
(Epidermal growth factor receptor) biomarker-based personalized anti-lung cancer 
drug IRESSA, to be sold not only in Asia, but also in Europe and Canada.
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As will be discussed, the development of the HUGO Pan-Asian SNP Consor-
tium was partly driven by scientists attempting to take control of the definition 
of “Asian” genome variation and, thereby, counter the perceived hegemonic 
authority of the West in genomic science. Such counter-hegemonic move-
ments do not have a monolithic base, however, and can take form as regional or 
national initiatives. In other words, one can begin to speak of the rise of multiple 
centers in genomic science and medicine. In line with this observation, I will 
explore the relationship between ethnic and racial categories and genomic public 
health policies in the nation-state of Singapore, a former British colony and the 
current location of the Human Genome Organization’s (HUGO) international 
headquarters.
Though the main empirical site of the investigation is Asia, this book engages 
the literature on genomic applications in developing countries. Séguin et al. 
(2008) point out that developing countries – Mexico, Thailand, South Africa, 
and India – are initiating their own genotyping projects, and characterize such 
investment in, and adoption of, innovative genomic science and technology 
as “breaking the cycle of dependence on industrialized countries.” Instead of 
assuming that this relationship is one of dependence, I will explore the com-
plex connections between developed and developing countries. Daar and 
Singer (2005:241) argue that “pharmacogenetics has significant relevance to 
the health of people in developing countries. . . . [F]or this benefit to be real-
ized, we need to take into account not just differences between the genotypes 
of individuals. . .but the differences in genotypes between different popula-
tion groups.” Séguin et al. (2008:487) further suggest that, “at the very least, 
such approaches will help [us to] understand disease susceptibility and drug 
responses in the local population.” Integral to all of these projected develop-
ments is, again, the fluid nature of the relevant “population” in which a (pro-
spective) patient is located.
There are patterned genetic and genomic differences among human popula-
tion groups –for example, one can talk about clinal variations. However, this 
book alerts the readers to other worrisome developments. For instance, one pos-
sibility for constituting a “population” is a racialized formulation (e.g. Caucasian 
versus non-Caucasian), as hinted by Daar and Singer as such (2005:243):
For pharmaceutical companies worldwide, developing countries are not only 
potentially huge markets for drug therapeutics but are also depositories of 
important human genetic diversity. Understanding this diversity is valuable 
because it better defines those population subgroups that will benefit more 
from a particular drug than others, and allows the detection of side-effects 
that might not be seen in populations that are mainly Caucasian. . . . It will 
therefore be increasingly important to include non-Caucasian populations in 
clinical trials.
Benjamin (2009:341) conceptualizes “postcolonial genomics as a nationalist 
project with contradictory tendencies – unifying and differentiating a diverse body 
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politic, cultivating national scientific and commercial autonomy and dependence 
upon global knowledge networks and foreign capital.” In other words, to fully 
appreciate the construction of the population category, one needs to understand 
the forces that “unify and differentiate.” In this book, I explore the ways in which 
racial and ethnic variability operate.
Current research infrastructure and development 
concerning personalized medicine in Asia
It is clear that Asian countries are interested in and have invested in research and 
development of genome-based personalized medicine. For instance, the Inter-
national Cancer Genome Consortium (ICGC) is a global collaboration aimed 
at research on various cancers and the development of potential personalized 
treatment (Jain, 2015a:368–369). Currently, four Asian nations serve as both 
members and research hubs: China (Chinese Cancer Genome Consortium), 
India (Department of Biotechnology, Ministry of Science and Technology), 
Japan (RIKEN and National Cancer Centre), and Singapore (Genome Institute 
of Singapore). Each research project is estimated to cost US$20 million. Nations 
funding the projects include China, India, Japan, Saudi Arabia, and South Korea.
The Pan-Asian SNP Consortium (PASNP), a transnational research team 
within the Human Genome Organization (HUGO), mapped genetic variation 
and migration patterns in 75 populations, with data from ten countries: Japan, 
Korea, China, Taiwan, Singapore, Thailand, Indonesia, Philippines, Malaysia, 
and India. I will briefly review the development of personalized medicine in the 
ten countries that participated in the HUGO PASNP below.
In Japan, the most notable project is the “BioBank Japan Project on the Imple-
mentation of Personalized Medicine,” led by researchers at the RIKEN Center 
for Integrative Medical Sciences. The project began in 2003 and is now in its 
third phase (starting in 2013).8 In addition, in a partnership with Seattle Genetics 
Inc., the Tokyo-based Takeda Pharmaceutical Company Limited is in the midst 
of developing both specific personalized medication and the means to clinically 
execute it (Jain, 2015b).
China is involved with major global collaborative efforts, including the Phar-
macogenetics for Every Nation Initiative (PGENI) (Pasha and Scaria, 2013; 
Jain, 2015c), the 1000 Genomes Project (Pasha and Scaria, 2013; Jain, 2015d), 
HapMap (Mitra, Gope and Gope 2013; Pasha and Scaria, 2013), and, as noted 
above, the ICGC (Jain, 2015e). PGENI is a collaboration involving 104 nations. 
China plays a crucial role as one of the five key coordinating bases with the goal 
of integrating pharmacogenetics with public health care and enabling the spread 
the spread of genome research to the Global South. The 1000 Genomes Pro-
ject, with an estimated US$30 to US$50 million in funding, is a collaboration 
between the Beijing Genomics Institute, the US National Genome Research 
Institute, and the UK Wellcome Trust’s Sanger Institute. Its goal is to sequence 
the genome of 1000 people across the world and produce a petabyte worth of 
data. The HapMap project, started in 2002, seeks to uncover genetic variation 
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between individuals by pinpointing the haplotype. One of its goals is to under-
stand the relationship between genetic variations and drug responses. It is an 
extensive collaboration between China, Japan, the United States, Canada, the 
United Kingdom, and Nigeria. A 2012 news article from the Asia-Pacific Bio-
tech News entitled “Personalized Medicine Receives a Boost” noted that, “Affy-
metrix Inc. (NASDAQ: AFFX) recently announced that its GeneChip System 
3000Dx v.2 (GCS 3000Dx v.2) has been approved by China’s State Food and 
Drug Administration (SFDA) for in vitro diagnostic use.” Affymetrix Inc. is the 
genome technology partner of HUGO PASNP Consortium. Andy Last, execu-
tive vice president of the Genetic Analysis and Clinical Applications Business Unit 
at Affymetrix, is reported to have said that “this registration clearance is a sig-
nificant accomplishment for Affymetrix and supports our global clinical strategy. 
It connects us more closely to physicians in China wanting to utilize clinically 
relevant genomic biomarkers that improve their patients’ health and wellness” 
(Asia-Pacific Biotech News, 2012).
Similarly, according to the Korean government’s official website, “demand for 
personalized medicines [sic] . . . has been on the rise” in South Korea9. Korea 
has a strong local research foundation. The Korean Genome Project “is an open 
access endeavor to collect, analyze and distribute Korean genomes” (Pasha and 
Scaria, 2013). Its objective is to enable both researchers and the general public 
to access personal genomic information. Furthermore, the Korean Pharmacog-
enomics Research Network is acclaimed for having “laid a strong research infra-
structure” at Seoul National University (Reddy et al., 2011:161). The network 
also works with the Korean Ministry of Health and Welfare and established a 
genomic bio-bank in 2011. Currently, it is involved with researching means to 
translate genomic research into clinical and medical applications.
In Taiwan, Chen and Chen (2010) have explored practical approaches nec-
essary to enable Taiwanese hospitals to establish the clinical practice of phar-
macogenetic tests. The current status of health care expenditure is centralized 
with the Bureau of National Health Insurance (NHI). Given Taiwan’s policy 
of universal health care, the assumption is that the NHI functions as the reim-
bursement agency for all patients. However, in 1998, the NHI plunged into 
a financial crisis, annotating a growing concern within the state that “the pre-
mium received from the payer is insufficient to cover the expenses of NHI” 
(Chen and Chen, 2010:503). Thus, it has been proposed that reimbursements 
be reserved for patients “who have wild-type K-ras gene and epidermal growth 
factor receptor (EGFR) expression” (Chen and Chen, 2010:503). These two 
biomarkers – the wild-type K-ras gene and the EGFR mutation – and their 
relationship with the efficacy of cancer treatments have been established and 
replicated.
In India, BioSpectrum reports that “the future of pharmacogenomics in India 
is bright and will be the key in bringing the reality of personalized medicine 
to the masses in India” (Murarka, 2012). The essential purpose of the Indian 
Genome Variation database (IGVdb) is to “further research on disease predis-
position” (Séguin et al., 2008:489), with the hope that available data lead “to 
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improved diagnostics for treatment of patients” (Séguin et al., 2008:490). The 
government’s Department of Biotechnology (DBT) is also funding the $20 mil-
lion Indian Genome Initiative (IGI) (Acharya et al., 2004). This has enabled the 
establishment of the Center for Human Genetics (Bangalore) in order to intro-
duce a credible bioinformatics infrastructure. The Center for Human Genet-
ics “was set up to enhance Indian contributions to computational genomics, 
proteomics and drug design” (Asia Pacific Biotech News, 2004:949). Other 
well-funded organizations in India’s genome research infrastructure include 
the Research Centers of the Indian Council for Medical Research (ICMR), the 
Center for Cellular and Molecular Biology (CCMB), and the Institute of Genom-
ics and Integrative Biology (IGIB) (Asia Pacific Biotech News, 2004:950–955).
In Singapore, according to an article in The Business Times:
[E]ven as pharmaceutical giant Novartis remains focused on producing 
blockbuster drugs in the next five years, Singapore’s biomedical research – 
linked to economic outcomes and investment dollars in recent years – heads 
down a narrower path of personalized medicine. A new program called 
Polaris, which receives $20 million from the [national] Agency of Science, 
Technology and Research (A*Star) over three years, is the starting point for 
stratified medicine where drugs are matched to a patient’s biomarker.
(Kan, 2012)
Thailand’s involvement in genomic research is also momentous. The hope, 
it appears, is for Thailand to benefit from the superior research infrastructure 
of its partner countries in the HUGO Pacific Pan-Asian SNP Initiative (Séguin 
et al., 2008). Apart from this partnership, the Thailand Center for Excellence 
in Life Sciences (TCELS) Pharmacogenomics Project has undertaken an SNP 
genotyping project vis-à-vis drug response. Examples of diseases tested include 
HIV and leukemia. TCELS is also “collaborating with the RIKEN institute in 
Japan” to study the relationship between genetics and post-traumatic stress disor-
der (Seguin et al., 2008:490). Finally, the Thai SNP Discovery Project is one that 
partners state organizations, academic and medical institutions, and the private 
sector with research centers in France.
Malaysia, Indonesia, and the Philippines are also in the developing stages. For 
instance, the “Malaysia Human Genome Variation Consortium” (the Malaysian 
node of the Human Variome Project) is concerned with mapping genome diver-
sity in the country (Pasha and Scaria, 2013). Also, it specifically “aims to deter-
mine the migratory history of the country’s populations, the genetic similarities 
between them and the implications of these variations on the various facets of 
research including pharmacogenomic” (Pasha and Scaria, 2013:197).
As investments in research in Asia have risen in recent years, scientists with 
Asian backgrounds who have been trained in Europe and the United States are 
returning to Asia. In an article entitled “Flocking to Asia for a Shot at Greatness” 
(Normile, 2012) published in Science on 7 September 2012, Dr. Tan Chorh 
Chuan, President of the National University of Singapore (NUS), was quoted as 
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saying, “conditions are right for Asian universities to attract top faculty from the 
rest of the world.” Indeed, it was reported in the same article that:
Hong Kong and Singapore schools aren’t alone in recruiting globally. The 
National Research Foundation of Korea has committed $728 million for a 
5-year World Class University Project that has attracted 321 foreign aca-
demics, most on full-time appointments. Three years ago, Japan’s Ministry 
of Education began a program to internationalize both the faculty and the 
students at its universities, although budget constraints have crimped the 
effort. And Taiwan’s Ministry of Education has an Aim for the Top Uni-
versity Project that supports overseas recruitment. China has employed a 
variety of schemes in the past decade to lure back scientists who went over-
seas for advanced degrees or jobs. These include the Ministry of Education’s 
Changjiang Scholars Program and the Chinese Academy of Sciences’ 100 
Talents Program.
Finally, given the region’s remarkable economic growth and aging popula-
tions, the Asia-Pacific region has become a major block in the global oncology 
market. According to IMS Health, a provider of pharmaceutical and health care 
market analysis, in 2009, the Asia-Pacific region’s oncology market was worth 
US$10.97 billion, and “by 2011, the global oncology market was growing by 
6.8 percent, driven by 15.2 percent growth in emerging markets. . . . Japan, 
China, and Australia together represented more than 85 percent of the oncol-
ogy market share within the Asia-Pacific region.” The IMS report lists the top 
ten countries in terms of market shares in 2009 as follows: Japan (63.7 per-
cent), China (15.6 percent), Australia (6.5 percent), Korea (4.6 percent), Tai-
wan (3.6 percent), Thailand (1.5 percent), Hong Kong (1.0 percent), Singapore 
(0.6 percent), India (0.6 percent), and Indonesia (0.6 percent). Indeed, negotia-
tions for drug commercialization rights have resulted in an agreement wherein 
“firms are funding development costs on a 50:50 basis worldwide,” with the 
exception of Japan along with the United States and Canada (Jain, 2015a:336).
But as we highlighted earlier, Kato et al. (2010) write that “while determining 
genomic sequence data is becoming faster and more accurate, interpretation of 
the clinical significance of genomic information is dependent on a science that is 
still immature and potentially changeable over time” [emphasis in original].
Existing social-science studies of science  
and medicine performed in Asia
There is a comparatively small but growing number of studies of human genome 
science by researchers from backgrounds in the humanities and social sciences in 
Asia. However, these studies have yet to subject notions of “Asian” and “ethnic-
ity” to close and systematic examination. This is an important task, however, 
given the possibility raised by Ong (2013) that “with Genome-wide Association 
Studies (GWAS) as a guiding tool, drugs can be determined as safe or dangerous 
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for some patients but not others, depending on their ethnic group” (Ong, 2013:79, 
emphasis mine). Indeed, as Daar and Singer (2005:241) point out, “we need to 
explore the nexus between pharmacogenetics, genotyping projects in developing 
countries, and the evolution of the pharmaceutical industry in both the devel-
oped and developing worlds.”
Within Asia, there are country-level analyses that are instructive concerning the 
problematic nature of population categories in genomic science and medicine. In 
the case of Japan, Kuo (2008:500) writes that “anthropologists Hiroshi Wagat-
suma and Toshinao Yoneyama argue that minzoku includes all qualifications of 
being Japanese that, like staves, together make up a barrel called nihonjin (the 
Japanese). . . . [T]he staves include holding Japanese citizenship, following Japa-
nese etiquette, speaking Japanese, having Japanese bodily characteristics, having 
been born in Japan, understanding traditional Japanese stories, naniwabushi, liv-
ing in Japan, eating sashimi, and other Japanese traits.” In studying Taiwan’s bio-
bank, Tsai (2010:433) points out that Taiwan’s “four great ethnic groups (sida 
zuqun) – the Hoklo, Hakka, Mainlanders, and aboriginal peoples – exist only as a 
social construction that arose in the 1990s in a specific political-cultural context.” 
In South Korea, Hyun (2015:1) showed that “[antidoping scientists] used racial 
categories in their studies of the UGT2B17 gene without concern, and their 
research reinforced the shaping of racialist discourses on the idea of Asians as a 
doping-friendly race in the media and cyberspace.”
My hope is to provide an empirically grounded understanding of the for-
mation and usage of specific human taxonomies in the development and 
implementation of personalized medicine as it unfolds in Asia. Here, we raise 
questions such as: if there is no consistent and standardized genetic basis for 
classifying populations based upon race/ethnicity, then why do large-scale 
mapping projects continue to use such categories in identifying research popu-
lations? Personalized medicine for whom? Is it possible to reconcile claims that 
“there are no genes for race” (Dupré, 2008) with the notion that “ethnic 
groups are genetically different” (Evans and Relling, 1999)? Finally, who 
gets to determine and define the category Asian? Who is Caucasian, and why 
does it matter?
The illuminating question could be, when are you from?
Instead of an almost exclusive focus on the question of where a person is from, 
Duster (2015:84) has pointed out that “when we shift and raise the question 
‘when are you from?’ we become far better equipped, conceptually, to see and 
examine the inexorable convergence of science and society.” Kahn (2015) sug-
gests that the time period in which scientists and researchers constructed ideas of 
“pure” race and/or ethnicity matters:
The idea that there are somehow ‘pure’ types of African, European, or Asian 
DNA is a fiction, constructed not only by artificially bounding geographic 
areas but also by arbitrarily designating distinct points in time as marking the 
temporal moment of purity.
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In other words, it is of fundamental importance for the analyst to take a step 
back and to examine the social histories embedded in the population categories 
that scientists and medical researchers in contemporary times take for granted in 
their laboratories. This task is essential because it allows us to then critically reflect 
upon what the scientists and researchers are telling us about those categories, 
what they are doing with those categories, and what ethical and social implica-
tions may flow from those assumptions and practices.
Following this line of inquiry, it is important to note, first of all, that the mod-
ern nation-states in Asia that this book discusses are primarily creations of the 
twentieth century. Moreover, as shown in Appendix A, most nation-states have 
colonial histories. Secondly, a rich body of literature has demonstrated that the 
contemporary ethnic categorizations in postcolonial nation-states have been sig-
nificantly shaped by the Western colonial administrations. India, Malaysia, and 
Singapore were under British colonial rule. The Spanish and American colonial 
administrators in the Philippines and their Dutch counterparts in Indonesia all 
actively engaged in the naming and labeling of peoples under their colonial rule. 
Nation-states that have not been colonized by “the West” have their own politi-
cal histories. For example, between 57 BCE–668 BCE, the three kingdoms of 
Goguryeo, Baekje, and Silla dominated the Korean Peninsula and parts of Man-
churia, the area now known as “Korea.” Before turning to illuminate and explain 
the emergence of these issues as they relate to Asia, in Chapter 2, I first draw 
analogies and parallels to how Europe went through remarkably similar processes 
of ethnic and racial “emergence.” Then, in Chapters 2 and 3, I further suggest 
that the dynamic construction of ethnic and racial categories in the contexts of 
a global genomic science and the pharmaceutical industry is not only about the 
relationship between the contemporary Asia and “the West,” but also regional 
dynamics within Asia. In Chapter 4, I elaborate on the point that ethnicity is a 
function of the construction of “nationhood” as well.
What is at stake when populations are  
ethnically or racially labeled?
While large-scale genetic variation projects calculate allelic frequencies of genetic 
variants among racial and ethnic groups, Marcus Feldman, a biologist, and Rich-
ard Lewontin, a population geneticist, have stated that “the actual distribution of 
human genetic variation, including the distribution of genotypes that are directly 
relevant to the diagnosis and treatment of disease, is such that race is not a useful 
biological concept when applied to humans” (Feldman and Lewontin, 2008:98). 
Indeed, humans are essentially identical in about 99.5 percent of their DNA 
(Weiss 2007). More fundamentally, “it is possible to make arbitrary groupings of 
populations defined by geography, language, self-identified faiths, other identi-
fied physiognomy and so on and still find statistically significant allelic variations 
between these groupings” (Duster, 2006a:434). In Asia, for instance, Takezawa 
et al. (2014:3) note that “even among mainland Japanese, statistically meaningful 
genetic differentiation was found among individuals in different regions, such as 
Tohoku, Kanto, Kinki, and Kyushu.”
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Perhaps, most importantly, as anthropologist of science Jonathan Marks (2006:6) 
explains:
[P]roviding health care can obviously benefit by knowing something of the 
self-identification of the subject, given that different groups have different 
risks, due to their histories or life circumstances. But that does not presup-
pose that there are fundamental biologically-based divisions between the 
groups. . . . The therapeutic intervention would have to be based on geno-
type, not on any racialized identity. Otherwise it would be far more likely to 
kill people than to cure them.
The main point that these first four chapters makes is that identity categories 
of “Asian” or “Caucasian,” “Japanese” or “Malay,” are demonstrably integral to 
the social process of “(self-)othering” in particular contexts, such as colonialism 
or establishing the boundaries of the nation-state, and yet some researchers are 
uncritically using these categories as if they were intrinsically biomedical. Chapter 5 
problematizes such widespread usage of ethnic and racial categories as proxies for 
human genetic variation and provides the turning point in this book. In particular, 
I draw on interviews with oncologists to explain and highlight the serious limita-
tions of using patterns of genomic differences that seem to differ between ethnic 
and racial groups in their clinical practices. In other words, even though population-
based genomic research is couched in the rhetoric of advancing cancer treatment 
and prevention, this chapter delineates physicians’ concerns about using findings 
from such a research agenda. Chapter 6 further emphasizes the ethical dilemmas 
that physicians face in the delivery of genome-based medicine for cancer patients, 
as well as their concerns for potential discriminatory practices at the societal level.
Chapter outline
Chapter 2 – Regionalism and the study of human genetic  
variation in a transnational context: Asianism, nationalism,  
and the racialization of ethnicity
The first phase of the HUGO Pan-Asian SNP Consortium (PASNP) project was 
completed in 2009. The primary conclusion that “there is substantial genetic 
proximity of SEA [Southeast Asian] and EA [East Asian] populations” was pre-
sented in “Mapping Human Genetic Diversity in Asia,” published in Science (The 
HUGO Pan-Asian SNP Consortium, 2009). The Pan-Asian Population Genom-
ics Initiative (PAPGI) is the next phase of PASNP.
This chapter analyzes this influential publication in Science along with the con-
texts of the production of such scientific knowledge. Specifically, drawing on 
interviews with leading geneticists in the HUGO PASNP Consortium and on 
documentary analysis, it describes how and why the PASNP study changed from a 
disease-oriented study to a study of migration history, and how participating scien-
tists used “ethnicity” as a population sampling frame while defining it subjectively. 
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Reacting against Western domination in human genome science, human geneti-
cists in Asia organized themselves to gain control over the definition of “Asian” 
genome variation. Moreover, this chapter provides descriptions of historical, polit-
ical, and legal processes that have shaped the “ethnic” groups used in the genome 
variation analysis. It concludes that the PASNP’s work engages a dynamic tension 
that simultaneously undermines (for some) and reifies (for others) the biologi-
cal bases of socially constructed notions of race and ethnicity, and highlights the 
implications for pharmacogenomics studies and personalized medicine.
Chapter 3 – Capitalizing on being “othered”: precision medicine 
and race the context of a globalized pharmaceutical industry
Before genome-based personalized medicine can be administered in clinical set-
tings, the question is what shapes drug marketing and development. This chapter 
closely examines the story of gefitinib (IRESSA, marketed by the pharmaceutical 
company AstraZeneca), a targeted drug for treating non-small-cell lung cancer 
patients with EGFR mutations. It suggests that the case of IRESSA deserves a 
closer look, not least because it has been hailed as an exemplary case of person-
alized medicine. It illustrates that, in some instances, lurking just beneath the 
surface of molecular-based personalized medicine is the reality of racially and 
ethnically designated population-based drug development in the context of a 
globalized pharmaceutical industry. In addition, this chapter analyzes the ways 
in which some geneticists and medical oncologists in Singapore have re-centered 
Asia in their empirical pharmacogenomic studies of cancer drug toxicity with an 
emphasis on ethnic diversity, typically adopting comparisons between “Asians” 
and “Caucasians” in the context of Phase IV clinical trials. As such, it provides 
examples of the transnational implications of racially and ethnically framed phar-
macogenomic studies for countries beyond Asia.
Chapter 4 – Managing otherness: genomics and  
public health policy in Singapore
This chapter describes the ways in which Singapore’s government is incorporat-
ing genomic science for public health policy decision-making. In the national 
context, the internal social diversity of the “nationally Asian” population is high-
lighted in studies of genomic medicine in terms of cost-effectiveness. Specifically, 
the chapter explores the ways in which medical doctors and health economists 
try to use census population categories such Malay, Chinese, and Indian, and 
how these health professionals think in terms of sampling (as if these were dis-
tinctive populations), providing the basis for ethnically- or racially-based public 
health policy guidelines. Moreover, the chapter offers a social-historical-political 
account of the unfolding character of the category of the “Malay” population to 
suggest that while medical researchers are actors of contemporary times and do 
not think in terms of historical contingencies, we can see the complexities inher-
ent in these population categories once we examine the actual history.
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Chapter 5 – Cancer genomics in clinics
Chapter 5 returns to the key promise of genomic science in advancing human 
health. I suggest that “making genomic medicine” is not only about acquiring 
and understanding knowledge about human genome variation, but also about 
judgment as to whether and how to translate knowledge into practice. This chap-
ter describes the ideal of personalized medicine that most medical oncologists in 
Singapore hold – which is to use the molecular characteristics of individuals to 
improve the prevention, detection, and treatment of cancer. As such, the chapter 
highlights the tensions between the racial and ethnic categories constructed in 
the contexts of global genomic science, the pharmaceutical industry, and national 
genomic public health policies at the macro level, and clinical practice at the 
micro level. Doctors are on the front lines of delivering health care, and they 
articulated their concerns about using ethnic or racial identities as proxies in 
deciding drug efficacy, drug toxicity, and preventive medicine for individual can-
cer patients. This chapter identifies some of the social and economic conditions 
under which racial and ethnic patient identities shape treatment decisions, which 
are seen as suboptimal by most, if not all, clinicians.
Chapter 6 – Socio-economic factors and ethical dilemmas  
in personalized medicine provision
Socio-economic factors are ultimately related to ethical issues. This chapter 
highlights the lessons learned from medical oncology in terms of the promise 
and limitations of collective interventions at the molecular level, as opposed 
to the environmental level, to address the complex disease of cancer. It sug-
gests that genome-based personalized medicine is expansive, but not curative. 
Given this characteristic, we focus on the ethical dilemmas and knowledge gaps 
of personalized medicine provision from the perspectives of physicians. In rela-
tion to bioethics, for example, should doctors recommend genetic testing, and, 
afterwards, should they recommend certain kinds of genome-based personal-
ized medicine? As a doctor, should one provide all available information or only 
information as needed by the patient? Doctors have different ways of resolv-
ing such ethical dilemmas, and their resolutions can, potentially, be challenged. 
With regard to biopolitics, we discuss some concerns potential discriminatory 
practices against ethnically or racially identified groups. This issue is important 
because of how population-based genomic studies identify and construct refer-
ence populations along racial and ethnic lines that are significantly a function of 
history and politics.
Chapter 7 – Conclusion: personalized medicine and  
population-based genetic/genomic studies
No two patients are alike, even if they come from the same racial or ethnic popu-
lation. In the (post-)genomic era, will medicine be “personalized” according to 
an individual’s unique genetic makeup, or will it be developed and administered 
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in relation to that individual’s racial and ethnic identities? This book analyzes 
social forces shaping possible outcomes. Moreover, it provides empirical evi-
dence to suggest that the emergence of “Asia(n)” DNA or ethnically demar-
cated genomics is partly a function of various strategies of centering Asia in the 
genomic science and medical fields, and partly a function of the ways in which 
population geneticists and medical researchers in Asia cope with otherness. As 
such, these racial and ethnic categories have no a priori naturalness, even though, 
at first glance, they may appear to. Thus, the majority of the medical oncologists 
interviewed do not support using race or ethnicity as a proxy in their clinical 
decision-making, not least because, as they put it, genetic mutations do not rec-
ognize racial or ethnic boundaries. Through closely examining what is happening 
in Asia, this book hopes to contribute to our understanding of the co-creation of 
racial categories and production of knowledge in this global era.
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Introduction
How do you define an ethnic group? . . . We decided we won’t define. We will 
have the scientists define an ethnic group. Because they know best how to define 
an ethnic group.
HUGO PASNP interviewee Dr. Zhang
Over the past decade, advances in human genomics work in Asia have been rapid 
and expansive. In 2009, the Pan-Asian SNP Consortium (PASNP), a transna-
tional research team within the Human Genome Organization (HUGO), mapped 
genetic variation and migration patterns in 75 populations, with data from 10 
countries: Japan, Korea, China, Taiwan, Singapore, Thailand, Indonesia, Phil-
ippines, Malaysia, and India. The primary conclusion that “there is substantial 
genetic proximity of SEA [Southeast Asian] and EA [East Asian] populations” 
was presented in “Mapping Human Genetic Diversity in Asia,” published in Sci-
ence (The HUGO Pan-Asian SNP Consortium, 2009). In alluding to this genetic 
proximity while excluding Australia, this high-impact publication seemed to lend 
support to the argument that “Asian” is a coherent racial/ethnic category.
This chapter revisits this premise that “Asian” is a coherent racial/ethnic cat-
egory and analyzes the social and political contexts of the production of scien-
tific knowledge in human genetics. Most notably, it addresses how a scientific 
collaboration has reshaped epistemological claims in medical science about the 
significance of ethnic and racial differences between and among Asians. More spe-
cifically, I begin here to explain and reconcile the seemingly contradictory claims 
made by some scientists that, genetically, “all Asians probably came through 
South-east Asia and migrated northward . . . as one people” (Singh, 2009), on 
the one hand, and that “notable genetic differentiation from Korean and Chinese 
populations has been found” (Fujimoto et al., 2010:931), on the other.
If geneticists are simply concerned with diversity, why does “Asian” enter as 
a category at all? This chapter highlights the role of regionalism with respect 
to Asia and how it has generated a new version of the “Molecular Reinscrip-
tion of Race” (Duster, 2006), which might be called “regional racialization” in 
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genomics. Moreover, I suggest that we cannot fully understand scientists’ current 
attempts at regional integration without an understanding of the larger historical 
contexts and developmental phases of regionalism. As Sun (2007:9) suggests, 
“the discussion of Asia [has] involved not only the question of Eurocentrism, but 
also the question of hegemony within the East.” This was perhaps most notable 
in Japan’s attempt at regional integration before World War II. Saaler (2007:1) 
writes: “Pan-Asianism [is] an ideology that served not only as a basis for early 
efforts at regional integration in East Asia, but also as a cloak for expansionism 
and as a tool for legitimizing Japanese hegemony and colonial rule.”
In addition, this chapter documents how, within the HUGO PASNP, ethnic 
variation was molecularized. Drawing on existing literature, I illustrate how the 
“ethnicities” that HUGO PASNP Consortium members used were politically, 
socially, and historically constructed. In addition, drawing on interview data, 
I note that the molecularization of ethnicity in Asia by the Consortium is sig-
nificantly a function of the members’ decision to switch from an initial plan for a 
project to understand the genetic causes of diseases to one focused on migration 
history in Asia, and the concomitant ways in which the population sampling for 
the migration project was done.
This chapter begins by drawing on the dominant scientific literature of the 
mid- to late-twentieth century, which suggests that nation states and ethnicities 
are primarily social-political constructs. It then shifts to explain how the histori-
cal phase of Japanese colonialism crystallized what had been the fluid boundaries 
of ethnic identities, including some of those that ultimately were used by the 
HUGO PASNP Consortium members.
However, before turning to illuminate and explain the emergence of these mat-
ters as they relate to Asia, it will be of heuristic value to draw analogies and paral-
lels to Europe’s remarkably similar processes of ethnic and racial “emergence.”
The fundamental question of, when are you from?
Despite the widely publicized conclusion – based on the human genome map – 
that race does not exist at the molecular level, Duster (2015) articulates how 
some developments in molecular genetics research continue to re-inscribe race as 
a biological category. Moreover, there are fundamental problems with the ways 
in which racially and ethnically labeled populations are used for research focusing 
on differences, such as “admixture research” (Duster, 2015; Kahn, 2015). As 
Duster puts it:
Since there was no such thing as “Germany” before 1871, should Prus-
sian and Bavarians be categorized as “admixture” in 1873, but then would 
each be conceptualized as a “purer” version of “ethnicity” in 1850? Since 
there was no such thing as “Italy” in 1858, what, genetically, were Milanese 
and Romans and Neapolitans with respect to their regional “ethnic admix-
tures” once the nation state was unified? And who gets converted into single 
genetic ethnic category in 1865?
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Indeed, the terms “Germany” and “Germans” would have had different mean-
ings before 1871. At that time, “Germany” was fragmented, with independent 
kingdoms, city-states, and empires (O’Brien, 1992), its boundaries changing 
under different rules and war conditions. Deciding whether Prussians should be 
considered an “admixture” or “German” is not a straightforward task. Prussia 
had long been affiliated with Poland, but was later integrated into “Germany” 
in 1871 (Friedrich, 2004). Would a “Prussian” ancestry render an individual an 
“admixture” or “German” in today’s context? Furthermore, in 1947, Prussia was 
legitimately abolished by an Allied decree (Friedrich, 2004). What would it mean 
to be a “Prussian” should the name “Prussia” lose its official legitimation?
In other words, intricate power relations, with wars and conflicts, are bound 
to influence the naming, identifications, and categorizations of people. This is no 
less true in the context of the region known as “Asia.” For example, Okinawa 
was known as the Ryukyu Kingdom before becoming the Okinawa prefecture of 
Japan in 1879; the first Sino-Japanese war happened between 1894 and 1895. 
Similar examples can be found in the partition of India into Pakistan and India in 
1947, the split between Bangladesh (East Pakistan) and Pakistan (West Pakistan) 
through the Bangladesh Liberation War, and so on and so forth. . . .
In the following section, I illustrate the emergent and fluid nature of the “Japa-
nese” category.
Once upon a time: the unfolding character  
of the “Japanese” category
Japan was first politically unified in the seventh and eighth centuries, with the 
introduction and implementation of institutions of central government modeled 
after China (Jansen, 2002). However, similar to European history, with its medi-
eval period following the fall of the Roman Empire, Japan went through its own 
medieval period between, approximately, the twelfth and seventeenth centuries. 
In 1600, the military government of the Tokugawa shoguns, with the support of 
regional lords, successfully reunited Japan (Howell, 1994). February 11 was offi-
cially declared a “Japanese” national holiday in 1872. To construct the categori-
zation of “Japanese” and the boundaries of “Japan,” the government strategically 
employed different terms. The term “Japanese” (nihonjin) can mean “a citizen 
of Japan” (kokumin, which can include people of different ethnic backgrounds, 
though this is uncommon) or a person of the Japanese ethnic group (minzoku, 
which can include people who are not citizens of Japan). The Ainu inhabiting 
Hokkaido, inhabitants of the Ryukyu Islands (Okinawans), and outcasts (Bura-
kumin) scattered throughout the main islands were denied membership in the 
Japanese population in the nation’s initial stage (Howell, 1994). In other words, 
the Ainu, the Ryukyuans, and the Burakumin are what Winichakul (2000:41) has 
termed “the Others Within.”
More recently, the situation has changed, as these groups now fall within the 
broad category of “Japanese” (Nihonjin-minzoku). However, such minority 
groups remain internal others (non-Wajin). Wajin is the dominant majority 
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group among all who are regarded as Japanese citizens. Japanese law has sup-
ported and privileged the promotion of Wajin ideology (大和民族意識), 
contributing to the idea of a “mono-ethnic order” (Levin, 2008:10). Impor-
tantly, the national narrative of homogeneity and monoethnicity emerged 
after Japan’s defeat in World War II (Arudou, 2013). Drawing on critical race 
theory scholarship on whiteness, Levin (2008:11) argues that “Wajin are . . . 
Japan’s white people.” The Wajin majority is, according to Arudou (2013:162), 
“largely ignorant about the realities of life for Japan’s ‘invisibilized’ minorities, 
and generally views Non-Wajin residents as elements exogenous to Japanese 
society.”
In other words, the non-Wajin have been rendered invisible and/or treated 
differently from the Wajin through official policies. In fact, it was only in 2008 
that the Ainu were recognized as an indigenous people by the Japanese gov-
ernment. Looking back at Japan’s history, the changing classification of minor-
ity groups has also been influenced by external factors. For example, the Ainu 
population has come a long way toward being recognized as an indigenous 
population. In 1855, in response to Russia threatening Japan’s sovereignty over 
Hokkaido, the shogunate government assumed direct administration and began 
assimilation programs in Hokkaido so as to secure territorial rights to the island 
(Howell, 1994). Later, when the Meiji state came to power, the cultural norms 
of the Ainu were suppressed (Howell, 1994), as they were forced to give up their 
hunter-gatherer lifestyle to learn farming (McGrogan, 2010). The Ainu were 
officially renamed “former aborigines” in 1878 and gradually became subject to 
the same laws governing the “Japanese” (Howell, 1994). It was not until 2008 
that the Ainu were officially recognized and granted the status of an indigenous 
people.
According to McGrogan (2010), indigenous rights have become an increas-
ingly prevalent international norm, and Japan wanted to adhere to such norms 
and be seen as an advanced country. Japan was also facing explicit pressure from 
United Nations member countries that were raising Ainu issues. These fac-
tors, together with activism on the part of the Ainu, contributed to the shift in 
Japan’s official position. The Ryukyuans, however, at the time of this publica-
tion, are not recognized as an indigenous people by the Japanese government. 
While it is beyond the scope of this chapter to address the question of why some 
groups actively fight to be assimilated while others want to be treated as sepa-
rate, the relevant observation here is that these groups were assigned minority 
group status for profoundly historical, economic, political, and social reasons. 
Moreover, the majority Japanese identity was formed through the othering of 
minority groups.
Effects of Japanese colonialism and regional  
integration on the notion of “Japanese”
In addition, complex relationships exist between Japan, South Korea, and Tai-
wan, and answers to the questions of who is Japanese, who is Korean, and who is 
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Taiwanese/Chinese depend on historical and political contexts. Japan was an 
imperial and colonial power during the first half of the twentieth century. Accord-
ing to Robertson (2002:192):
[T]he new scientific order in Japan was introduced under the aegis of nation-
alism and empire-building. Beginning with the colonization of Okinawa in 
1874 followed by that of Taiwan in 1895, Korea in 1910, Micronesia in 
1919, Manchuria in 1931, North China by 1937, and much of Southeast 
Asia by 1942, the state consolidated through military force a vast Asian-
Pacific domain, the so-called Greater East Asia Co-Prosperity Sphere (Dai-
tō-a Kyōeiken), a rubric coined in August 1940.
The dominant view among Koreans is that they all belong to a “unitary 
nation,” descending from a common ancestor, and, thus, are ethnically homog-
enous. According to Shin (2006), however, this sense of ethnic homogeneity 
was created only in the colonial era as a response to Japan’s assimilationist poli-
cies. Specifically, Korea was colonized by the Japanese in 1910. Japanese colonial 
rulers claimed that Koreans and Japanese were of common origin, but the latter 
were superior. Hence, Japanese rulers took the position that Korean cultural tra-
ditions should be replaced with Japanese ones in order to achieve parity between 
the two groups. Korean nationalists countered that view with an alternative 
myth, claiming connection to the primordial mythical figure Dangun, from 
whom all Koreans are supposedly descended (Myers, 2010; Hong, Song and 
Park, 2012), suggesting a distinct and homogenous nation. Tikhonov’s (2012) 
analysis of race and racial discourses in the two decades prior to the annexa-
tion of Korea by Japan also supports the argument that the narrative of Korean 
ethnic homogeneity took root only in the early twentieth century. Following 
World War II, antagonism toward the “Japanese other” has continued to be 
instrumental to the strengthening and maintenance of Korea’s national identity 
(Lee, 2013). For example, there are three national holidays that commemorate 
anti-Japanese resistance.1 On every Gwangbokjeol (Liberation Day), the presi-
dent addresses the people with a speech that includes prominent references to 
Japanese colonialism.
During the Japanese colonial era, Japanese identity (nihonjin) was conferred 
on Japan’s subjects in Korea and Taiwan, and a sizeable number of these “impe-
rial subjects” went to reside and work in Japan. When Japan lost its colonies fol-
lowing World War II, Japanese citizenship was stripped from these people, and 
they became “non-Japanese.” In an incisive analysis of how the Japanese colonial 
regime urged Taiwanese aboriginal groups to die as Japanese (nihonjin) for the 
Japanese empire, Ching (2001) has described the colonial cultural constructions 
of “Japanese” (nihonjin as nihon minzoku and/or as kokumin), which had life-
and-death implications for the colonized:
The dominant Japanese colonial discourse of doka (assimilation) and 
kominka (imperialization) does not simply signify a shift or a conversion from 
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one category of identity to another, such as from “aborigines” and “Tai-
wanese” to “Japanese” or from “colonized peoples” to “imperial subjects.” 
Rather, these are ideological formations that purposely obfuscate and 
deflect the issue of the legal and economic rights of the colonized to that 
of some generalized cultural process of becoming “Japanese” and “imperial 
subjects.” Doka and kominka, by urging and then insisting that the colo-
nized become “Japanese” (nihon minzoku), conceal the inequality between 
the “natural” Japanese, whose political and economic privileges as citizens 
(kokumin) are guaranteed, and those “naturalized” Japanese, whose cul-
tural identities as Japanese (nihonjin) are required, but whose political and 
economic rights as citizens are continuously denied. . . . The instrumental-
ity of this Japanese colonial discourse is remarkably demonstrated in the 
encounter between the Taiwanese aborigines and the guardian of Japanese 
nationalism.2
The crucial distinction made by Japanese colonialism between “natural” Japa-
nese and “naturalized” Japanese is also instructive in understanding the Zainichi 
in Japan. Most of the Zainichi (Korean-Japanese) were involuntary migrants to 
Japan between 1910 and 1945, and were required to use Japanese names.3 After 
World War II, they lost Japanese citizenship and were given alien status. To be 
sure, a legal identification of a person as “Japanese” (ninhonjin-kokumin) is not 
equivalent to being treated as “Japanese” (Ninhonjin-minzoku), and the answer 
to the question of who is “Japanese” continues to be shaped by historical, politi-
cal, economic, social, and cultural forces.
Understanding ethnicity and race as an “emergent” phenomenon is crucial as 
we now turn to an analysis of the HUGO PASNP Consortium’s work. As I shall 
show, one of the main findings in the interview data with Consortium members 
is that the scientists have uncritically adopted the given racial (i.e. “Asian”) and 
ethnic categories in Asia (e.g. the “Japanese”) in their construction of popula-
tion in genome science, the foundation of genome medicine. However, as I have 
attempted to illustrate in discussing “who is Japanese,” such ethnic categories are 
historically and politically constructed, sometimes through colonial encounters. 
By looking into the history of Asia and using the case of Japan, I attempt to 
make three points: first, there is a continuity in the contexts of Western domina-
tion and the usage of “Pan-Asianism” as an ideology, which helps to explain the 
appeal and adoption of the “Asian” category in earlier Japanese regional integra-
tion and, again, in current genomic science. Second, racial and ethnic categories 
are historically and politically constructed; for example, “Koreans” and “Taiwan-
ese” were considered “Japanese” during the Japanese colonial era. Finally, it is 
not merely that the category of the “Japanese” has been taken for granted and 
treated as if it were a biological category by scientists; the internal “others” – the 
Ryukuyan and Ainu ethnic minorities in Japan, for example – have also been 
“geneticized” because geneticists have used such social diversity categories as 
proxies for genetic diversity in Japan.
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Resisting being “othered”: scientists in Asia  
define “Asian” genome diversity
As Cho, Bullock, and Ali (2013) point out, the HUGO PASNP Consortium is 
the first intra-Asian genomics collaboration. It had its genesis in the dissatisfac-
tion of Asian researchers with international genomics projects. For example, the 
International HapMap Project’s use of only Chinese and Japanese DNA samples 
as representatives of Asia was “seen by some researchers as a semi-imperialistic 
essentializing of Asia” (Cho, Bullock, and Ali, 2013:295). Thus, “Asian” soli-
darity served as a rallying point against the Eurocentrism of prevailing scientific 
discourse and being “othered” in genomic science, and Consortium members 
gathered to define “Asian” genomic variation. One of the founding members, 
Dr. Zhang, a self-identified Asian geneticist, emphasized this sense of collectivism 
among researchers: “Importantly, I developed a network of friends across Asia. 
This was a work that was conceived by Asians, executed by Asians, funded by Asians 
as a collective” [emphasis mine].
This emphasis on how “Asians” managed to conceive, fund, and complete the 
project from beginning to end reveals the researchers’ pride in this being an 
“Asian” project, which highlights the continuing relevance and importance of 
Pan-Asian ideology. It is important to note, however, that Japan’s colonialism, 
with its goal of constructing a “New East Asian Order” and “Greater East Asia 
Co-Prosperity Sphere,” was also tightly linked to Pan-Asian ideology as a reac-
tion against “Western” domination (Hotta, 2007). In other words, the actions 
taken and leadership roles involved have changed, but the essential idea of com-
ing together as “Asians” to showcase that “Asians” are not inferior to “Western-
ers” remains a recurrent theme. Hence, it is no surprise that the HUGO PASNP’s 
project of studying migration history in Asia was proudly acclaimed by many 
as an “independent” Asian breakthrough in human genome science. However, 
I will highlight three dimensions through which the Consortium had deep trans-
national connections, particularly with the United States.
First, the Consortium’s primary technology partner was Affymetrix (Agency 
for Science, Technology and Research Singapore, 2009; HUGO Pan-Asian SNP 
Consortium, 2009), a company based in the United States that develops and pro-
vides technologies that aid in analyzing biological data at various levels, including 
at the genetic level. Consortium researchers used GeneChip Human Mapping 
50K Xba array sets provided by Affymetrix (HUGO Pan-Asian SNP Consortium, 
2009). In addition, Affymetrix provided these arrays at a discounted price or for 
free, funded a research lab, sponsored one of the Consortium’s meetings in San 
Francisco, and provided staff training in eight genotyping centers (Cho, Bullock 
and Ali, 2013). Thus, Affymetrix played a key role in many ways. Indeed, since 
the establishment of the Consortium, Affymetrix has moved more of its opera-
tions to Singapore. The HUGO PASNP Consortium used a technology platform, 
developed by Affymetrix, which is used and understood by most professionals 
conducting genome-wide association studies (GWAS).
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Second, the Consortium used the Bayesian analytical software program Struc-
ture (HUGO Pan-Asian SNP Consortium, 2009), which was developed in the 
United States as well. The software helps users to investigate and infer population 
structure and assigns individuals to populations (Bolnick, 2008; Cho, Bullock and 
Ali, 2013). One of Structure’s developers has warned that inferring the value of K 
(i.e. the number of population cluster in the sample) can be difficult and contentious 
(Pritchard, Stephens and Donnelly, 2000). Specifically, when researchers choose dif-
ferent values of K, Structure can produce substantially different results, and the same 
person may be assigned to different population groups. Also, even with one value 
of K, a rerun can generate different results, as there may be two or more possibili-
ties of maximizing the Hardy–Weinburg equilibrium in each population (Bolnick, 
2008). However, such human agency gets lost, and the published result becomes 
“the one and only” scientific statement, even if there is a lapse in reporting all exist-
ing biological information and data (Bolnick, 2008). For instance, in the Consor-
tium, values of K = 2 to K = 14 were used to run analyses, in accordance with the 
geographic divisions deemed meaningful by the researchers (Cho, Bullock, and Ali, 
2013). With the different runs, there were different results, and researchers might or 
might not agree on which value of K was most suitable. Jong Bhak, the Director of 
the Korean Bioinformation Center, has said that his group deemed K = 12 to be the 
best descriptive value, but the Chinese group chose another value (Cho, Bullock, 
and Ali, 2013).
Third, a number of professionals involved in the Consortium received their 
professional training in or were affiliated with universities in the United States. 
Most notably, Dr. Edison Liu, who successfully led the first phase of the Con-
sortium’s investigation, with its resulting publication in Science, is a graduate of 
Stanford University, and he eventually returned to the United States to head 
the Jackson Laboratory, in Sacramento, California (Teater, 2012). Other Con-
sortium members, such as Li Jin and Mark Seielstad, were trained under Luigi 
Luca Cavalli-Sforza, a founder of the Human Genome Diversity Project (HGDP) 
and renowned population geneticist and linguistic anthropologist, who is also at 
Stanford (Cho, Bullock, and Ali, 2013).
Hence, the perception of the HUGO PASNP Consortium as an independent 
“Asian” project conducted by “Asians” is only partially accurate, given that the 
primary technology partner, technological software, and expert training came 
mostly from the United States.
The transnational links presented above facilitated the Consortium’s work, but 
the internal dynamics between researchers from various countries in Asia should not 
be neglected. Researchers in the HUGO PASNP Consortium who were interviewed 
mostly emphasized the cooperative nature of their relationships. Dr. Kang said: “So 
HUGO Pan-Asian was to me . . . absolutely 100 percent cooperation. I was not 
interested in competing with anybody.” He added that the PASNP Consortium 
helped to uplift the capabilities of some Asian countries in genomic research:
. . . India, and Pakistan, all these countries, instead of being left out, which has 
always happened in the past by the Western countries and researchers. Now they 
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feel that they are also in the mainstream. So we have our own genomic commu-
nity in Asia, at least PASNP. So we have this fabric, a network. Although the 
actual outcome[s] aren’t so significant yet, definitely we laid the foundation, 
in Malaysia and definitely in Korea as well. Although the success was fairly 
moderate, there was indeed, huge progress making these emerging Asian 
countries embrac[e] these technologies [emphasis mine].
The scientists also highlighted the so-called “host-guest” arrangement as 
instrumental in fostering a “Pan-Asian” partnership. The essence of this arrange-
ment was for more advanced research institutions (“hosts”) to provide assistance 
in genome sequencing to less advanced institutions (“guests”). The crux of this 
arrangement was that the ownership of DNA samples and data would reside with 
the “guest.”
As noted by Dr. Zhang, the “host-guest” arrangement created the impression 
of a partnership of equals within the Consortium, despite significant differences 
in technological and financial capabilities between its member institutions:
The idea [of the host-guest relationship] solved the problem of chain of 
custody of the DNA. So a country like Indonesia which didn’t have these 
technical capabilities, the scientists would carry the DNA with them to a 
host nation. And so the host nation says two things. Number one, I will 
do it, the genotyping, and I will pay for it and I will teach you how to do 
it. . . . [I]t was structured so that even the people who were least enabled 
to do the science were equal partners . . . this was a win-win situation, they 
brought samples, they didn’t relinquish any control, but they learned how 
to do the work.
In other words, the host-guest framework invented by the HUGO PASNP 
Consortium helped reduce the problem of hegemony in Asia and served to miti-
gate the national genomic sovereignty issue (Benjamin, 2009). Dr. Kang said that 
this arrangement will similarly be employed in the second phase of work of the 
PASNP, known as the Pan-Asian Population Genomics Initiative (PAPGI):
[For] PAPGI we’re trying to have this special scheme called [the] guest-host 
scheme. So the guest is this poor lab [that] doesn’t have much sequencing 
resources and money, but they have good samples, and good biologists, 
and excellent biological research, but they don’t have much funding from 
the government. Because they are in say, Thailand, or Indonesia. And the 
rich labs [are in] say Japan, Korea, or Saudi Arabia, Singapore. We have 
funding, but to do really good . . . Consortium work, we need really good 
samples and biological background information. So these host labs invite 
these guest labs, work together. So one gives samples, the other one gives 
money, and sequencing, and then they analyze together, and then auto-
matically this goes to [the] PAPGI Consortium. No one actually dominates 
anything.
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While the PASNP members emphasized “Pan-Asianism” in their intellectual 
collaboration, and their findings even seem to suggest that there appears to be 
a genetic basis for being Asian, as the following interview data shows, regional 
politics and histories shaped the process of data sharing. Moreover, the perceived 
neutrality of Singapore allowed it to play an important role in the Consortium. 
According to Dr. Zhang:
. . . in order to really take the lead, Singapore volunteered and [it] turns out 
that Thailand, Malaysia and Indonesia all used us as their host. . . . Actu-
ally, Philippines even came to Singapore, so basically, we were the major 
hosts. . . . Koreans had some Mongolians, the Chinese had some central 
Asians, the Indians had the great diversity of themselves but in actual fact 
Singapore played the major role. . . . Singapore played the role that Brus-
sels plays in the EU. It’s a neutral, small, non-threatening, you know – so 
if Japan wanted to lead it, the Japanese-Koreans would have a problem and if 
China wanted to lead it, some others would have a problem. So Singapore was 
a neutral body and they accepted that [emphasis mine].
Concrete examples of the positive aspects of the Consortium’s work can be 
seen in its effects on genome science in Malaysia and the Philippines. This is par-
ticularly true in the case of the Philippines. Because of the guest-host relationship, 
its success, and what was learned, the government contributed money to setting 
up infrastructures for Philippine researchers to examine the genetic structure of 
indigenous populations. Because Consortium researchers in Malaysia published 
a high-impact paper, the government decided to dedicate a significant amount 
of money to genomics; therefore, the country is now more or less independent 
in terms of doing genome sequencing. In this sense, PASNP did act as a catalyst.
Moreover, national pride and national identities seemed to be equally impor-
tant within the HUGO PASNP Consortium. After the initial publication in Sci-
ence, researchers published offshoot papers analyzing the data pertaining to their 
respective countries.
In the case of Japan, some spin-off studies focused on the “others within” – 
namely, the Ainu and Ryukyuan populations. For instance, in “The History of 
Human Populations in the Japanese Archipelago Inferred from Genome-wide 
SNP Data with a Special Reference to the Ainu and the Ryukyuan Populations” 
(Jinam et al., 2012), researchers made use of several datasets, including those 
from International HapMap and the HUGO Pan-Asian Consortium, to con-
duct both individual and population analyses to garner insights into the genetic 
histories of these populations in Japan. The conclusion of the study was that, 
genetically, the Ainu are closer to the Ryukyuan than they are to the Mainland 
Japanese population. This result was interpreted as indicating that the Ainu and 
Ryukyuan possibly share a common ancestry, which is different from that from 
the Mainland Japanese. From a scientific viewpoint, these results could be con-
sidered substantial, as indicated by publication in the peer-reviewed Journal of 
Human Genetics. However, upon closer inspection, one should note that the 
study hinged upon the use of social constructs (the categorizations of the Ainu, 
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Ryukyuan, and Mainland Japanese populations). It is not unreasonable to sug-
gest that not only the ethnic groups, but also their ancestral linkages and histo-
ries, are being geneticized.
Ethnicity as a proxy for genetic diversity and  
the molecularization of ethnicities in Asia
Several HUGO PASNP Consortium geneticists interviewed expressed the view 
that ethnicity has a genetic basis. Dr. Sato, a self-identified Japanese geneticist, 
and Dr. Lee, a self-identified Chinese geneticist, were particularly convinced. 
Dr. Sato said, “. . . one of the biggest findings from the Pan-Asian Consortium 
is just [that] ethnic classification correspond[s] to the genetic classification very 
well.” Dr. Lee expressed a similar conviction: “What is the implication of demar-
cation? Well, ethnic populations are genetically different. It’s true. Right, if you talk 
about even Koreans and Chinese, you can still see difference, the point is how 
different [when] you talk about on the world scale” [emphasis mine].
While acknowledging genetic similarities among different ethnic groups, 
Dr. Kang was confident about finding genetic markers that differentiate between 
two ethnic groups: “One ancestor, but sufficiently different to define ethnicity. 
So Koreans are very similar to Chinese. However, I can define it. Physically. Actu-
ally a lot of people are trying to find the markers [that differentiate the] Koreans 
from Japanese.”
Thus, for some scientists, the “findings” of the PASNP Consortium study 
appear to suggest that there is a genetic basis to ethnicity. Indeed, Yang et al. 
(2014) published a paper entitled “Identification of Ethnically Specific Genetic 
Variations in Pan-Asian Ethnos” in Genomics and Informatics. It seems important 
to ask: how and why did this genetic attribution happen? In the following para-
graphs, I suggest that “how” this genetic attribution happened has to do with 
the Consortium’s use of ethnic diversity as a proxy for human genetic diversity, 
and that “why” can be attributed to the study’s shift from a disease-oriented 
project to one investigating population diversity and migration history in Asia. 
Most importantly, the interview data reveal that Consortium researchers treated 
contemporary ethnic categories as static when they claimed to have found “ethni-
cally specific genetic variants” (Yang et al., 2014), even though, as noted in the 
introduction to this chapter, such categories are “emergent” and “unfolding.”
The PASNP Consortium originally intended to undertake a disease study, but 
key members determined early on that choosing which disease to study would 
prove problematic. There were also concerns about sovereignty and, thus, con-
trol of genetic data, which reinforced a lingering concern that researchers from 
technologically developed countries could gain at the expense of their techno-
logically backward counterparts. Dr. Sato articulated the complex difficulties of a 
disease-oriented study design:
Actually before starting this [HUGO PASNP Consortium] cooperation, we 
discussed very much about the project, whether we can start with some dis-
ease studies, or if we should start with population studies. And finally we 
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start with population studies. How to explain? Less biased. Some people like 
to study hypertension, others want diabetes . . . maybe [in] some countries 
diabetes [has] become more serious, but other countries [are] more inter-
ested in infectious diseases. So population studies are rather unbiased [,] you 
know?
In short, to embark on a disease-specific study was seen as almost impossible, 
and the alternative of a population study was comparatively appealing. Dr. Zhang 
explained this:
It [the HUGO PASNP Consortium] started out as a disease-specific discus-
sion and it started in 2002 in Shanghai. . . . They wanted to find a disease. 
But it became very clear from the onset, several things were problematic. 
Number one, there were a lot of haves and have-nots. The have and have-not 
divide was huge in Asia. [The “have and have-not” refers to] technologies. 
In those days, things were not quite standardized, so there were only a few 
institutions, like . . . mainly Japan. . . . [But] countries didn’t want to send 
DNA to Japan or anywhere else. There was this issue of genetic sovereignty 
that was rising. . . . So no country wanted to give their genetic treasure to 
Japan so that they would have a patent on the diagnostic. It’s an issue of 
where your funding comes from.
[For t]hose countries with aspirations in genetics, most of the research was 
funded in Asia by trade and industry, not by health [institutions]. Or if it is 
by education [institutions], it usually has an industrial KPI.
To summarize this section, political, logistical, and financial factors dictated the 
failure of a disease-oriented study. For example, while Japan had technological 
competence, no countries were eager to share their genetic materials with Japan. 
Recruiting clinicians and hospitals presented another formidable obstacle. Finally, 
research for treatment of diseases, a public health matter, is largely funded by 
industry rather than public health institutions in Asia.
It was for these reasons that the PASNP study eventually morphed into a popu-
lation study, a shift of focus also partly motivated by the practicability of the 
population diversity design. Dr. Zhang said:
The first thing when I realized what was happening, I started to talk to 
key players, to suggest that we move away from disease and do population 
genetics, which has a much easier design. You don’t have to have cases and 
controls; you just basically have people’s DNA. As long as you know what 
dialect they speak, and who their grandparents are, which virtually every-
body can tell you. Furthermore you don’t need big numbers, you just need 
to have diversity, because it’s a sampling issue . . . in actual fact it doesn’t 
matter how many people you have in your country. It matters more how 
diverse they are. So countries like Thailand and Indonesia and India became 
much more important than Korea and Japan. So the ease of design was a 
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key driver. . . . We put a framework and the framework was that we don’t do 
disease, we do diversity.
In short, the fact that the goal of understanding the relationship between dis-
ease and genes was dropped and replaced with the goal of understanding migra-
tion history in Asia had to do with the belief that the latter (migration history) 
was easily achievable and would require little effort. Specifically, obtaining sam-
ples for a population study would be easier, particularly when one assumed that 
social diversity represented genetic diversity. Dr. Zhang went on to explain eth-
nicity as a proxy for genetic diversity: “I need a surrogate for genetic diversity in 
order to get my first sampling. So the surrogate is ethnicity. . . . You stratify according 
to ethnicity within the states” [emphasis mine].
As it turned out, using ethnicity as a proxy was crucial and motivated “hosts” 
to help “guests” because such cooperation could increase the diversity of samples 
for the study. Dr. Zhang noted, “those who were least enabled tended to be peo-
ple with the greatest diversity of samples, so they were valuable.”
However, the interviews provide extensive documentation of the extent to 
which there is no coherent definition of ethnicity, but only varied local interpre-
tations. As shown in Dr. Zhang’s interview, the term “ethnicity” could draw no 
consensus: “So we [the HUGO PASNP Consortium members] had a discussion. 
How do you define an ethnic group? . . . We decided we won’t define. We will 
have the scientists define an ethnic group. Because they know best how to define 
an ethnic group.”
DR. ZHANG WENT ON TO HIGHLIGHT COUNTRY-LEVEL VARIATIONS IN DEFIN-
ING ETHNICITY: Ethnicity is defined locally by language and geographical 
localization, and then lastly, race. [Referring to the use of Chinese, Indian, 
and Malay to define diversity in Singapore’s population] That’s race, right? 
That’s usually a race construct. . . . You don’t define diversity in Singapore by 
whether you’re North Indian or South Indian. . . . Now if you’re in China, 
you define by what language you speak and where your parents lived, or 
where your grandparents came from.
Along the same lines, Drs. Kang, Sato, and Chua explained local bases for 
defining ethnicity, which rely essentially on self-identification:
DR. KANG: The way we define[d] [who] the Koreans were at that time [was] 
people who had three generations of knowledge that they have been in 
Korea, no external influence, and people who are from two cities, one called 
Ansung, the other one Ansan. . . . We took the original samples from a previ-
ous study in Korea, Korean Study, so they collected this. So essentially they 
just defined geographically, these two cities.
DR. SATO: Usually we consider about three generations back . . . or just ask the 
person if your father, mother, grandparents reside in the same area. Not very 
complicated. Because Japan has not much immigrants in recent years.
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DR. CHUA: We use the three generations. So this is for HUGO Pan-Asian. And 
also our definition of Han Chinese. In all my studies when we talk about 
Han Chinese, this is the definition. For us, [it is] difficult to get the four 
generations because nobody knows the four generations. Difficult to find. 
I mean . . . you know your parents are Chinese, your parents will know 
whether their parents are Chinese, but your grandparents may not be there 
to know the fourth [generation]. . . .
Self-identification plays a large part in defining ethnicity – if subjects consid-
ered themselves, their parents, and their grandparents to belong to a particular 
ethnic group, then for the purposes of the PASNP, they belong to that ethnic 
group. In sum, ethnicity became a locally defined term in the PASNP study. It is 
important to note that the researchers took ethnic categories such as “Japanese”, 
“Korean”, and “Han” for granted, bracketing the historical and political histories 
embedded in them. As demonstrated earlier in this chapter, “Japanese” is a his-
torically, politically, and culturally constructed category. Similarly, Chow (1997) 
has demonstrated the ways in which ancestral worship was deployed as a crucial 
concept in discourses to create the “Han” race as different and superior to the 
Manchus in China in the twentieth century.
Dr. Zhang was correct that, in Singapore, ethnicity is commonly used to refer 
to three main population groupings: Chinese, Indian, and Malay. As PuruSh-
otam (1998:51) has brilliantly demonstrated, however, while “the most com-
monsensically available ethnic names in Singapore that are applied to self and 
others are ‘Chinese,’ ‘Malay,’ ‘Indian,’ and ‘other’[CMIO],” such categories 
emerged out of a long political and historical process of expansion and consolida-
tion. According to PuruShotam (1998), the first census in Singapore, produced 
in 1871, consisted of 33 ethnic categories: “Europeans and Americans, Arme-
nians, Jews, Eurasians, Abyssinians, Achinese, Africans, Andamese, Arabs, Ben-
galis and other natives of India not particularized, Boyanese, Bugis, Burmese, 
Chinese, Cochin Chinese, Dyaks, Hindoos, Japanese, Javanese, Jaweepekans, 
Klings, Malays, Manilamen, Mantras, Parsees, Persians, Siamese, Singhalese, 
Military – British, Military – Indian, Prisoners – Local, Prisoners – Transmarine” 
(PuruShotam, 1998:61). In the census of 1881, a decade later, there were 47 
ethnic categories. These categories were “reclassified . . . under six main cat-
egories . . . these six categories were “European and Americans,” “Eurasians,” 
“Chinese,” “Malays and Other Natives of the Archipelago,” “Tamils and other 
natives of India,” and “Other Nationalities.” Once instituted in this way, these 
six divisions were retained in this form for the following two censuses” (Puru-
Shotam, 1998:61–62). Further differentiations of race categories were made in 
all categories except for “Eurasians.” Then, the census of 1921 identified 56 
races, and the number increased yet again in the 1931 census – it was reported 
that over 70 races had been identified by Vlieland (the census superintendent at 
the time). The contemporary Chinese-Malay-Indian-Others (CMIO) model to 
which Dr. Zhang referred was a result of administrative consolidation of these 
earlier categories.
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Yet another example of socially constructed ethnic labels is the manner in 
which ethnicity in Thailand was defined by Consortium members – the ethnic 
groups identified are “Hmong, Yao, Tai Lue, Tai Yong, Tai Kern, Tai Yuan, 
Mlabri, H’Tin, Plang, Lawa, Keran, and Palong.” Upon closer examination, 
most of these groups are “hill tribes” or forest people in Thailand. As Win-
ichakul (2000:41) articulates, however, the labeling and official treatment of 
these tribes is a project concerning “Others Within.” Specifically, Winichakul 
(2000) writes:
Ethnographic construction, generally speaking, was part of the colonial pro-
ject to formulate and control the Others of the West. Alongside the colonial 
enterprise, the Siamese rulers had a parallel project of their own . . . a project 
which reaffirmed their superiority, hence justifying their rule, over the rest 
of the country within the emerging territorial state. . . .
The two principal categories of people, of ‘Others Within,’ are the chao pa, 
the forest, wild people, and the chao bannok, the multi-ethnic villagers under 
the supremacy of Bangkok [emphasis in original].
What may be some implications of the PASNP Consortium’s work? It has been 
established that the genetic makeup of a patient, as an individual, can affect drug 
efficacy and drug toxicity in the case of certain drugs. Based on the purported or 
assumed genetic basis of ethnicity among Asians, could the development of medi-
cine for different ethnic groups become possible? The geneticists interviewed 
agreed on the importance of taking genetic diversity into account in drug devel-
opment. Most argued that it is inappropriate to lump Chinese, Koreans, Japa-
nese, Indians, and so on under one “Asian” framework, as is often the practice in 
clinical trials conducted in the United States. Dr. Zhang remarked:
When I was growing up as a young researcher . . . when we did stratifications 
in American clinical trials, it was Asian, Africans, African Americans, Hispan-
ics, and Caucasians. They cannot do that! My point here is that . . . they 
threw Japanese and Chinese and Indians altogether under one Asian frame-
work. . . . In the past, if you were doing a study in the US, you called Indians, 
Japanese, Chinese, Malays . . . all Asians and you lumped them under one 
ethnic demarcation in your clinical trial studies . . . you can’t do that [empha-
sis mine].
However, the researchers had different views as to whether drugs should be 
developed along ethnic lines. On the one hand, geneticists like Dr. Kang hold 
the view that there is sufficient diversity to merit the development of ethnicity-
specific drugs, even while acknowledging that, genetically, human beings have far 
more similarities than differences:
. . . we’re very similar to each other. That’s for sure. Because we are human 
beings, we’re not some ants. . . . So that means a lot of drugs we share, have 
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good impacts. . . . However, we are sufficiently different to have Chinese 
specific and Korean specific drugs.
Dr. Chua, for his part, did not see any problem with a population-based 
(ethnicity-based) approach to drug development:
I really don’t see any tension. Basically new drugs in the clinical trial, now 
you have to do in different populations . . . different population[s] have dif-
ferent safety profile[s] and different toxicity. . . . [T]he US FDA require[s] 
the different population statement. And when they [the drugs] come to 
Singapore, Singapore may ask [for] a bridging study if they don’t think 
there’s . . . enough data for [the] “Chinese” population. . . .
Dr. Chua cited examples of drug efficacy (BiDil and IRESSA) and drug toxicity 
(carbamazepine) to emphasize the importance of a population-based approach 
that would involve conducting clinical trials along ethnic lines:
If the [carbamazepine] clinical trial were done in [a] Chinese population, 
that drug [would] never have gone to the market. That particular drug is 
a major cause of the Stevens-Johnson syndrome in Southeast Asia. But it 
is very very safe in [a] Caucasian population. And this was 30–40 years ago 
when the clinical trial was done, and that primarily was done in the Caucasian 
populations, so [it was] approved and [brought] to the Asian market and 
everybody use[d it]. . . .
By using this population-based knowledge, one may able to, to revive 
those already dead drugs. Because one drug may not be good for Cauca-
sian populations. Usually they’re testing on Caucasian populations. Effi-
cacy is not good, discard. But recently, a drug for treating heart failure 
in African Americans [BiDil] . . . that is the example that you can actu-
ally stop the clinical trial but you can come back to [it], to test on other 
population[s].
IRESSA . . . drug was off the [US] market. Because the EGFR mutation of 
lung cancer is very rare, it’s less than 10 percent. But in [the] Chinese popu-
lation, 30–40 percent of our lung cancers [patients] carry this mutation. But 
this IRESSA is no longer in the market of the US, but it’s here, it’s available 
for Asians. Asians have a much higher, higher mutation.
Dr. Zhang noted that genetic diversity contributes to scientific discovery, but 
also cautioned against overemphasizing genetic differences between different 
ethnic groups:
Diversity provides discovery . . . IRESSA is a great example. IRESSA is a 
dead drug in the US, but it became alive because of the responses they saw 
in Asians. It is fallacious to think that just because of that one example, we 
are completely different from our Caucasian counterparts. We’re all human. 
But there is diversity and that diversity has some order to it.
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At the same time, Dr. Zhang expressed ambivalence about developing ethnicity- 
specific drugs. His reservation stems from the difficulty of defining ethnicity, 
which is perhaps an implicit acknowledgment that ethnicity is, in fact, a social-
political construct rather than genetically based:
[W]hat you’re asking is . . . “is there ever going to be ethnic specific therapy?” 
Let me ask you what’s ethnicity then. You define for me ethnicity. . . . There 
is no question that there will be genetically-based therapeutics. But if you 
ask me if there’s going to be ethnically-based therapeutics, then I have a 
real problem answering, because I don’t know what your term of ethnicity 
is. . . . If ethnicity is a surrogate for genetics, then I would say there is a pos-
sibility. But I think it’s a very weak surrogate for genetics.
On the subject of genetic diversity in China, Dr. Zhang drew connections to 
a case study modeled after the HUGO PASNP Consortium’s study of diversity 
in Asia:
. . . there’s another study that is an offshoot of this [HUGO PASNP Con-
sortium model], [which looked] at the diversity in China and found that 
there’s a clear north-south variation and diversity [is] greater in the south 
than in the north. China is a microcosm of the whole Asian migration issue 
and therefore genetic stratification is a problem within a nation-state. That 
is, you can’t lump all Chinese together now.
In other words, genetic differences could almost inevitably be “found” due 
to the sampling methodology that researchers adopted, whether between racial 
or ethnic categories or geographical locations. As such, it remains to be seen 
whether and how racially and ethnically labeled populations may contribute to 
the development of personalized medicine in the postgenomic era, a topic we will 
explore further in the next chapter.
Conclusion
In this chapter, I emphasize the importance of empirically-grounded under-
standing of “biocuration” (Howe et al., 2008), that is, researchers decoding the 
human genome make choices regarding what to interpret (and what not to inter-
pret), as well as how to interpret, analyze, and present data (Fullwiley, 2007, 
2008; Fujimura and Rajagopalan, 2011; Shim et al., 2014). More fundamentally, 
as Duster (2006:434) points out:
[I]t is possible to make arbitrary groupings of populations defined by geog-
raphy, language, self-identified faiths, other-identified physiognomy, and 
so on, and still find statistically significant allelic variations between those 
groupings. . . . When researchers claim to be able to assign people to groups 
based on allele frequency at a certain number of loci, they have chosen loci 
that show differences between the groups they are trying to distinguish.
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In other words, such groupings – even when they are social rather than 
biological – can be molecularized in the laboratory, and it is critical to under-
stand how and why scientists decide to define a population group in a specific 
way. Along similar lines, while one often hears that science and society are co-
produced, as Reardon (2011:327) suggests, “it is at the point of emergence, 
when actors are deciding how to recognize, name, investigate, and interpret new 
objects, that one can most easily view the ways in which scientific ideas and prac-
tices and societal arrangements come into being together.” For instance, in her 
analysis of the construction of populations using the latest “admixture” technol-
ogy, Fullwiley (2008:706) concludes:
It should be clear by now that the very continents and people chosen for 
this product [for ancestry determination] were selected due to their per-
ceived proximity to what we in North America imagined race to be. . . . In 
other words, the assumed bounded groups on which the AIMs draw (Afri-
can, European, Native American and Asian) correspond to American cultural 
ideas of race, which, in the case of many scientists, also ends up shaping 
where across the globe they collect the DNA of ‘populations.’
In her examination of the case of the “Quebec founder population” at a private 
genome research laboratory in Canada, Hinterberger (2012:82) demonstrates 
that “the emphasis on the homogeneity and purity of the Quebec founder popu-
lation . . . is laden with historical negotiations of racialized population mixing in 
the settlement of the new world.” Montoya (2007) examines how scientists used 
“Mexican” in genetic epidemiology of type 2 diabetes, demonstrating that the 
varied social and historical forces shaping the life histories of groups remain key 
elements in scientists’ decisions to use a particular category. He coins the term 
“bioethnic conscription” to highlight the point that genetic differences between 
ethnoracial groups bear not only descriptive but also attributive significance.
These groundbreaking studies – primarily carried out in North American 
contexts – show us the ways in which racial differences are constructed within 
human genome science. While they are attentive to the national and global con-
texts of the practice of science, few researchers have incorporated regional-level 
factors into their analysis, which is the emphasis of this chapter. Moreover, a con-
ventional idea distinguishes the notion of “race” from the notion of “ethnicity.” 
According to McIntyre (2011):
Race is a socially constructed attribute that is tied to beliefs about differences 
in the physical makeup of different individuals. Ethnicity is different. When 
most people speak of “ethnic differences,” they are referring specifically to 
cultural differences. Thus, ethnicity has to do with shared cultural heritage.
In this chapter, I have tried to show how “ethnicity” and race become equiva-
lent in the PASNP’s work, and that ethnicity was given genetic attributes due 
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simply to the fact that geneticists used it as their population sampling frame and 
a proxy for genetic diversity. It is in this context that we can say that a process of 
the molecular racialization of ethnicity has occurred.
Additionally, the eugenics movement of the late nineteenth and early twentieth 
centuries was seen by some scientific and political leaders as holding the key to 
future human progress. It was believed that the eugenic ideal could be pursued 
in two ways: by restricting the reproduction of persons believed to be of inferior 
genetic potential (negative eugenics) and, conversely, by encouraging individuals 
thought to possess desirable genetic characteristics to increase their fertility (posi-
tive eugenics) (Bittles and Chew, 1998). Hereditarian theory was the foundation 
of the eugenics movement in the United States that inspired ideals of “racial 
hygiene” in Nazi Germany (Proctor, 1988). To put it differently, one of the pos-
sible implications of treating racial or ethnic categories as if they were biologically 
or genetically determined categories is the elimination of socially or politically 
undesirable groups. In the (post-)genomic era, according to Duster (2003), “the 
front door to eugenics is closed,” but it may open again “under the guise of 
disease prevention policies.” In light of this concern, and to lower the chances of 
molecular science being used for inhumane political purposes, perhaps it is useful 
to remind ourselves that countries in Asia have, historically, had their own share 
of eugenic policies and practices. A succinct review in the cases of Japan, Korea, 
China, and India is provided in Appendix C.
Notes
 1 The three public holidays are: (1) Gwangbokjeol (Liberation Day of Korea); 
(2) Samiljeol, which celebrates Korea’s declaration of independence from Japan 
on March 1, 1919; (3) Hyeonchung-Il, a memorial day honoring those who died 
not only in military service but also in independence efforts.
 2 Aboriginal soldiers who were “Japanese” (nihonjin) during the war are collec-
tively enshrined in the Yasuguni, just like other Japanese soldiers. However, survi-
vors and their families continue to be denied the reparations and redress given to 
citizens of Japan, as they are no longer “Japanese.” In both the colonial and post-
colonial eras, culture (being “Japanese” or non-“Japanese”) continues to arbitrate 
and deny access to legal procedures and economic benefits.
 3 Korea’s own colonial government in Korea also imposed sōshi-kaimei in 1939–
1940, a policy of pressuring Koreans to adopt Japanese names.
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Introduction
Lurking just beneath the surface claim of molecular-based personalized medicine 
is the reality of racially and ethnically designated population-based drug develop-
ment in the context of a globalized pharmaceutical industry. In contrast to the 
previous chapter, in which the term “Asian” was deconstructed in the context 
of globalized genome science, the following pages reveal a scenario in which 
“Asian” and “Caucasian” are reinterpreted and injected with a heavy dose of 
genetic reification.
Before genome-based “personalized medicine” can be administered in clinical 
settings, the question of what shapes drug marketing and development needs to 
be addressed. Existing studies have shown that population groups can be strate-
gically appropriated by interested parties to the detriment of the health care of 
individuals designated as members of said groups. For example, Kahn argues that 
“the primary forces driving the re-invention of BiDil [a drug for treating heart 
failure] as an ethnic drug . . . were legal and commercial, rather than biomedical” 
(Kahn, 2004, 2013). Indeed, rather than receiving more affordable treatments, 
the targeted population found that costs increased (Sankar and Kahn, 2005).
While the case of BiDil is now relatively well known (Roberts 2011a, 2011b; 
Kahn 2013), how IRESSA (for treatment of non-small-cell lung cancer) became 
an Asian-focused drug has attracted less critical examination. We suggest that 
the case of IRESSA deserves a closer look, not least because it has been hailed 
as an exemplary case of personalized medicine. As noted in the European Sci-
ence Foundation publication Forward Look, health care professionals must “raise 
awareness of examples in which stratified approaches have already begun to be 
used effectively in the clinic as precursors of a wider vision of personalized medi-
cine” (European Science Foundation, 2012:15). “Drugs such as gefitinib and 
erlotinib, for instance, are being used to treat patients with non-small-cell lung 
cancer who have mutations in the epidermal growth factor receptor (EGFR)” 
(European Science Foundation, 2012:13).
Moreover, from 2005 to 2012, a global migration of clinical trials occurred 
(Drain, Robine, Holmes and Bassett, 2014). While the United States conducted 
the largest number of clinical trials (58,980, or 30 percent of all trials) during 
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this period, there was an absolute increase in the number of clinical trials con-
ducted outside of the United States, Canada, and Europe. Most significantly, 
“the absolute increase was greatest for the Asian region (489 percent)” (Drain 
et al., 2014:166).
Lung cancer has been the most common cancer worldwide for several dec-
ades1. In 2012, out of an estimated 14 million new cases of cancer worldwide2,3, 
13 percent were new lung cancer cases (approximately 1.8 million). In the 
United States alone, it was expected that there would be 224,210 new cases 
and 159,260 deaths from lung cancer in 20144. Lung cancer, classified as either 
non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC), is esti-
mated to be responsible for about one-fifth of deaths from cancer worldwide 
(approximately 1.59 million deaths)5. More than 80 percent of patients suffer 
from NSCLC6,7.
IRESSA is the trade name for gefitinib, marketed by AstraZeneca. The follow-
ing is from AstraZeneca’s website (2014):
IRESSA (gefitinib) is a once-daily 250 mg oral medication that targets 
and blocks the activity of the EGFR-TK, an enzyme that regulates intra-
cellular signalling pathways implicated in cancer cell proliferation and sur-
vival. . . . Studies have shown that tumours with an EGFR mutation are 
particularly sensitive to IRESSA. A mutation in the EGFR is a characteristic 
occurring in about 10–15 percent of non-small cell lung cancers (NSCLC) 
in Europe and around 30–40 percent in Asia. . . .
AstraZeneca secured regulatory approval for IRESSA in Japan in 2002. In the 
United States, IRESSA was first approved by the Food and Drug Administra-
tion (FDA) in May 2003, under accelerated approval regulations. Accelerated 
approval is granted on the condition that the manufacturer will continue testing 
the drug in clinical trials to demonstrate that it indeed provides a clinical benefit 
to patients.
Then, on June 17, 2005, the FDA disallowed the administration of IRESSA to 
new patients. This was because clinical trials did not show that IRESSA benefited 
patients, as noted on the US National Cancer Institute (NCI) website (2011):
The FDA has carefully reviewed data from two failed clinical studies of 
gefitinib, one of which was required by the agency as part of the drug’s 
accelerated approval. This trial enrolled patients with regionally advanced 
or metastatic NSCLC who had failed one or two prior treatment regimens. 
In this large study, 1,692 patients were given either gefitinib or [a] placebo. 
There was no significant survival benefit either in the overall study popula-
tion or in patients who had high levels of a surface marker called “EGFR.”
In the second trial in patients with stage III NSCLC, after completion of 
induction and consolidation chemotherapy and radiation therapy, patients 
were given either gefitinib or placebo maintenance therapy. No gefitinib sur-
vival benefit could be demonstrated.
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When these results were announced, the FDA began a review to assess whether 
the drug should be pulled from the market. However, when the data were reas-
sessed by race and ethnicity, scientists found that “Asians” had a 9.5 month pro-
longation of life on the medication, which was nearly double the 5.5 month 
average for the general population. AstraZeneca touted these findings as signifi-
cant and began marketing strategies and sales in Asian countries (Zamiska and 
Whalen, 2005).
Then, in 2009, researchers in Hong Kong, China, Thailand, Taiwan, and 
Japan conducted the IRESSA Pan-Asia study (IPASS), with participation from 
87 medical research centers in 9 Asian countries. The main findings of this 
study were: “Gefitinib [i.e. IRESSA] is superior to carboplatin-paclitaxel [i.e. 
chemotherapy] as an initial treatment for pulmonary adenocarcinoma [a type 
of lung cancer] among nonsmokers or former light smokers in East Asia. The 
presence in the tumour of a mutation of the EGFR gene is a strong predictor 
of a better outcome with gefitinib.” The IPASS results were subsequently pub-
lished in the prestigious medical journal The New England Journal of Medicine 
(Mok et al., 2009).
Partly as a result of this new study, the European Commission approved the 
marketing of IRESSA for EGFR-mutation-selected patients with non-small-cell 
lung cancer in July 2009. In 2010, Health Canada also approved IRESSA as a 
first-line treatment for locally advanced or metastatic non-small-cell lung cancer 
in patients positive for the EGFR mutation.
These regulatory approvals were landmark achievements for IRESSA, now seen 
as a first step toward personalized medicine in oncology. For instance, Hughes 
(2009:758) suggests that the success of IRESSA and the IPASS means that there 
is “a need for [pharmaceutical] companies to identify the right patients for tar-
geted therapies.” Mok et al. (2009) call the IPASS “a small step towards person-
alized medicine for non-small cell lung cancer,” further describing its importance 
as such:
Personalized medicine for NSCLC is now a reality. . . . [The] IPASS and 
three other randomized studies have confirmed higher tumour response 
rates, longer PFS, and less toxicity with EGFR TKI over empiric cytotoxic 
chemotherapy as first-line therapy for EGFR mutation-selected patients. 
This small step may eventually lead to a big leap towards personalized medi-
cine for NSCLC.
Part of what is striking about the changing fortunes of IRESSA is the drug’s 
troubled history in Japan; as of March 2010, there were 810 reported deaths due, 
allegedly, to adverse reactions to IRESSA. Patients and their bereaved families 
lodged lawsuits against AstraZeneca and the Japanese government for failing to 
include proper warnings about IRESSA’s serious side effects. The Osaka Dis-
trict Court ruled in favor of patients and their families in February 2011, but in 
May 2012 the Osaka Court of Appeals overturned this judgment and ruled in 
favor of AstraZeneca (The Pharma Letter, 2012).
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In addition to a closer examination of the IRESSA case, on a broader scale, 
we hope to contribute to a discussion of the question, whose interests are being 
served by pharmacogenomic and pharmacogenetic studies that focus on inter-
racial or inter-ethnic differences of drug responses? As mentioned in the intro-
ductory chapter, according to Daar and Singer (2005:241), we need to take into 
account not only differences between the genotypes of individuals, important as 
they are, but also differences in genotypes between different population groups. 
Moreover, Suarez-Kurtz (2008:337) writes that “pharmacogenomics’ concep-
tual development and praxis remain contingent upon a better understanding of 
human genomic diversity and its impact on drug pharmacokinetics and pharma-
codynamics. Ethnic specificity has become an integral part of pharmacogenetic/
pharmacogenomic research.”
Indeed, as Tate and Goldstein (2008) note, “there is no shortage of gene vari-
ants known to influence drug response that have substantial differences in fre-
quency among racial or ethnic groups.” That such differences are found should 
not surprise us, as noted in the introductory chapter. As Duster (2006:434) 
points out: “it is possible to make arbitrary groupings of populations defined 
by geography, language, self-identified faiths, other identified physiognomy and 
so on and still find statistically significant allelic variations between these group-
ings.” The key question is, why is there a strong interest in searching for such 
differences at the level of populations categorized by race and ethnicity?
Drawing on interviews with medical oncologists, we argue that such knowl-
edge regarding the distributions of genetic variants among ethnic or racially 
labeled groups is being pursued as a key coping strategy adopted by pharmaceu-
tical companies to deal with the high unpredictability of the success or failure of 
their often billion-dollar investments in drug development.
What is at stake? As Kahn (2013:234) points out:
The issue . . . is not whether commerce should affect biomedical research 
or practice, but what the proper balance between commerce and science 
is. . . . Certainly the choice of which drugs or diagnostics to develop has 
always been influenced by commercial considerations, but when commercial 
considerations affect not only the choice but the actual framing, interpretation, 
and presentation of scientific data, then something is wrong. Such has been 
the case, witting or not, with the distinctive rise of ‘ethnic’ biomedicine in a 
postgenomic era [emphasis mine].
In addition, Chin (2011) notes the internationalization of clinical trials and 
suggests that issues of cost, availability of patients, and quality of research results 
are the main factors driving this current trend. Our data and argument here 
complement Chin’s work by adding that, in so far as the increasing volume of 
clinical trials in Asia is concerned, the picture involves a particular (re)formulation 
of the American racial taxonomic system as adopted by the FDA in the United 
States, ambitions and policies of local governments, and an emerging sense of 
self-determination and assertion among scientists.
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Before turning to whether or not pharmaceutical companies stand to benefit 
from profiling (potential) patients racially and ethnically, it is important to first 
draw attention to the ways in which the genomics revolution is being felt by the 
pharmaceutical industry.
The first important theme emerging from the interview data, ironically, is that 
it is not in the apparent interests of pharmaceutical companies to develop drugs 
that are effective for patients with specific biomarkers, particularly when these 
markers may be only present in a small subset of the whole patient population – 
such subsets can be demarcated along biomarker lines and/or race and ethnicity 
lines.
There have been noted efforts by pharmaceutical companies to produce 
biomarker-based personalized medicine, in addition to “blockbuster” drugs (i.e. 
generic medicines for everyone). However, in general, the relationship between 
pharmaceutical companies and the making of drugs based on either biomarkers 
or racialized categories is neither simple nor straightforward.
As Dr. Hsu put it:
In fact, drug companies are the ones that are trying to resist all these [genetic] 
tests. Actually, even the drug company . . . [has] this dichotomy. The mar-
keting people . . . don’t want these tests, because the more you define the 
group to be narrower and narrower, fewer people buy the drug. So you’re 
actually reducing the market size. [For] example, the Erbitux. Erbitux used 
to be used for 100 percent of colon cancer. Since the KRAS testing came out, 
only 60 percent of [patients] will use [it]. Now [with] NRAS [testing] and 
all that, now only 42 percent will use [it]. So if there are more tests coming 
out, eventually maybe only 20 percent will use [it]. So the more tests you 
do, the fewer people will buy your drug, but that is from the marketing point 
of view.
The corporate headquarter[s], as well as the medical people, like to do the test, 
because it is the politically correct thing to do. And you cannot run away 
from the test, because the scientists will be asking to test them. The scientist 
will challenge you: I found this test in the lab, and I tested it in mice . . . can 
you show me data in human[s]? So drug companies are held [for] ransom, 
because they cannot avoid doing tests. . . .
Dr. Hsu continued:
Would the drug company purposely as a business strategy try to limit their use 
to a certain ethnic group? [W]hy would they? They wouldn’t. Unless, by 
not limiting it, other people get side effect[s]. . . . [T]hat’s a different story, 
because they are liable to be sued. But if the drug [is being used, but] is 
not very effective, they will say, bad luck. So I think drug companies, if pos-
sible, they like the drug to be used by everybody in the world. The wider 
the definition of usage, the better. No drug company wants to narrow its 
indication[s]. Everyone wants to widen the indication[s].
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Indeed, biomarkers affect the efficacy of the drugs, but these markers are not 
present in everyone. This fact poses a dilemma for pharmaceutical companies 
because the potential market size of the drug will be much smaller. Considering 
that pharmaceutical companies have to spend significant resources in research 
and development before a drug is approved, this could mean that the unit price 
of the drug will have to be increased in order to still make a significant return 
against a lower demand.
Not surprisingly, costs of cancer medications have steadily increased over 
recent years as human genome science has entered the drug development pro-
cess. According to Jackson and Sood (2011), in 1995 “the only widely used 
cancer drug that cost more than US$2,500 a month was paclitaxel. By contrast, 
many recently approved targeted drugs have entered the market priced at many 
times that amount, with more than 90 percent of anticancer agents approved 
by the FDA in the past four years costing more than US$20,000 for a twelve-
week course.” Similarly, Chiang and Million (2011:895) provide documenta-
tion that:
Prices of novel agents in the oncology space have steadily risen in the past 
decades. . . .The launches of Yervoy (Bristol-Myers Squibb) and Provenge 
(Dendreon) have grabbed headlines with prices of around $100,000 per year 
per patient. The pricing of oral oncolytics such as Tarceva, Gleevec, Xeloda, 
Sutent and Nexavar shows an average increase in price of over 76 percent 
since 2006. Pfizer has recently announced a $9,600 cost per month for 
Xalkori, in line with Roche/Plexxicon’s expected $9,400 cost per month 
for Zelboraf.
While drug companies are generally reluctant to produce racialized medicine 
because of the smaller market size noted above, there are commercial considera-
tions under which doing so makes sense, as the following section shows.
Saving IRESSA
This chapter suggests that pharmaceutical companies seem particularly prone 
to racialize clinical trials (and, therefore, to produce racialized medicine) in the 
aftermath of poor or irregular drug performance in large-scale clinical trials. As 
noted above, IRESSA was originally found to be of low efficacy when the trial 
was run against a standard sample in the United States. When a further analysis 
revealed that the “Asian” population in the sample was more responsive to the 
drug, the IPASS was initiated.
Dr. Hsu explained:
You know the story of IRESSA? IRESSA was approved before 2005, right? And 
later on was withdrawn because the drug wasn’t very effective. The drug was 
about to be buried, the company was suffering big-time. . . . So the only 
way to salvage it is the fact that they do see some occasional successes, and 
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therefore they decided to explore the Oriental slant to this one. So it’s not as 
if they willingly wanted to do the test. This test was needed to salvage a drug 
that was about to be buried, you see . . .
  But for a drug that works very well, and [the] FDA fully approve[d], [the] 
company will resist testing it, because the more they test, the smaller . . . the 
market size. But this drug was condemned by the US. If they don’t do the 
IPASS study, the drug usage will be zero. So the IPASS study . . . it’s des-
peration, they have no other choice – they don’t do the test, they’re gone. 
Alright, so, they were lucky that the Asia study turned out positive. So they 
were given a second lease o[n] life. Therefore, this strategy is very good, if you 
have a drug that is erratic in its outcome [emphasis mine].
More importantly, Dr. Yeh pointed out that the IPASS did not select patients 
based on genetic profile:
I think [the] IPASS . . . in its own merit is the first study which compared in a pop-
ulation study of non-smokers, and heavy smokers and light smokers . . . now 
they did not test for EGFR mutation prior to enrolling the patients onto the 
study. In other words they have no a priori knowledge of the genetic makeup of 
this group of patients. . . . So I would say that [the] IPASS did not . . . in a 
sense, impact personalized medicine in a genomic manner. Because you did 
not test a priori ahead of time for the EGFR mutation and select the patients 
for therapy [emphasis mine].
The IPASS selected patients and grouped them according to phenotypes 
instead of genetic markers, and only later did IPASS researchers establish genetic 
connections to its results.
Dr. Yeh continued:
They didn’t select [based on] genetic [makeup], they just selected based on clini-
cal phenotype. But, when they went back, retrospectively, to analyze the 
data, they found that those with EGFR positive have much higher responses!
Dr. Hsu made a similar observation:
A good example is [the] IPASS for Iressa. It was done in 2009, they never pre-
specify everyone must have EGFR, they specify the clinical profile8, knowing 
that within the profile, EGFR was common. That was already the perception 
then, but the [data] wasn’t strong enough . . . to say they were confident to 
restrict to the only EGFR positive patient. But, fortunately, the trial analysis 
showed that most of the patient[s] happened to have [the] EGFR mutation 
anyway, so it kind of fulfilled the criteria.
Eventually, it was discovered that responsiveness to the drug was linked to the 
EGFR mutation, which can also be found in different racial and ethnic popula-
tions, albeit at varying frequencies.
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Dr. Wu pointed out:
There was the pan Asian study . . . [that] only looked at Asian patients with ade-
nocarcinoma, and female[s] who [were] non-smokers. But that was because, 
in the earlier study, there was a hint that the benefit was only in this group. 
That’s why the trial did it in this group. After that they found that even 
among this group, it was not the group that mattered, but because EGFR 
mutations were more common among this group. So once you find the 
genetic cause . . . then the genetic variant is the determinant. . . . So it may 
be that, in Caucasians, this mutation is less common. But once you have it, 
it doesn’t matter that you’re Caucasian or Chinese, you will benefit equally. 
So the new trials are based on the EGFR mutation status [emphasis mine].
The underlying reason for the differences in drug efficacy should be explored 
rather than simply stopping at an ethnicity-based explanation, as Dr. Deng 
suggested:
We accept that there may be ethnic differences, but we need to find what is the 
basis of th[ose] differences. So once you have that basis . . . be it a polymor-
phism from genetic testing . . . then that should be the subsequent strategy 
in terms of ensuring that it can be extended to the broader population and 
not just based on ethnicity.
Indeed, as Wilson et al. (2001) point out, “it is well known that there are 
inter-ethnic differences in DME [Drug Metabolizing Enzyme] allele frequencies 
and thus in drug response. . . . Not only can these [genetically inferred] clusters 
be derived in the absence of knowledge about ethnicity (or geographic origin), 
but they are also more informative than commonly used ethnic labels.” With 
respect to EGFR mutation status and targeted therapies, Saijo (2013:6) notes: 
“all four of these trials [conducted in Japan, Korea, China, and Europe] pro-
duced similar results, suggesting that the biological character of EGFR mutated 
NSCLC was similar in East Asians and Caucasians despite differences in mutation 
frequencies.”
If we are moving into an era of molecular biomarker-based drug development, 
this would seem to mean that categories of race and ethnicity have decreasing 
relevance. To what extent should one treat the IRESSA case as a single isolated 
case, an exceptional misuse of race?
In the following section, I present interview data to suggest that IRESSA is not 
an isolated case; rather, identifying somatic mutation patterns among racial and 
ethnic groups has become embedded in the pharmaceutical industry’s routine 
practices. To begin with, the US FDA published the Demographic Rule (CFR 
314.50 d(5)) in 1998 and a guidance document in 2005 on collection of race 
and ethnicity data in clinical trials9. Standard ethnic categories, as recommended 
by the Office of Management and Budget and followed by the FDA, are “His-
panic/Latino” and “Not Hispanic/Latino.” For race, the minimum categories 
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recommended are American Indian/Alaska Native, Asian, black or African Amer-
ican, native Hawaiian or other Pacific Islander, and white.
At the same time, there has been rapid growth in international clinical tri-
als. While the United States still has the largest proportion of clinical trials, it 
is facing slower growth. The largest proportion of non-US clinical trials is in 
Western Europe, and Asia has experienced the greatest absolute increase. Specifi-
cally, while previously confined to in and around the United States, as of 2008, 
according to Chin (2011): “80 percent of marketing application for drugs and 
biologicals approved by the US Food and Drug Administration contained data 
from US clinical trials conducted outside the USA.”
According to yet another report cited above, “over the 2005–2012 period 
overall, 127,314 (67 percent) of 189,213 registered trials were conducted in 
the United States, Canada or Europe” (Drain et al, 2014:166). “The United 
States was the single largest country conducting clinical trials, with 58,980 
(30 percent). The absolute increase was greatest for the Asian region (489 per-
cent) and the Latin American/Caribbean region (112 percent); the smallest 
increase occurred in the North American region (9 percent)” (Drain et al, 
2014:166).
Why has the Asian region experienced such a dramatic increase in its share of 
clinical trials? While the answer is certainly complex, part of it lies in the broader 
significance of the IRESSA case and the particular way in which the “Asian” cat-
egory in the FDA regulations has been redefined and reified at the transnational 
level.
The larger significance of the story of IRESSA
While scholars have established and articulated the lengthy historical and politi-
cal processes of racial formation in the United States (Omi and Winant, 2015), 
which include the creation and particular understanding of the “Asian” category, 
in this transnational setting, “Asian” is formulated as a geographically based con-
cept. Drs. Yeh and Hu discussed this formulation in terms of IRESSA:
INTERVIEWER: Why is it important to conduct clinical trials in Asia?
DR. YEH: Even if the disease looks very similar, for example, lung cancer, in 
Asians, the percentage of EGFR mutation is about 30 percent. And in the 
West, it’s three times less. . . . So, sometimes, if you study in the West, 
you may miss something. For example, [when] IRESSA [was] initially devel-
oped in the West, they did a phase III study, [and] found that [results were] 
negative. Didn’t find it to be beneficial. So, [the] FDA actually reversed the 
approval, but subsequently this drug [was] tested in [an] Asian population. 
Then found that . . . by selecting the appropriate characteristics . . . that time 
we still didn’t know[whether] it’s due to EGFR mutation. Those with Asian 
phenotype, non-smoker, Adenocarcinoma, this group of patients tend to benefit. 
That subsequently led us to know [that] it’s EGFR mutation. So, because 
of the different incidence of the tumour subtypes, treating it in one country 
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doesn’t necessarily [indicate that] you’ll get the same result in another coun-
try, so that’s another reason why you need to do clinical trials in Asia.
DR. HSU: I must say that the IRESSA, probably is the landmark drug that 
change[d] the way the world views Asian trials. Because until the IPASS data 
came out in 2009, nobody believed our data, but the data is so convincing 
that now people understand – any time they talk about oral TKI [tyrosine 
kinase inhibitor] for lung [cancer], they better believe Eastern data, because 
we know what we’re doing. Right, so there is a trend.
The interchangeability of the usage of “Asian” and “human subjects in Asia” 
is significant because it serves as an example of how the pharmaceutical indus-
try is biologizing geographically based social groupings for the sake of pro-
tecting commercial interests. Moreover, drug development is a risky business. 
While it has almost always been the case that major pharmaceutical companies 
seek approval by the US FDA, there has been a noted divergence of research 
and development spending and new product approvals by the FDA in the 
genomic era. That is, since the human genome was sequenced a decade ago, 
the number of compounds in development has increased 62 percent, and total 
research and development expenditures have doubled. Yet, the average num-
ber of new drugs approved by the US FDA per year has declined since the 
1990s. Hay et al. (2014:41) find that “approximately one in ten (10.4 percent, 
n = 5,820) of all indication development paths in phase I were approved by 
[the] FDA.” When only the lead indication was used in the study, they found 
“nearly a one-in-six (15.3 percent) probability [that] a drug will advance from 
phase I to FDA.”
It is in this context that the success of the IPASS study has been understood, as 
Drs. Wang and Zhao pointed out.
DR. WANG: . . . they [the drug companies] don’t want to miss a situation like 
IRESSA again. Because it means a huge thing to them. It’s either you get 
drug registered or drug not registered. So they’re all here in Asia.
DR. ZHAO: There’s two factors: one is that there’s all [of these] EGFR results and 
so forth, showing that if you don’t test in Asians, your drug may fail . . . so 
that’s why a lot of the drug companies are coming down here, because they 
may be able to find successful drugs here, that they couldn’t find in Western 
populations . . . because the Western population did not have the frequency 
that was suitable for having enough numbers for the drug to be successful.
Differentiating by disease types, Hay et al. (2014:43) found that oncology 
drugs had the lowest likelihood of approval. Specifically:
[U]nfortunately, in oncology, when all indications are considered, only 
around 1 in 15 drugs entering clinical development in phase I achieves FDA 
approval compared with close to 1 in 8 using the lead indication methodol-
ogy . . . using the lead indication methodology to determine success rates, 
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the scope of the challenge in oncology drug development would be dramati-
cally underestimated.
By turning the concept of the “Asian” from a geographically based concept 
into a biomedically relevant object, drug companies are not only better posi-
tioned to win regulatory approval(s), but also stand a greater chance of gaining 
access to overseas markets. Indeed, the “Asian” market is perceived as a significant 
one, as Drs. Lin, Zhao, and Wang point out:
DR. LIN: If you’re [a] pharmaceutical company, you develop a drug, [and] you 
want your drug to be widely used. And for years, they’ve not come to Asia. 
They don’t care if you Asians have a different profile, okay? Because [the] big 
market is [the] US and Europe. Nowadays, they know where the market is.
DR. ZHAO: . . . now, cancer, for example, half the world’s burden is actually in 
Asia, and you know, China and India [are] huge markets. So the pharmaceu-
tical companies have got two big reasons to come down here. In fact, from 
what I hear . . . now, the major growth is in Asia, from Asia[n] markets, so 
they’ll be very foolish not to engage in Asia.
DR. WANG: Why do you think they are all here in Asia? For several reasons. One, 
all the patients are here in Asia. Asia [ha]s a huge population. Like 3 billion 
people in Asia. So the patients are here.
Most certainly, it is not only the size of the market (understood in a racial and 
ethnic manner) but also the perceived consumption power of potential patients 
that matters in the decision-making of the pharmaceutical company. That is to 
say, the interest in developing drugs that are effective on biomarkers that are 
more prevalent in the “Asian” population is linked to the rising affluence of some 
people in Asia, as indicated by Dr. Hsu:
They [the pharmaceutical companies] think that Asian[s] [represent] a big popu-
lation, so [for example] the Chinese . . . they [the companies] think of the 
1.3 billion people, straightaway their eyes open big, because they think that, 
oh, suddenly you’ve got a big population to capture.
Dr. Tang made a similar observation:
INTERVIEWER: Why do pharmaceutical companies come all the way to Asia?
DR. TANG: The “Asian” population is still more in this part of the world. And 
the other thing is that that they would want the oncologist treating the 
patients to be familiar with the drugs. So by participating in clinical trials, 
you become familiar with the drugs so when the drugs get approved, they 
are more likely to continue to use the drug. So, it serves [a] dual purpose.
Conversely, when the biomarkers are present in populations that cannot afford 
the drug, the company may have less interest in developing the drugs for these 
populations.
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Racializing clinical trials as a routine phenomenon
Even in the “new” biomarker-based drug development paradigm, it remains true 
that pharmaceutical companies have to channel their research and development 
efforts to areas where positive outcomes are likely. Moreover, one of the ways in 
which companies try to predict success is to rely on the frequency of a particular 
mutation “enriched” in certain racial and ethnic populations, as indicated by 
Dr. Tang:
Drug companies when they plan their trials, they are given a budget. So they, 
at least, [at] the start of every budget year, they have to plan how are they 
going to use the budget, so having all the knowledge about demography and 
incidence is very helpful for them in planning their budgets and in allocating 
budget[s] to run clinical trials in particular parts of the world.
. . . let’s say a drug that is effective against a particular genomic alteration, it 
will go to the place where this problem is prevalent and it will approach the 
center where they see [the] most of such patients. Like for instance . . . they 
have been focusing on East Asians when they come to EGFR TKI.
Indeed, as Saijo (2013) points out: “70 percent of patients in the LUX-
LUNG3 global trial for afatinib [an EGFR TKI drug] are East Asian.” How do 
we understand the choice of centers – including those in Hong Kong, China, 
Indonesia, Japan, Malaysia, the Philippines, Singapore, Taiwan, and Thailand – in 
the IPASS? Dr. Tang continued:
They [pharmaceutical companies] are picky. When they want to come to conduct 
the clinical trials, they want to make sure that the center can deliver because 
to conduct clinical trials is very expensive. So first of all they want to make 
sure that whatever research protocol they have, that the center is capable of 
being compliant with the protocol to the letter. [This] [m]eans that it must 
be conducted in accordance [with] GCP [Good Clinical Practice]. . . .
Initially, there are only a few centers that are, that are of standard for phase I 
study, like in Korea, Taiwan, Hong Kong, Singapore, these are the four main 
ones. . . . And [for] any drug that is registered in Japan [the trials] must be 
done in Japan. So Japan is always considered separately. But Japan is also 
very advanced in doing phase I work. So these are the few Asian centers that 
drug companies will approach. . . . [For] phase III, they are usually a bit 
more lenient, [and] they will approach centers that will be able to just give 
the patients treatment, monitor for response, make sure [of] their survival, 
follow up. The patients are compliant to follow up. . . . [These] phase III 
trials usually, they can conduct in countries like Thailand, Philippines, maybe 
Indonesia, Malaysia.
However, the question remains, what boundaries are used to define East 
Asians? Are patients in these countries considered East Asians? For example, the 
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IPASS results suggest that “[g]efitinib [i.e. IRESSA] is superior to carboplatin-
paclitaxel [i.e. chemotherapy] as an initial treatment for pulmonary adenocarci-
noma [i.e. a type of lung cancer] among non-smokers or former light smokers in 
East Asia” (Mok et al., 2009:947). Dr. Tang clarified:
East Asians [are] basically ethnic Chinese or Malay. Indian is not considered East 
Asian. [Interviewer: Why?] [P]eople tend to associate . . . Indians more with 
[the] Caucasian group. [Interviewer: Why?] I think . . . there is a[n] SNP 
consortium called the HapMap consortium. The HapMap, I think, will tell 
you the basis for defining the populations as such.
In other words, while the claim was made about the suitability of the drug for 
patients in a particular geographical area (i.e. East Asia), upon closer examina-
tion, the reference is to the ethnic, or non-Indian, patients.
Dr. Deng commented that, in general, certain ethnic groups may be left out 
of clinical trials:
So in the drug development phase . . . [in which] your trial is very much in a 
fragile space and the successes and failures are determined by those trials, you 
want to maximize the chances of success. How you do that, you may have 
to resort to excluding certain ethnic populations that you know will actually 
dilute . . . your results.
More significantly, such racial and ethnic profiling of human genetic varia-
tion in the drug development process is unlikely to be explicit, as Dr. Zhao and 
Dr. Hsu pointed out:
DR. ZHAO: There are so many people very sensitive about racial profiling and 
ethnicity that I think the smart way to approach it is to really say it’s about 
molecular alteration that is more frequent in Asians, rather than, you know, 
designed specifically for Asians.
DR. HSU: I find it politically a bit sensitive to really launch a trial to specify the 
ethnic group. I think that would be difficult. But so what they do is, they 
would report the ethnic distribution, in the results, and they will have a sub-
set analysis based on the subgroup. But you can’t exclude them from enter-
ing the trial in the first place.
Local transformations
As indicated above, to gain regulatory approval, a drug has to demonstrate a 
certain level of efficacy. If a drug’s efficacy is linked to biomarkers that are preva-
lent only in certain populations, pharmaceutical companies will channel research 
resources to those populations in order to demonstrate higher efficacy. Thus far, 
we have tried to suggest that (re)formulations of racialized populations allow 
powerful pharmaceutical companies trying to win approval of regulatory agencies 
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in developed countries to move their clinical trials seamlessly into developing 
countries and to enter markets there.
At the same time, the greater rate of increase for trials in Asia is about not only 
the strategies adopted by companies motivated by economic profits, but also 
the pursuit of genomic research in developing countries. Indeed, if developing 
countries do not have necessary infrastructure or credibility, pharmaceutical com-
panies will not be able to set up clinical trials in those locations.
In leading countries like Singapore, infrastructure and technology for clinical 
trials, as well as the expertise of researchers, have vastly improved. Decades ago, 
there was minimal research in drug development in most, if not all, of Asia. As 
Dr. Zhang indicated, the research he conducted then was merely data collection, 
with little analysis:
Twenty years ago, all [of this] research [was] done in the west. There was hardly 
any research done here, over this part of the world. When I was a trainee, 
when we [saw] research, research basically means that the drug companies 
come to you and say, “I need 30 patients in Singapore, can you get me 30 
patients?” So, my function is no different from a vendor that suppl[ies] lab 
mice. I will just get patients and all I did was to collect data. The drug com-
panies will come and analyze for me, and put it in a pool of 600 patients – a 
few from Hong Kong, a few from Malaysia, a few from Indonesia. My job 
and that is called research. That was those days.
However, the situation has changed. The Singapore government, for exam-
ple, has invested millions in pharmaceuticals and biotechnology, including setting 
up infrastructure, training professionals, and even coordinating partnerships. In 
fact, according to the Singapore Economic Board, “Singapore has committed 
S$16.1 billion in continued support of research, innovation and enterprise activi-
ties between 2011 and 201510.” Researchers themselves have noted vast improve-
ments, as Dr. Zhang and Dr. Neo put it:
DR. ZHANG: Today, it is different. They come to us and our lab will do all the 
genetic analysis. Our lab will tell them . . . , “there is this particular gene that 
we can target with that molecule.” And then using that kind of basic knowl-
edge, we translate that into clinical practice. So that is called translational med-
icine. So now . . . , drug companies are more interested in doing this. This is an 
untapped field. In the past, that w[ould] be done in the Caucasian population.
DR. NEO: I don’t think it is true that drug companies were not interested in us. 
I think you know it is by and large in a way where the infrastructure is for 
them to do the trials. . . . And now that you see that our infrastructure has 
improved, our science has improved to the level where they’re confident that 
we’re doing things the right way. . . . I actually think that they [we]re always 
interested; it is just that now . . . they can do those studies.
DR. TANG: So Singapore, we do participate in all three phases. . . . If the center 
is deemed capable of participating in phase I, it means that the center has 
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advanced infrastructure. So if a country is labeled as up to phase I standard, 
the country should be proud of their country.
In addition to the ambitions and policies of local governments, there is an 
emerging sense of self-determination and assertion among scientists, as Drs. Hsu, 
Lin, and Teo described:
DR. HSU: So what the Western world like[s] to do is to do trial in the West, but 
ask . . . the Asian people to accept the trial data based on that. But Asian 
people now are stronger, they’re becoming more self-assertive. So they will 
say why do I accept your data? I repeat the trial here to see how it goes, 
you see.
DR. LIN: Things have changed. Because China, Korea, Japan, they’re getting more 
powerful, they also want to have their own results and trials.
DR. TEO: In fact, [the drug] Sorafenib came out from two very famous studies. 
One is the SHARP trial from Spain. And the other one is Professor Ann-Lii 
Cheng’s study from Tai Da [i.e. the National Taiwan University] . . . the 
two big studies managed to convince the FDA that this is the drug for liver 
cancer. Okay?
The FDA said “Well, you know you did this Spanish trial [i.e. the SHARP trial], 
it’s really cool and you showed that Sorafenib works better. But I don’t buy 
that story in Asia. None of the Asian oncologists bought that story when we 
had our advisory board meeting. The reason is because we think Asian liver 
cancers are genetically different. . . .
So Bayer was very clever. Bayer is the company that basically has the drug 
Sorafenib. They say “let’s do an Asian study.” And Professor Ann-Li Cheng, 
was the Principal Investigator and so they ran it and it had exactly the same 
results. Because they had exactly the same results, they [i.e. the Asian oncolo-
gists] said “we think this’s gonna be fine.” The FDA approved it.
In sum, while the increase in clinical trials conducted in Asia is primarily a func-
tion of global pharmaceutical companies trying to earn more profits (Asia is a big 
market, and rising affluence of patients in Asia allows them to purchase drugs), 
other cultural, political, and social forces – such as improved infrastructure, tech-
nology, and expertise, coupled with a sense of emerging pride among scientists 
and observed phenotypes – are also contributing factors.
Pharmacogenomics, race, and post-marketing  
clinical trials
Given financial interests, the pharmaceutical companies are less driven to thor-
oughly examine potential adverse drug reactions than to establish drug efficacy, 
particularly during the post-marketing phase. However, they are required to do 
so. Phase IV studies are conducted after a drug or treatment has been marketed 
to gather information on its effectiveness and any side effects associated with 
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long-term use. Those studies are mandated by the regulatory authority to be 
conducted in real world conditions – observational, non-interventional trials in 
a naturalistic setting (as opposed to pre-marketing randomized controlled trials 
[RCT] for Phase I–III) – are called post-marketing surveillance (PMS) studies. 
Results from such studies can possibly reveal rare adverse reactions that might not 
have been detected in earlier clinical trials. In turn, this informs decision-making 
on whether, for instance, there is a need to conduct further controlled studies; 
make labeling changes with a modified undesirable effects section, indications, 
and/or dosing schedules; and/or regulatory action (boxed warning, risk minimi-
zation action plan, withdrawal).
This section analyzes the ways in which categories of race and ethnicity penetrate 
pharmacogenomic studies of cancer drug toxicity, typically adopting comparisons 
between “Asians” and “Caucasians” in the context of Phase IV clinical trials.
To begin, in contrast to pharmacogenomic studies of drug efficacies that 
mostly rely on a better understanding of somatic mutations, pharmacogenomic 
studies of drug toxicities typically involve examining germline genetic variants 
for adverse drug reactions. Regardless of whether a study concerns somatic or 
germline mutations, pharmaceutical companies seem consistently interested in 
obtaining data on racialized differences. For example, in the public online data-
base ClinicalTrials.gov, an ongoing trial is titled “Verification of a Pharmacoge-
netic Approach to Customizing Chemotherapy to Asians.” There, we see the 
following (U.S. National Institutes of Health, 2013):
Recently, based on meta-analysis of studies on germline pharmacogenetic 
variant frequencies and clinical trials, the investigators found that chemo-
therapy outcomes between Asian and Caucasian colorectal cancer (CRC) 
patients could potentially be inferred from the frequencies of variants 
between the ethnic groups and their respective biological functions. In this 
study, the investigators seek to further clarify the validity of using pharma-
cogenetic variants to customize chemotherapy between ethnicities through 
the following specific aims[:] (1) to verify the differences observed in the 
frequency of germline pharmacogenetic variants related to chemotherapy 
between Asian and Caucasian CRC patients and (2) to test whether varia-
tions in the frequency of somatic pharmacogenetic gene mutations between 
Asian and Caucasian CRC patients could be used to infer differences in clini-
cal outcomes between the two ethnicities.
In the clinical trial cited above, it is noted that “samples will be obtained from the 
Tissue Repository, National University Hospital, St. John of God Hospital, Perth, 
Australia and Kanazawa University, Japan.” Earlier, in collaboration with Astra-
Zeneca, Lee et al. (2005) carried out a clinical study in Singapore to examine rosu-
vastatin pharmacokinetics and pharmacogenetics in white and Asian subjects, and 
the results were published in the journal Clinical Pharmacology and Therapeutics.
Drugs approved by the US FDA are routinely sold in countries other than the 
United States. Racial politics in the drug development phase – demonstrated 
to be highly problematic in medical sociologist Steven Epstein’s Inclusion: The 
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Politics of Difference in Medical Research (2007) – have now migrated transna-
tionally through racialized trials outside of the United States. Specifically, we 
found that studies of drug toxicities conducted outside of the United States are 
typically framed in relation to the lack of minority group participants in US bio-
medical research. For example, Ling and Lee (2011) note that “data is often 
extrapolated from landmark studies generated from Caucasian patients to Asian 
populations for clinical use, which may not be relevant for some drugs.” Similarly, 
in a study of the cost-effectiveness of HLA-B*1502 genotyping in adult patients, 
the authors note that “the effectiveness data are from clinical trials in Caucasian 
populations” (Dong, Sung and Finkelstein., 2012:1259), thus uncritically adopt-
ing the existing racialized framework in justifying the need for further studies of 
the usage of carbamazepine and HLA-B*1502.
However, while a heightened awareness of a lack of minority group participants 
during the drug development phase may be the rhetorical frame through which 
the existence of racialized clinical trials is justified (i.e. by adopting the categories 
of “Caucasian” versus “non-Caucasian”), this is not the full story. The interview 
data also reveal that, sometimes, researchers emphasize the “Asian-ness” of their 
work in order to distinguish themselves from researchers in other parts of the 
world. Scientists and clinician-scientists need to show the uniqueness of their work 
in a highly competitive scientific community, as observed by Dr. Chong:
You know, you sort of have to invent for yourself, a niche, right? I mean, you 
can’t be fighting with the big boys in researching colorectal cancer or breast 
cancer and everything. . . . You’ll be trashed, instantly, you know. So what 
can you do that is very niche? [Something] no one else is interested [in 
doing], and yet seems to be potentially useful? So how do Singaporeans, or 
how do Southeast Asians, or Asians respond to a certain drug, and are their 
genotypes different? You know, so it’s very common, it’s very very common, 
but I think a lot of it just seems to be good for churning out papers, and 
getting grants, you know. . . .
Considering that Singapore is a small country, and as a way of capitalizing 
on its ethnic diversity, some researchers frame their Singapore-based studies as 
“Asian” in order to boost their significance. Dr. Paul Lin commented:
Sometimes when your paper says . . . “Asian Population Study,” it sounds better 
than “Singapore Population Study.”
Adopting an Asian-Caucasian frame in one’s human genetics research agenda 
requires a definition of “Asians” and “Caucasians.” As the interview data reveal, 
there are several ways in which such categorization and identification can be done.
Who is Asian?
Geographically, Asia (if it can be unambiguously defined at all) is such a broad 
region that it would be difficult, if not prohibitive, for a research project to take 
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a randomized sample that would be truly representative. In practice, researchers 
may simply use the prevailing ethnic classification in their societies to make a 
claim about “Asians.” For example, Singapore-based researchers place Chinese, 
Malays, and migrants from the Indian subcontinent in the Asian category, as 
Dr. Zhang succinctly pointed out:
DR. ZHANG: Okay, our “Asian” probably refers to Chinese, Indian, and Malay.
INTERVIEWER: So if a Caucasian lives in Singapore, which is part of Asia, he/
she is not Asian?
DR. ZHANG: [He/she]’s not Asian.
At the same time, researchers have pointed out the difficulties of defining 
“Asia” or “Asian.” For instance, Dr. Lin discussed this in relation to the defini-
tion of “Asian” in the IPASS:
Asia is so complex! I tried to write up this thing on Asian breast cancer 
patients. . . . [T]rying to define Asia is just a problem [including such matters 
as [w]hether you include India and Pakistan]. . . .
If we go and look at the study of, let’s say, “Asian” patients, for example. Why 
do they call themselves Asian? [An] IPASS study says “Asian patient.” So, 
[in the] IPASS report . . . did they self-report ethnicity? Were they tested for 
certain genes that made sure they are Asians? Or is it just because they hap-
pened to be living there?
Asia is also conveniently delineated by political boundaries (i.e. identifying an 
entire state to be in Asia or otherwise). But, even so, the category can become 
ambiguous and debatable when it comes to states at the edges of the region. As 
Dr. Huang put it:
. . . so anything that is 6 hours flight from here [Singapore] . . .
. . . I mean I think that the easy ones are easy. Thailand is Asia. South Korea is 
Asia, then you get . . .
. . . I would consider Japan Asia . . . maybe not South-East Asia. So . . . I would 
say anything that’s not Western Europe or North America. . . .
Is Russia Asia or not? That becomes a bit of a blurry line. So it’s a, it’s a nice title 
to have [for a scientific paper presentation]? . . . But obviously, where does 
Asia end? Is Australia part of Asia, I don’t know [laughs].
Moreover, diasporic communities create additional complexities for the defini-
tion, as Dr. Rajaratnam put it:
If you tell me [about] “American Asians,” I am also very skeptical. Because Asians 
from the West, they may be mixed blood. They may have intermarriages with 
other ethnicities, Caucasians, Africans. . . . They may have so many different com-
binations of generations, belonging to different ethnic populations involved, so 
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it is very difficult. That is one reason why when you look at the data, sometimes 
originating from the west, [for] just Asians, recruited in the west, [compared to] 
the pure Asians from our side, you can see [genetic] differences. Because they 
have a lot of intermarriages but they classify themselves as Asians.
Finally, inter-ethnic marriages are routinely seen as complicating the picture of 
who is Asian, as Dr. Lin pointed out:
[S]ome of the patients [have a] Chinese father, Caucasian mother, or vice versa. 
[In] what ethnic group do you place them?
INTERVIEWER: I don’t know.
DR. LIN: Ya! Exactly! That’s the problem! When you’re trying to categorize like 
this, aren’t you . . . it is frustrating! Because you are categorizing things that 
are not categorizable neatly, you see?
Who is Caucasian?
Turning our attention to the categorization of “Caucasian,” we see that this term 
is demonstrably fluid and arbitrary. Figure 3.1 illustrates an advertisement call for 
“Caucasian” trial subjects in Singapore.
Sometimes, it can be geographically defined, other times it is preconceived 
racial thinking, and still other times it can be based on Singapore’s National Reg-
istration Identity Card (NRIC), as garnered from interview data:
INTERVIEWER: The next question is, what’s the definition of Caucasian?
DR. ZHAO: Well, I think in this sort of study done in Asia . . . I think it’s just basi-
cally anybody from European heritage or American heritage.
INTERVIEWER: What about Europeans?
DR. TANG: Those that are in Europe. Australians are considered to be of European 
descent. . . . [U]sually, it’s more of the racial thing rather than the geography.
INTERVIEWER: How [are] Western European[s] different?
DR. TANG: Caucasian appearance.
INTERVIEWER: Not location based?
DR. TANG: No. Like Chinese migrants who migrate to Europe or US will not 
be considered . . . Western European. They will still be called East Asian in 
[terms of] their ethnicity.
“Defining” Asians or Caucasians is different from “identifying” them as such. 
What are the ways in which identification may be done? In Singapore, it can 
be based on patients’ self-identification, sometimes followed by the physician’s 
checking it against their NRICs:
INTERVIEWER: So for this paper, the first paper, that’s the latest, can you share 
with us how you identify a healthy individual as a Chinese, Indian, Malay, or 
Caucasian[?]
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Figure 3.1  A poster revealing how clinical trials are sometimes racialized through 
seeking targeted participants by race.
DR. RAJARATNAM: By verbal. Verbally asking them, and by their IC [i.e. NRIC]. 
Because that is their national identification. So that’s the only proof we have.
INTERVIEWER: When you say verbal, do you mean you ask the human subject to 
fill in a questionnaire?
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DR. RAJARATNAM: Not really a questionnaire. We call it a “patient informa-
tion and consent” form. We have . . . patient information telling them 
what . . . this study [is] about, [and] that will be followed by a consent form 
where the patients will sign and their clinician and the witness will sign. If 
the patient is unable to give consent, then normally his relative or next of kin 
will agree and will decide also.
INTERVIEWER: In other words it’s already protocol; there is a protocol to follow?
DR. RAJARATNAM: Yes.
INTERVIEWER: And then you ask, just to confirm, two generations right? You ask 
the parents and grandparents?
DR. RAJARATNAM: Yes.
INTERVIEWER: What about patient? That was for healthy patients, right, [the] 
normal healthy population? How do you know . . . the ethnic background 
of patients?
DR. RAJARATNAM: Similar method.
INTERVIEWER: Why do you need to verify their self- reported ethnic identifica-
tion with their IC card?
DR. RAJARATNAM: Because . . . the name, and I think the race is written there. 
Ya, because that’s their national registry, that’s what they are supposed to be. 
I mean . . . their ethnic identification is stated there. We presume that that’s 
what they are.
However, ethnic identification on the NRIC is not limited to “Chinese,” 
“Malay,” “Indian,” and “Eurasian.” In total, there are currently 95 races (inclu-
sive of the four mentioned) under which Singapore citizens can choose to be clas-
sified. Although the “Chinese,” “Malays,” and “Indians” constitute the majority 
(99 percent), the remaining one percent is constituted mostly of Eurasians and 
Arabs (0.6 percent in combination), followed by a distribution of the remaining 
90 races (0.4 percent). Typically, a citizen’s race follows that of his or her father, 
but can be registered differently if he or she is of mixed parentage (e.g. a child 
of Chinese and European descent can be registered “Chinese,” “European,” or 
“Eurasian”).
In January 2010, it was announced in the Parliament that the registration of 
overlapping and mixed-race options for Singaporean children born to parents of 
different races would be implemented. For couples of inter-ethnic marriages, in 
addition to the existing options of choosing only one of the two different races 
for their children, they would now be able to choose to reflect both. For instance, 
if a child is of Chinese and Indian descent, his or her race can be recorded as 
“Chinese,” “Indian,” “Chinese-Indian,” or “Indian-Chinese.” This policy sub-
sequently came into effect in January 2011. The government has explained that 
such added flexibility of registering race is consistent with the continual review 
of policies in order to recognize and respond to the evolving social landscape in 
Singapore.
Identifying a person as Asian or Caucasian can be arbitrary. As Dr. Rajaratnam 
suggests, for instance, in the Singapore context, a patient would self-report his or 
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her race followed by a verification of this information against his or her ID card. 
The information provided would be assumed to be accurate. However, patients’ 
identifications or races are not as straightforward as they seem, particularly for 
those of mixed parentage, as it is left to parents’ arbitrary choosing of whether 
their child should be identified by their father’s or mother’s race.
If the study involves international collaboration, then the identification can 
become even more challenging. Dr. Rajaratnam explained:
One thing I am very careful of is with Indonesians. Indonesians, they may 
have Malay names, but they can be Chinese, they can be Indians. But all of 
them, their names are Malay, you know. So I am very careful.
I am very careful, unless I can get at least two people to verify for sure that 
that person, that Indonesian is a Chinese or Malay, [and same for verifying] 
Caucasians also. . . .
As the interview data indicate, such identification can also be based on the 
patient’s physical appearance in the eyes of the physician or on other witness 
accounts based on local understanding. Other times, it can also be based on the 
words of an international collaborator:
INTERVIEWER: How do researchers know whether the person is Caucasian?
DR. POH: Because one of my colleges is from Germany . . . and he gave us sam-
ples. Normal German, Caucasians. . . . They tell us.
Thus far, we have highlighted the socially fluid definition and identification of 
“Asians” and “Caucasians.” It is worth reiterating that such fluidity, in itself, is 
not a problem; it becomes problematic, however, because racial categories can be 
used to frame medical research and can potentially influence clinical practices, as 
the following comments by Dr. Yuan, regarding linking ethnicity to research on 
drug toxicity, illustrated:
One of the key drugs in lung cancer treatment is . . . Docetaxel. And we in 
Singapore are the first group to show that Docetaxel stays in the system in 
Orientals much longer than [in] Caucasians. So, if I inject the same dose of 
Docetaxel in [an] Oriental versus a Caucasian, the Caucasian clears the drug 
much faster. . . . The bulk of the Caucasians of course came from Australia. 
We supplied the bulk of the Asians.
And Dr. Lin explained how ethnicity is related to clinical decisions:
DR. LIN: I generally would know [that] you are Asian, right? [Since] you speak 
with little bit of [an] American accent, but you are [of] Asian descent, if 
I were using Taxotere, I would be a bit careful with the dosing, check your 
blood count. Whereas if you are sitting here, Caucasian, then I generally 
would think that you might respond to a higher dose of the drug and so 
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on. BUT, but this is not absolute. This is . . . generalized, so I suspect. But 
I can’t be absolutely sure, just because you look Asian that you [are]. . . .
Both doctors illustrated that in clinical practice, their perceived identification 
of a patient’s race would influence decisions on drugs they would prescribe to 
their patients. Moreover, these decisions are made based on results from race-
based research on drug toxicity. If a particular drug is found to be less toxic 
to a patient perceived to be Caucasian and more toxic to a patient perceived 
to be Asian, a doctor might be tempted to adjust the dosage of the drug to be 
prescribed accordingly, even if he or she is not entirely sure of why and how its 
toxicity would affect the particular patient.
Conclusion
The overarching question with which this book is concerned is why catego-
ries of race and ethnicity have become dominant in interpreting and measuring 
human genomic diversity. We suggest that pharmaceutical companies often rely 
on information regarding the frequency of a particular genetic mutation or on an 
expanded panel of genes associated with drug responses in populations catego-
rized by race and ethnicity in their decision-making about the kinds of medical 
interventions they will develop. This chapter makes a few key points. First, while 
IRESSA for non-small-cell lung cancer patients is publicly portrayed as an exam-
ple of personalized medicine based on analysis of the EGFR-mutation status of 
a patient’s tumor, it is revealed that the IPASS was a clinical trial that selected 
patients based on the Asian phenotype. Notions of Asian and East Asian are 
constructed based on geography (people in Asia) and ethnicity (i.e. non-Indian), 
respectively.
Second, while the success of the IPASS encouraged pharmaceutical compa-
nies to treat the “Asian” category as real, it was later proved that what mattered 
was the patient’s EGFR-mutation status, not whether he or she was Asian or 
non-Asian. In this case, racialization of clinical trials was a matter of survival and 
reduction of attrition rates for a pharmaceutical company. As such, IRESSA may 
not be an isolated case of misappropriation of racial categories in the context of a 
globalized pharmaceutical industry.
Given the increasing affluence of the “Asian” market, increasing competence 
of medical professionals, and better research into infrastructure, governments in 
Asia also sometimes frame the continued monitoring of drug toxicity in racial 
terms – that is, testing them in “Asian” populations when drugs come to Asia. 
Moreover, there are now drugs that were first tested and developed in Asia, and 
the concern is that in order to sell the drug in the perceived core market, the 
“Caucasian” market, there has to be more monitoring and testing. Indeed, we 
present evidence for the usage of racially and ethnically labeled populations in 
all four phases of clinical trials, including Phase IV, post-marketing surveillance.
While previous studies have identified the role of the ethnic niche market in the 
medicalization of race (Duster 2007; Lee 2003), I argue that such a phenomenon 
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cannot be fully explained without an understanding of the choices and rationale 
underlying the cooperation of participating clinical trial centers and doctors.
Finally, and perhaps most importantly, this chapter shows that definitions and 
identifications of Asians and Caucasians are based on fluctuating and often arbi-
trary criteria. One cannot be sure of how an individual is identified and catego-
rized. For example, as noted, a doctor can place a person in a particular ethnic 
category based on his or her appearance or self-identity. If an individual has a 
“Chinese” mother and a “Caucasian” father, it is possible to self-report as “Chi-
nese,” “Caucasian,” or both. Moreover, while it may appear to scientists and 
physicians that using NRIC is more “scientific,” such census categories remain 
arbitrary and are, significantly, a colonial legacy.
To summarize, ethnic identities are shaped by social processes and indi-
vidual choices. Parents may choose to identify a child who is of mixed par-
entage, whose mother is Chinese and whose father is French, for example, as 
“Chinese,” “French,” “Chinese-French,” or “French-Chinese.” If the child is 
perceived by a doctor as European because he/she looks more French than 
Chinese, but the child’s parents chose “Chinese” as his/her registered ethnic-
ity, what would the doctor use as the basis for a prescription, the seemingly 
more apparent “European” identity or what is registered on the child’s ID? 
Likewise, if the child’s parents had chosen the double-barreled race option to 
register their child, what should the doctor do in terms of providing prescrip-
tions? In the case of, for example, ethnic quotas for state-subsidized public 
housing applications, the Singapore government’s policy is that the first race 
stated in the double-barreled race option will be used. Would this be the case 
for drug prescriptions too?
There are currently 95 races that can be registered on an ID in Singapore. 
However, the list may not be exhaustive and can vary over time. In a Singaporean- 
Malay female friend’s case, she is married to a citizen from Kazakhstan. Her son 
is a Singaporean citizen, but Kazakh is the declared ethnicity. What if the category 
“Kazakh” is new, bringing the total number of races on the list to 96? (There is 
no other Singaporean-born citizen registered as Kazakh, unless there are new 
naturalized citizens. Other local inter-ethnic Kazakh marriages are between Chi-
nese men and Kazakh women, so therefore their children are likely registered as 
Chinese). She could have chosen “Malay” for her son, for practical reasons, such 
as to apply for tertiary tuition subsidies, even though the child hardly “looks” 
Malay (personal communication, Amalia Rahmat). What would doctors make 
out of such rare ethnic groups such as Kazakh?
Given the arbitrariness of how Asians and Caucasians are identified for clinical 
trials, the results are questionable. But such results can in reality constrain physi-
cians’ actions to prescribe drugs along racial or ethnic lines. In the end, patients 
may spend a lot of money for drugs that may not be effective or safe for them. 
Even more worrisome, we may be moving to a new platform in which produc-
ers and consumers of human genetic research are now more inclined to believe 
that racially and ethnically labeled groups are biologically meaningful categories 
because of the existence of racially or ethnically based medicine.
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Introduction
In contrast to the previous chapter, in which I focused on the interest of phar-
maceutical companies in formulating and capturing the “Asian” and “Cauca-
sian” markets in genomic medicine, this chapter explores how governments may 
incorporate genomic science in public health policy-making processes. The first 
section describes the ways in which medical researchers, doctors, and health 
economists have attempted to incorporate genomic data for the purposes of 
public health policies in Singapore. In particular, this chapter shows that, in the 
context of cost-effectiveness studies for managing public health resources, there 
is a tendency for social actors involved to think in terms of, and use, prevailing 
Chinese-Malay-Indian-Others (CMIO) census population categories as if these 
were biologically distinctive populations, thus providing a structural impetus for 
the implementation of “personalized medicine” that may be actually based on 
ethnic or racial categories.
I then move on to suggest how and why the pattern of using these ethnic cat-
egories, as if they were coherent, is problematic. First, interview data with medi-
cal doctors suggest that there is a tension between treatment decisions based on 
analysis of an individual’s biomarkers versus his or her ethnic and racial identities. 
Second, using the formation of the “Malay” category as an example, I suggest 
that, in general, categorization by ethnicity is an ongoing process and one that is 
demonstrably shaped by social, political, and historical forces.
In sum, I argue that we need a better understanding of the evolution and con-
tinuing fluidity of these ethnic categories, which have become an integral part of 
the public health genomics rubric.
Population aggregate data, ethnicity, and  
post-market drug vigilance
Why is there a need to look at population groups when individual testing is 
possible and becoming increasingly affordable? Part of the answer lies in the 
area of public health resource management. Singapore has joined other nation-
states in shaping the framework of genomic research. For instance, the authors of 
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“Interethnic Comparisons of Important Pharmacology Genes Using SNP Data-
bases” note that:
Drug-development programs of new molecular entities are becoming more 
global, with increasing clinical trial activity in Asia. However, at present, these 
programs still generally focus on Caucasian subjects. For regulatory authori-
ties of countries with majority . . . non-Caucasian populations, a mandate 
for clinical trial data in the local population would delay the introduction of 
innovative medicines into clinical practice.
. . . We present the first steps in an effort to mine the wealth of pharma-
cogenetic data available from international [i.e. the International HapMap 
project] and local population genetic studies and databases [i.e. the Singa-
pore Genome Variation Project] in order to help those in drug development 
and regulation quickly assess the magnitude of genetic differences between 
populations [emphasis mine].
(Chen et al., 2010:1085)
Governments may be interested in pharmacogenomic studies of drug toxicity 
and adverse drug reactions because patients suffering from severe toxicity can 
drain public health resources. In the case of Singapore, when researchers attempt 
to answer questions including, but not limited to, who is at risk for developing 
toxicity and is it cost-effective to incorporate pharmacogenetic testing, we find 
that the “population” category used for their analysis is typically based on Singa-
pore’s contemporary ethnic categories.
Irinotecan and UGT1A1 genotyping
An example of this is the UGT1A1 gene and its variants, which are linked to drug 
toxicity with regard to Irinotecan. The authors of “Pharmacogenetic Risk for 
Adverse Reactions to Irinotecan in the Major Ethnic Populations of Singapore” 
state:
[F]or genetic polymorphisms known to alter drug effect or safety, regula-
tory authorities can tap into population genomic databases and other sources 
of allele and genotype distribution data to make a more informed decision 
about the anticipated impact of such variants on the main ethnic groups in a 
country’s population.
(Sung et al., 2011:1167)
Indeed, a Health Science Authority advisory notes the prevalence of gene vari-
ants in the three main ethnic groups in Singapore: “The prevalence of double 
heterozygotes (*6/*28) in Singapore is 6.9 percent, 1.2 percent and 2.9 percent 
in Chinese, Malays and Indians, respectively” (Health Science Authority, 2010).
Dr. Rajaratnam explained that patients with two variants of the UGT1A1 
gene, UGT1A1*6 and UGT1A1*28, are at increased risk of adverse reactions to 
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Irinotecan. The prevalence of these two gene variants are found to differ for dif-
ferent ethnic groups, and such difference has informed health authorities’ deci-
sions in terms of whether to introduce testing for these gene variations in their 
respective jurisdictions. Dr. Rajaratnam stated:
Ethnicity matters; it does. So, for example, the UGT1A1; this is a very good 
model drug to study how pharmacogenomics is really important. This poly-
morphism is very common only in Indians and less common in Malay[s] 
and Chinese. But, comparing Asian[s] as a group, to Caucasian[s], if you 
compare *6, it is completely absent in a Caucasian and it is only present in 
an Asian. . . .
[W]hat I meant was ethnic group matters . . . because this involves . . . reg-
ulatory bodies introducing the test. The FDA [in the USA] did not introduce 
*6 testing because it is totally absent in Caucasian[s]. Whereas [the] HSA 
introduced both *6 and *28 testing. That’s where ethnicity matters.
However, doctors have different views concerning the usefulness of testing 
for UGT1A1 gene variants. The presence of the gene variants merely suggests 
increased risks of adverse reactions to Irinotecan, but is by no means definitive. 
Moreover, the severity of drug toxicities differs among patients. The doctors 
interviewed emphasize that clinical judgment is still required at the end of the 
day on whether to prescribe the drug and the dosage. According to Dr. Zhang:
Toxicity . . . there are some tests but many people still think that [they] are 
not very specific nor . . . very sensitive. So, we can’t use these genetic tests to 
see if a patient should or should not receive a particular drug. A lot of time 
it is still based on our clinical judgment.
Other than the current technical limitations of UGT1A1 genetic testing, the 
significance of test results is a concern. Dr. Koh assessed the utility of genetic 
testing in terms of its ability to influence clinical decisions, a criterion that he feels 
UGT1A1 genetic testing fails to meet because of the small difference in risk for 
severe toxicity between normal and variant alleles:
[T]he norm, the normal allele, [is] maybe 20 percent, and the peo-
ple . . . with the heterozygous, the heterozygous alleles . . . the variants, 
are maybe 30 percent. So it’s not big enough for you to change your treat-
ment. Let’s say you get the result back, it doesn’t change what we do. We 
wouldn’t . . . not give those patients CPT11, we wouldn’t reduce the dose of 
the CPT11, based on the results that we have right now, and we can’t justify 
changing the schedule of the CPT11, so basically you get the result back, 
you’re not sure what to do with it, that’s why we don’t get the test.
While Dr. Xie agreed that risk percentage is an important factor, he also pointed 
out individual variability as an additional point of consideration. Discussion 
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between patients and doctors are thus necessary to ensure that patients under-
stand the test results and what it means for them:
I agree that the UGT1A1, with respect to certain drugs, [and this] means 
that you get much worse diarrhea and patients get toxic, very toxic and very 
unwell. But, then, the question is whether or not it applies to everyone and 
what is the option if you don’t have it, and if you develop toxicities, is it man-
ageable? I mean, how bad is the diarrhea? If you tell the patient . . . if I give 
you this drug, there is a risk that you might develop really bad diarrhea; 
but if you are willing to take that risk, we can see what happens and then 
you, if subsequently the patient does well, responds to treatment . . . they 
might accept that they are having diarrhea ten times a day – that it is worth-
while. . . . So it’s really down to what that test actually means and then dis-
cussing it with the patients.
In sum, although UGT1A1 genetic testing can help to supplement the decision- 
making process, the limited sensitivity and specificity of the test, as well as the 
small differences in risk values between normal and variant alleles, do not instill 
confidence in changing clinical practices. Moreover, applying a sweeping assess-
ment of an acceptable risk percentage may undermine some patients’ access to 
treatment, as the determination of severity and the degree of tolerable toxic effects 
differs between individuals. Doctors are thereby reluctant to rely on UGT1A1 
testing, emphasizing the importance of interaction between patients and doctors 
to facilitate clinical decisions.
Carbamazepine and HLA-B*1502 genotyping
Another example of a pharmacogenomic study of drug toxicity involves HLA-
B*1502 genotyping and its relationship with the carbamazepine (CBZ)-induced 
toxicity known as Stevens-Johnson syndrome. The Ministry of Health (MOH) in 
Singapore announced in 2013 that genotyping for the HLA-B*1502 allele prior 
to the initiation of carbamazepine therapy is now considered the standard of care. 
That is, subsidized patients from MOH-funded restructured hospitals and institu-
tions will qualify for a flat rate subsidy of 75 percent of the cost of the test. While 
75 percent may seem like a surprisingly large subsidy for a genetic test, it only serves 
to emphasize the government’s trust in the cost-effectiveness of this scheme. As 
explained by Dr. Huang, early identification of high risks of CBZ toxicity can help 
to circumvent the even larger expenditures incurred should the patient’s sensitivity 
to CBZ only show up at a later stage in the form of severe side effects:
Did anybody tell you about the carbamazepine test? . . . . [I]f you apply the 
test to every single patient . . . [y]ou can then avoid treating those patients 
[who test positive] . . . and you saved the costs of treating them if they 
wind up in the ICU [Intensive Care Unit]. So, from a global perspective, 
it becomes more cost-effective to measure everybody. Because the cost of 
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putting people in [the] ICU is very very high. So that’s a situation where the 
Ministry of Health has deemed it on a national basis that this is a standard of 
care. But it, this certainly doesn’t apply to all tests.
Dr. Huang’s argument is not unfounded. According to Dong, Sung, and Fin-
kelstein (2012), testing for CBZ toxicity before deciding on the course of CBZ 
therapy appears to be the superior choice even when presented with the alterna-
tive of simply prescribing drugs that will not induce CBZ-related toxicities to all 
patients regardless of risk profile. Moreover, Dong et al. (2012) suggest:
To avoid one case of SJS/TEN [Stevens-Johnson Syndrome/Toxic Epidermal 
Necrolysis], 142 Chinese, 28 Malay, or 833 Indian patients would need to be 
genotyped. To avoid one death resulting from CBZ/PHT-induced SJS/TEN, 
1,500 Chinese, 297 Malays, and 8,770 Indians would need to be genotyped.
As indicated, the cost-effectiveness analysis of incorporating pharmacogenetic 
testing in clinical practice is routinely based on population differences in terms 
of risk-allele frequency. Dr. Ballheimer, a health economist specializing in cost-
effectiveness studies of genomic medicine, explained:
Singapore increasingly is interested in understanding whether or not to 
promote or subsidize certain drugs, given their relative benefits and rela-
tive costs, compared to alternative treatments. . . . And if you’re thinking 
about . . . interventions that target low or middle income countries that are 
more public-health-oriented, you have a fixed [amount] of money and a mil-
lion things to fund, so cost-effectiveness is a way that helps you decide how 
to allocate resources from a public health perspective.
INTERVIEWER: There are many ways in which a particular population can be 
divided. Why is ethnicity in this case very dominant?
DR. BALLHEIMER: . . . The allele frequencies differ so the cost-effectiveness 
differs.
INTERVIEWER: But why do you use ethnicity as a frame to find out allele 
differences because you can also use, for example, a patient’s weight?
DR. BALLHEIMER: I don’t understand your question. 70 percent of Singa-
poreans are Chinese. We need to do a model that’s representative of 
the population. . . . We just use allele frequencies based on what the 
government gives us. And they give us frequencies based on Chinese, 
Singaporean, Chinese, Malay, and Indian. So we just use it. If they gave 
it to us in a different way, we would analyze it in a different way. . . .
As alluded to in Dr. Ballheimer’s remarks, researchers make use of genetic data 
calculated at the population-level not only for the purpose of controlling cases of 
adverse drug reactions, but also to engage in cost-benefit analysis of various genetic 
tests as part of the decision-making process. Typically, the distribution of risk allele 
among the population is a key component of such cost-effectiveness analyses.
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Dr. Ballheimer’s comments are very significant because they help us understand 
how health economists think about the national population. That is, while what 
constitutes a “population” can be conceptualized and analyzed in different ways, 
we found that ethnicity was adopted primarily because of the convenience of such 
categories for data collection and analysis. In other words, what Dr. Ballheimer 
said is that the primary reason that researchers are calculating allele frequencies 
using ethnicity is because these are the existing categories. If the data had been col-
lected and arranged by weight differentials, the researchers would have used those.
Indeed, according to other medical genetic researchers, it is the internal ethnic 
differences among “Asians” in local contexts – Singapore in this case – that matter:
[T]he category of “Asian” is very heterogeneous. [S]o . . . although we gen-
erally put down “Asian” . . . in our patient selection criteria, we would have 
to define [it] . . .
. . . to the specific races. Whether we’re talking about Chinese, we’re talk-
ing about Malay, we’re talking about Indian. We tend not to group them 
together. So, when we do an Asian study, that study may include Chinese, 
Malay or Indian, or sometimes just Chinese alone.
So, I think “Asian” may be a quite misleading term because it’s really very 
diverse. So it’s important that each study, even though we use “Asian” as a 
heading, we specify the specific race that you are looking at. And then if you 
don’t, when you analyze it, you may want to break them down into different 
races and see whether there’re any differences.
Dr. Yuan and Dr. Wang discussed how researchers typically define and identify 
individuals as Chinese, Malays, or Indians:
DR. YUAN: When we do studies, if ethnicity is involved, we usually ask for three 
generations. So okay that’s how we define. So . . . you know, how did your 
parents define themselves, how did your grandparents define themselves? So 
if the grandparents, parents and, and the patient, or the human subject, all 
declare themselves as Malay, then the person is classified as Malay.
DR. WANG: In these studies, the definition of Asian, definition of ethnic group 
is based on three generations. And what is written on the national registra-
tion identity card of these patients. So it’s more or less a self-declared ethnic 
group. And of course we excluded those individuals that . . . we’re a bit 
uncertain of. In other words if the patient were to say that my mom and my 
dad are Chinese and my grandparents are Chinese, we are okay. You’re Chi-
nese. If my mom and dad are Chinese, my grandparents one of them is not 
a Chinese . . . okay, you are not a Chinese.
Looking at three generations to define an individual’s ethnicity in Singapore 
appears similar to the US-based Ancestry Informative Markers, which ideally 
take into account all four grandparents. However, it is unclear whether Singa-
pore’s regulations include both paternal and maternal grandparents or simply 
focus on paternal grandparents, as is the convention in defining one’s ethnicity.
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Researchers and health economists in Singapore are certainly not alone in rely-
ing on existing ethnically labeled population-level data. Our review of the eight 
studies quoted by Singapore’s Health Science Authority in formulating its policy 
recommendations show that most studies have relatively small sample sizes (only 
one study included more than 300 individuals). The study population is usually 
defined based on medical conditions. However, the ethnic identities of subjects 
are consistently an area of focus for researchers. Nonetheless, only one in eight 
studies specified how it defined ethnicity – that is, in the journal article entitled 
“Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated 
with HLA-B*1502 allele in Thai population” (Locharernkul et al., 2008: 2089), 
one finds the following statement:
Ethnicity of all subjects was elucidated by racial history identification from both 
parents, two generations back. The individual is considered a ‘‘pure’’ Thai if 
none of the four biological grandparents came from other races. Individuals 
having at least one grandparent of non-Thai race were classified as mixed Thai.
As we saw in Chapter 2, however, the “Thai” category emerged in a specific time 
and place – indeed, no one can be called or identified as a “Thai” prior to 1932!
Dr. Ballheimer’s comments, noted above, together with those of Drs. Yuan 
and Wang, highlighted what I will discuss in great length in the section on 
the formation of the “Malay” category. As will be shown, while such ethnic 
categories – Chinese, Malay, Indian – may appear coherent to these contempo-
rary researchers, once we look into their recent social histories, we see the com-
plexities inherent in their formations.
Analysis of the prevailing practices noted above
When health economists and researchers accept predefined and seemingly static 
ethnic groups in their analyses, what is at stake?
First of all, there is a tension between the promise of “personalized/targeted 
medicine” and the practical usage of information based on “population-related” 
genetic markers and regions. Personalized drugs are, typically, expensive. The 
main question for a government responsible for delivering public health is 
whether it should subsidize these drugs. For cheaper drugs, whether to subsidize 
the genetic testing becomes a relevant issue. As Dr. Wu pointed out, in deciding 
how to allocate public health care resources, public policy makers analyze the 
aggregate data (i.e. what proportion of a population will benefit if a particular 
type of “personalized” medicine or screening is funded):
[Y]ou’re doing that because of a cost model, because it’s more prevalent 
in that population, and thus screening the population. So, for example, it 
could be that you have to screen one hundred Indians, and you will find 
seven people to intervene [i.e. treat]. Seven versus [having] to screen ten 
thousand Chinese to find one, in order to intervene that one, then, although 
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that one person would have benefited had you screened everybody, it just 
isn’t practically feasible. So it’s actually focusing your efforts where you’re 
most likely to get the benefit. . . . [I]t’s more for a pragmatic purpose. . . .
In sharp contrast to this, for many doctors, it is the individual case that matters, 
even if that case happens to be in the minority or even exceptional in the general 
profile of the population. Dr. Hsu explained:
[T]he differences here essentially relate to who is the person wanting the 
data, right? If it’s the Ministry of Health, a bureaucratic organization of any 
sort, they want a whole population-based [study], because that is to make 
policy, to decide who should be tested, who should be funded for the testing, 
and so on and so forth. . . . So [this is the] information wanted by organiza-
tions, that look at people in a faceless manner, right? Basically, for all Chinese 
I would do this, for all Indians, I would do this. But at the individual condi-
tion level, the person sitting in front of me is a human being, Homo sapiens, 
I don’t care [about] anything else.
In the following section, I draw on the social science literature to suggest that, 
in addition, these ethnic categories were significantly generated by the histori-
cal colonial encounters – that is, they are not biologically coherent categories. 
A paper published in the American Journal of Human Genetics titled “Deep 
Whole-genome Sequencing of 100 Southeast Asian Malays” (Wong et al., 2013) 
displays the special attention that has been paid to this group – as opposed to the 
Chinese or the Indian categories – by geneticists. Thus, for illustrative purposes 
of the argument, I focus on the example of the “Malay.”
The historical emergence of “Malay” as a  
group during the precolonial era
In searching for an understanding of the emergence of the “Malay” group, 
Andaya (2001) provides a narrative for the historical environment that birthed 
the conditions for a specifically Melayu1 ethnic awareness. He asserted, “in asking 
where and how Melayu ethnicity may have evolved, the issue is not to pinpoint 
the exact time and place of the origins of the group, but to reveal the process of 
ethnic formation” (Andaya, 2001:316).
Linguists have claimed that proto-Malay was spoken in western Borneo by at 
least 1,000 BCE, and speakers of this language then spread to southeast Sumatra 
and the Malay Peninsula. In southeast Sumatra, Malayic speakers spread along 
the Musi and the Batang Hari and their tributaries and into the interior high-
lands. The name “Melayu” appeared for the first time in a seventh-century Chi-
nese document in reference to a settlement in southeast Sumatra (present-day 
Jambi). In the thirteenth and fourteenth centuries, Melayu was the name of a 
kingdom in the Jambi area. The conventional practice of naming people based 
on a settled area would suggest that the inhabitants of lands identified as Melayu, 
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wherever and however this word was defined, would be known as orang Melayu, 
or “the people of Melayu” (Andaya, 2001).
Settlements on the Malay Peninsula, on the other hand, were not associated 
with “Melayu” until the foundation of Melaka in the fifteenth century follow-
ing the arrival of Melayu immigrants from Palembang. Melaka then sought to 
assert its leadership in the Melayu world, inheriting the lifestyle and methods of 
governance of southeastern Sumatra and Western Borneo. The influential literary 
document Sejarah Melayu (History/Story of the Melayu) reaffirmed Melaka’s 
central position in Melayu and facilitated the reinforcement and export of Melaka 
values to other parts of Southeast Asia. The Melaka’s claims regarding Melayu 
leadership were, however, disputed by Sumatran contenders such as Aceh and 
Minangkabau; however, the identification of Melayu with the peninsula became 
increasingly rooted (Andaya, 2001).
Andaya (2001:330) further expounds:
With the division of the Melayu world into Dutch and British spheres by the 
Anglo-Dutch treaty of 1824 and the subsequent creation of independent 
nation-states in the mid-twentieth century, Melayu finally became identified 
politically and in the popular mind with the peninsula. Although to this day 
Melayu groups elsewhere, particularly in the Indonesian provinces of Jambi 
and Riau, claim to be the original and pure Melayu, their story is rarely heard. 
The political struggle for the right to claim to be the center of the Melayu has 
been won by Malaysia. It continues to monopolize the study of Melayuness, 
with the kingdom of Melaka made to represent the ‘core values’ of the Melayu.
“Malayness” during the colonial era
Before and during the early days of British colonial rule, a person’s identity was 
based on the sultan of whom the person was a subject, rather than membership 
in a particular race group (Manickam, 2009:596). Reid (2001:300) explains, “in 
the sixteenth and seventeenth centuries, Malayness in maritime Southeast Asia 
retained these two associations – a line of kingship acknowledging descent from 
Srivijaya and Melaka or Pagarruyung (Minangkabau), and a commercial diaspora 
that retained some of the customs, language and trade practices developed in the 
emporium of Melaka.”
The application of race gained momentum in the Malay Peninsula during the 
late nineteenth and early twentieth centuries, due in part because the printing press 
provided opportunities to voice allegiances to entities other than the royal courts 
and due to the cosmopolitan environment in which printing took place (Manickam, 
2009). Competition for readership was stiff, as most printed material, being expen-
sive and scarce, only reached the elite. According to Manickam (2009:597–598):
Under such circumstances, ideas of what constitutes a ‘Malay’ were used by 
some writers to build identities and to guard against perceived infringements 
on their place in Malaya. . . . To present oneself as Malay and to discredit 
the Malay-ness of others played a role in furthering the interests of those 
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newspapers. Being Malay was imbued with a variety of characteristics involv-
ing changeable boundaries depending on who was speaking.
Discourse in the vernacular press about Malayness in the archipelago contrasts 
sharply with British colonial scholars’ discourse of race during the same period. 
Manickam (2009:598) points out, “knowledge production by British authors 
was closely tied to territorial acquisitions in the Malay Peninsula during the nine-
teenth interplay century which saw the British government and Malay polities 
begin more extensive political relations than had hitherto been known.” Initially, 
the British were relatively unfamiliar with the peoples of Southeast Asia, even 
though they had been present in the region for some time (the British had been 
in Singapore for 50 years and in Penang for 85) (Hirschman, 1987). Manickam 
(2009:598) suggests that:
[M]any British authors had initially regarded all inhabitants of the Malay 
Archipelago as Malays, and considered only those east of the archipelago as 
a different group, the Papuans . . . arguably due to the fact that Malay was 
the lingua franca of the peninsula and its neighboring islands; it was thus 
the language commonly encountered by the British in the region, who then 
erroneously associated language usage with race.
In a similar vein, Reid (2001:305) adds:
[I]n the urban world of the nineteenth-century Straits Settlements, which 
from 1824 comprised Penang, Melaka and Singapore, modern European 
ideas of nationality (and later race) carried much weight. . . . In the Straits 
Settlements there were undoubtedly many Abdullahs, for whom Malayness 
was a new identity acquired in the ethnically competitive world of these port-
states. Austronesian Muslims seemed to be outnumbered and outcompeted 
by Chinese, Europeans and Indians in these ports. Although of various ori-
gins, they were too small a minority to carry much weight separately as Bugis, 
Aceh, Java or Mandailing, and in any case they intermarried with each other 
in the ports. The English rulers of the Straits used “Malay” as the collective 
term to refer to them, and to a considerable extent it became internalized. . . .
However, toward the end of the nineteenth century and in the first decades of 
the twentieth, the British had consolidated their control over the entire Malay 
Peninsula (Hirschman, 1987; Manickam, 2009). The expansion of their position 
of power influenced their “attitudes towards the kind of investigations that were 
deemed important and also towards the rhetoric surrounding Malays” (Man-
ickam, 2009:599). An influx of European, Chinese, and Indian migrants, who 
were encouraged to develop Malaya’s resources, led to the creation of a plural 
society (Reid, 2001; Shamsul, 2001a, 2001b), “in which the concept of Malay as 
race was there to stay” (Shamsul, 2001b:76). By the 1920s, Malaya had become 
one of the most affluent economies in Asia, and such lucrative development had 
been legitimized by the Malay rulers, thus prompting the colonial statesmen to 
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quickly develop a colonial discourse about “protecting” them and their people, 
while having a clear idea of what sort of Malay they should protect (Reid, 2001).
According to Reid (2001:306), “the ‘real Malay’ of colonial discourse was 
rural, loyal to his ruler, conservative and relaxed to the point of laziness.” 
Indeed, it seems that such a racial construction of the Malays by the British was 
used by the British to legitimize their rule in the Malay Peninsula (Hirschman, 
1987; Shamsul, 2001a; Manickam, 2009; Ong, 2010). The Malays, being sup-
posedly inherently incompetent, were seen as in need of assistance from the 
British to guide them lest they were left to falter, as Manickam and Hirschman 
describe:
The stereotype of lazy Malays and hardworking Chinese served the purposes 
of the British who wanted to develop Malaya’s economy using Chinese labor 
and at the same time, preserve Malays as they supposedly were. This position 
of stewardship was upheld by promoting the perceptions that Malays and 
Chinese could not coexist peacefully, and that Malays would be swamped 
economically and numerically by the Chinese if left to their own devices. The 
effect of this approach was the entrenchment of the position of the British 
as stewards over the Malays, and the rationale that it was Britain’s duty to 
develop the economy and the natural resources of the country on behalf of 
the Malays, who were unable to do so themselves. Furthermore, the British 
continued to pose indigenousness as a racial issue. Being part of the Malay 
racial group (and their associated groups such as those from the archipelago) 
meant being indigenous to Malaya. By this formulation, other racial groups 
were unable to gain access to indigenousness and the rights that were associ-
ated with that state of being.
(Manickam, 2009:600)
The new theory of race was founded on the idea that peoples were different 
not only in appearance and culture but also in inherent capacities or potential. 
According to this perspective, societal differences in technological advance-
ment were measures in the evolutionary march toward civilization. . . . Rac-
ism provided a rationale for the “white man’s burden” of leading, ruling, or 
conquering peoples at “lower evolutionary stages” throughout the world. 
This ideology fitted well with the British need to justify its empire. . . . I 
suggest that British attitudes toward the Malay community changed during 
the late nineteenth century in the direction of a more unquestioned belief in 
the weaknesses of the Malay character and the need for a strong paternalistic 
role for the colonial government. The problem was no longer the resistance 
of Malay rulers to British intervention but the British need for a justification 
for imperialism. Paternalism, the protection and guidance of the Malays, was 
the ideological justification for most of the colonial era.
(Hirschman, 1987:568)
Vernacular Malay-language schools were set up following the establishment of 
English and Chinese schools (Reid, 2001; Shamsul, 2001a, 2001b). The ostensible 
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function of such schools was to acquaint Malay schoolchildren with their histori-
cal identity. For instance, Shamsul and Reid pointed out, “in the textbooks for 
the ‘Malay’ schools, the British constructed a distinctly ‘Malay’ historiography 
and ‘Malay’ literature in which ‘Malay’ hikayats were used to create or implant a 
certain sense of historical identity and literary taste” (Shamsul, 2001b:76); “to 
rediscover the first of the nineteenth-century meanings of Malayness . . . a tradi-
tion of Malay kingship descended from Melaka – and impose it on the varied 
Muslim immigrants to the Peninsula” (Reid, 2001:307). The underlying logic 
of the schools’ function, that is, was to preserve the stereotyped Malay identity 
rather than to change it. Reid (2001:306–307) explains:
Despite its greater wealth, Malaya spent a smaller proportion of public 
money on education than did other Southeast Asian colonies. In 1920 only 
12 per cent of the Malay population aged 5–15 was in school, and virtually 
all of these were in the vernacular Malay-language schools the government 
believed best equipped to keep the Malays in their stereotyped place: “It will 
not only be a disaster to, but a violation of the whole spirit and tradition of, 
the Malay race if the result of our vernacular education is to lure the whole 
of the youth from the kampung to the town.”
Indeed, part of the “spirit and tradition” of Malays in the kampung was to par-
ticipate in agricultural peasantry, supposedly crucial in forming the backbone of 
the nation. In 1913, the Malay Reservation Act was introduced, an act “in which 
agricultural land could only be alienated to people defined as racially Malay, irre-
spective of their place of birth” (Reid, 2001:306). This further strengthened the 
definition of “Malay” and “Malayness,” as Ong (2010:20) points out:
This setting aside of special areas for Malay cultivations required a colonial 
legal definition of who constituted a “Malay”. In 1913, the Malay Reser-
vations Enactment Committee defined “Malay” as “a person belonging to 
any Malayan race who habitually speaks the Malay language or any Malay 
language and professes the Muslim religion” (FMS Enactment no. 15, 
1913). . . . Thus, in the name of “the continuation of the Malay race,” the 
reservations act was passed.
However, it is worth noting that as the enactment was instituted in the state 
constitution of each of the 11 provinces separately, the definition “Malay” varied 
slightly from one constitution to another. For example, someone of Arab descent 
might be identified (as a Malay) in Kedah but not in Johor, and someone of Sia-
mese descent might be considered Malay in Kelantan but not in Negeri Sembilan 
(Shamsul, 2001b).
The word “race” first appeared in official documents in the 1891 census, 
which delineated three racial categories: Chinese, “Tamils and other natives of 
India,” and ‘Malays and other Natives of the Archipelago” (Hirschman, 1987). 
Since then, the list of subcategories under the Malay (Malaysian) category has 
evolved over time (see Table 4.1). Hirschman (1987:570) suggests that while 
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the links between broader social currents and census classifications are unclear 
(since records describing the reasoning behind the formulation of ethnic clas-
sifications by census administrators are unavailable), he nonetheless concludes 
that:
[C]hanges in racial ideology had clear effects on ethnic classifications in 
censuses. Given the limitations of other forms of historical records . . . the 
census classifications provide important evidence on the development of 
European racism in colonial Malaya. Although many of the outward forms 
of racist thinking have been eliminated from census classification in the post- 
Independence era, the residue of racial ideology continues to haunt contem-
porary Malaysia.
Importantly, the conceptualization of the Malay race, Manickam (2009:601) 
argues, came not only from the British colonial perspective but also from Malay 
intellectuals:
[T]his knowledge of race among Malays coincided with some elements of 
British racial construction, but there were also key differences due to diverg-
ing strategies of race used by the Malays. Strategies are just that, courses of 
thought and action taken at particular times and places and ways of employing 
and deploying the discourses of race by some among the Malay intelligentsia.
First, in contrast to the British discourse on the disempowerment of the 
Malays economically and politically, the Malays’ strategy of race was not fatalistic. 
Manickam (2009:604) points out:
Taking on racialized groupings instead of state-bounded or smaller group 
loyalties made it possible to talk of a unified Malay subject within the 
breadth of territory under British protection and rule. . . . The radicalizing 
of a segment of the population enabled these writers to talk of Malays in 
relation to other groups less favored by the writers, such as Chinese and 
Indians, and sometimes even the British. This could arguably be called a 
“positive” use of racialization, as opposed to the negative use by the British. 
The radicalizing of Malays . . . produced knowledge that could be useful 
for the colonization of Malaya and everyday governance. . . . By turning 
these oftentimes stereotypical portrayals into elements which bound Malays 
together, the conceptual power of that knowledge entrenched them as the 
privileged race in the Malay Peninsula. . . . This is in contrast to the effects 
of writing histories of Malaya by the British, who instead took away ques-
tions of ownership.
Second, although the British and Malay authors appeared similar in that they 
positioned the Orang Asli (indigenous peoples of the peninsula) as lower in the 
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civilizational scale compared to Malays and most other races, the perception of 
the Malay authors that the Orang Asli are primitive by nature served, in Man-
ickam’s (2009:607) words, “to deprive Orang Asli of autonomy in their deal-
ings with Malays and put them out of the running for the right to govern the 
peninsula at least in their own affairs, again positioning Malays as the only true 
heirs to governance,” whereas British marginalization of Orang Asli “stemmed 
from wanting to claim that forest land inhabited by them was undeveloped and 
uninhabited” (Manickam, 2009:611).
Lastly, another divergence from British race knowledge involved the manner in 
which race was presented so that it would have enough currency to be seen as a 
nation. Calling a group of people a nation entails a trajectory as a separate state if 
they are under colonial rule, and, conversely, asserting that a group of people is a 
“race” sometimes means downplaying the status of that group as undeserving of 
self-government, as in the case of the Malays in Malaya. Yet, the Malay authors 
were undeterred, as Manickam (2009:609–610) describes:
Rather, references to Malays were used in the histories as a way to entrench 
the authors in Malaya and to argue for certain rights against other groups 
under the umbrella of British power in the peninsula. The elevation of 
Malays from a race category to that of a nation, which also entitled them 
to more rights, is most blatantly seen in Abdul Majid’s The Malays in 
Malaya, by one of them. . . . This raced nation, based on a population 
purportedly sharing similar racial characteristics, was used to bring up the 
issue of rights of Malays in Malaya, as well as the appropriateness of par-
ticipation in government by groups other than Malays such as Chinese 
and Indians.
In summary, with the consolidation of power by the British over the entire 
Malay Peninsula, developing a colonial discourse to justify colonization became 
crucial. The racial construction of the Malays was used by the British to legiti-
mize their rule in the Malay Peninsula. The logic followed that Malays, though 
loyal to their rulers, were “lazy natives” in need of assistance in developing their 
homeland, thus compelling the British to take on a paternalistic stance and rul-
ing role over the peninsula. Malays seemingly had a privileged status, however, as 
self-respecting agricultural peasants, and the idea was promoted among Malays 
that it was risky to leave such a livelihood in search of other opportunities. The 
condition of the Malays was maintained in part through vernacular schools. The 
Malays were also explicitly defined in the Malay Reservation Act in 1913. How-
ever, censuses collated over the colonial and postcolonial years show that defining 
the Malays as one essential race was a difficult task. The conceptualization of the 
Malay race should also not be seen as limited to discourse by the British colonial-
ists, but should be seen from the point of view of the Malay intelligentsia as well, 
whose construction of the Malay race diverged from that of the British to serve 
different ends.
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“Malayness” in the Malay Peninsula  
in the postcolonial era
In the first few decades of the twentieth century, “Malay” nationalism was invig-
orated, taking on, in Shamsul’s (2001a:364) words, “a cultural, rather than 
a political character; the discussions that made the ‘Malay race’ into a ‘Malay 
nation’ focused primarily on questions of identity and distinction in terms of 
customs, religion, and language, rather than politics.” Nah (2006) explains that 
“Malay intellectuals began to talk about themselves as ‘a Malay race’ (bangsa). . . . 
The ‘Chinese’ groups – who were economically successful in a number of 
industries – were seen as a ‘danger’ to them. It was felt that the Malay bangsa 
had to unite together . . . to defend their position in ‘their land.’ ” For instance, 
as Reid (2001) explains, for the young graduates of the Malay teachers colleges 
who wrote in the Malay press of the 1930s, the “Malay race” (bangsa Melayu) 
“was defined by what they perceived as two overwhelming facts – they were the 
‘natives with primary claim on the country, and they were the weakest group in 
it. They concluded that the bangsa required unity and solidarity to make stronger 
demands of the British” (Reid, 2001:308).
“Malay” nationalism seemed most pronounced when the British proposed a 
new form of government following the World War II, the Malayan Union, in 
their own vision of a “united nation” whereby plural communities would have 
a shared Malayan outlook and purpose (Shamsul, 2001a, 2001b; Nah, 2006). 
Part of the proposal stipulated equal citizenship rights to most residents of Brit-
ish Malaya (including non-Malays such as the Chinese and Indians) and further 
reduced the political authority of the sultans, consequently spurring the Malays 
to political action (Siddique and Suryadinata, 1981). The British were then 
compelled to replace the proposal with the 1948 Federation of Malaya, “in 
which the centrality of Malayness was explicitly expressed” (Reid, 2001:308). 
That is, according to Shamsul (2001a:364), “the ‘Chinese’ and the ‘Indians’ 
effectively became citizens of the independent state but they had to acknowl-
edge ketuanan Melayu, or Malay dominance, which implied they had to accept 
‘special Malay privileges’ in education and government services, and ‘Malay’ 
royalty as their rulers, Islam as the official religion, and the ‘Malay’ language 
as the official language of the new nation-state.” Lian (1997:71) describes this 
as such:
[T]he Federation of Malaya Agreement, which laid the foundation for the 
creation of an independent state in 1957, served to formalize the status of 
Malays relative to non-Malays. While citizenship was unconditionally con-
ferred on Malays, it was only given to non-Malays if they fulfilled certain 
conditions – including birth, duration of residence, and reasonable knowl-
edge of the Malay or English language. The special position of the Malays 
was also constitutionally recognized; this concerned land reservations and 
reservation of quotas in public service appointments, licenses and educa-
tional benefits.
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The Federation eventually achieved independence in August 1957. In the 
Federal Constitution (first introduced as the Constitution of the Federation of 
Malaya in 1957), the Malay was defined in Article 160(2) (Malaysia Constitu-
tion, Article 160, Section 2):
“Malay” means a person who professes the religion of Islam, habitually 
speaks the Malay language, conforms to Malay custom and – (a) was before 
Merdeka Day born in the Federation or in Singapore or born of parents one 
of whom was born in the Federation or in Singapore, or is on that day domi-
ciled in the Federation or in Singapore; or (b) is the issue of such a person.
Yet, the formation of the Federation of Malaysia in 1963 (when Sabah, Sarawak, 
and Singapore joined Malaya) gave rise to a new dimension to understanding the 
definition of “Malay” and “Malayness,” due to the inclusion of Muslim groups 
in Sabah and Sarawak, who, however, were minorities in their states, whereas the 
majority of the populations there consisted of non-Muslim natives and Chinese 
(Shamsul, 2001a, 2001b). This presented a political problem, as it meant that the 
Malay-dominated federal government in Kuala Lumpur “had to cooperate with, 
and attempt to co-opt, non-Malay Muslims as their political partners” (Shamsul, 
2001a:364).
Bumiputera (son of the soil) is a term used by the federal government to refer 
to the indigenous status of the Malays (Shamsul, 2001b) and is commonly used 
interchangeably with “Malay” (Siddique and Suryadinata, 1981). The bumi-
putera (the “Malays” and their Muslim counterparts in Sarawak and Sabah) had 
political dominance throughout Malaysia, except in Sabah, which was ruled by its 
own opposition party, which was Christian Kadazan. In order to win Sabah over, 
in the 1980s, UMNO (the United Malays Nationalist Organization, the leading 
party in the federal government) “opened itself to non-Muslim bumiputera so 
that eventually the UMNO-led Barisan National (‘National Front’) could regain 
control over Sabah” (Shamsul, 2001a:365), as explained:
[T]hese developments show that the need to define the borders and margins 
of a concept can have far-reaching effects on its central content: “Malayness” 
as defined by the Malay nationalist movement in the 1920s and 1930s and 
implemented and redefined by UMNO, had to be reformulated in Sabah 
once again, illustrating how flexible the concept or category of “Malay” is. 
It also shows that the ongoing discussions about “Malayness” are at once 
both important and irrelevant: the concept can easily shift in meaning, adapt-
ing itself time and again to new situations and making clear-cut statements 
impossible or incredible.
Economically, according to Lian (1997:71), the New Economic Policy (NEP) 
“was launched in 1971 for the specific purpose of propelling the Malays to a 
position where they would enjoy economic parity with the other ethnic com-
munities.” One important consequence of the NEP was the radical restructuring 
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of Malay society, whereby many Malays had moved from agricultural to urban 
settings, were occupying more middle-class jobs, and were more highly educated. 
This restructuring led to disengagement from the traditional patronage structure 
(Sultan-centered loyalty) of the rural environment (Lian, 1997). This initiated a 
metamorphosis of a new Malay identity, from bumiputera to Melayu baru (new 
Malay), as Lian (1997:74) explains:
With the emergence of a middle class, the continued presence of a rural 
proletariat – and now an urban proletariat, and a traditional royalty under 
siege and fighting to maintain its privileges, it has become a more obvi-
ously class-differentiated society. This has manifested itself in the consider-
able political acrimony generated within UMNO since the late 1970s. As if 
to articulate a new identity to make sense of these changes and to disengage 
it from the “old UMNO,” Dr. Mahathir at the UMNO general assembly 
of 1991, coined the term Melayu baru (new Malay) – which he defined as 
someone who possesses a culture in keeping with the times, prepared to face 
challenges, educated and knowledgeable, disciplined and efficient, honest 
and trustworthy. [That is,] the new Malays should not only be involved in a 
modern economy but also be able to compete internationally; in short, they 
should adopt the ethos of the immigrant community in the country.
In the long run, the concept of bumiputera may be phased out if the term Mel-
ayu baru gains wide acceptance, though this will depend on whether the Malays 
continue to make economic progress (Lian, 1997). This may be more acceptable, 
and according to Lian (1997:75), “because bumiputera is an exclusive status 
defined with an ethnic preferential bias, it may act as a disincentive to further 
overseas investments in the economic development of Malaysia.”
The case of the Malay in Singapore
Singapore achieved independence in August 1965 following its expulsion from 
the Federation of Malaya. The Malays in Singapore, once part of the major-
ity in Malaya, suddenly became a minority rather than a privileged group that 
had preferential treatment, as Singapore became governed by the principle of 
equal opportunity for all Singaporeans (Zuber, 2010). In the Constitution of the 
Republic of Singapore, the only reference to “Malay” is found in Article 152(2): 
“Malays . . . are the indigenous people of Singapore.” It provides no explanation 
on what attributes and traits make up a “Malay” individual (Constitution of the 
Republic of Singapore, Part XIII General Provisions, Article 152, Section 2).
In 1988, however, the state attempted to provide a more solid definition of 
“Malay.” Aljunied (2010) discusses the processes involved in the creation of the 
definition of Malay, through analyzing a public debate on Singaporean Malay 
identity, which occurred in November 1987 during the passing of two bills in 
the Singapore Parliament that resulted in the implementation of the General 
Representation Constituency (GRC) scheme. Aljunied’s analysis demonstrates 
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that the Malay identity in Singapore has been a source of continuous controversy 
and contention.
Aljunied (2010) argues that the establishment of a single official definition 
of the Malay identity by the Singapore state resulted from “the emergence of a 
network society that was shaped by global and regional developments and the 
rise of Malay ethnic resurgence on the island in reaction to state policies and the 
perceived threats of modernization and deculturation.” It was intended “to steer 
the minority community toward a more inclusive outlook, while recognizing the 
supreme authority of the state” (Aljunied, 2010:308). This was especially crucial 
for the government, which perceived that such an ethnic resurgence within the 
Malay community would cause the popularity of the ruling party (the People’s 
Action Party [PAP]) to wane.
Several social forces combined to create conditions to define the Malay identity 
in Singapore. One was “to lay emphasis on the notion that Malays in Singapore 
were different from Malays in Malaysia, as well as Muslims in other neighbor-
ing countries, due largely to many decades of shared experiences among Singa-
pore Malays that developed their sense of rootedness and belonging” (Aljunied, 
2010:316). Practically, “Muslims in Singapore were instructed to yield their con-
ception of a global imagined community (the Ummah) to the territorial edi-
fice and unifying myths of the nation” (Aljunied, 2010:316). Another strategy 
involved directing state rhetoric toward “imbibing the success of multi-racialism 
in Singapore, and assuring the Malay community that Malay rights were pro-
tected by the state” (Aljunied, 2010:316), through public dialogues organized 
by Malay Members of Parliament. Lastly, findings on the spread of deviant Islamic 
teachings formed a public perception that the Malay community had been influ-
enced by fundamentalist and extremist ideologies founded abroad. Together with 
extensive media coverage of social problems plaguing the Malay community, 
such as high rates of drug abuse and divorce, this strategy created the sense that 
much effort was needed to instill a strong consciousness of Singaporean nation-
hood among the Malays (Aljunied, 2010).
Two bills pertaining to the GRC scheme, introduced in November 1987 and 
passed in May 1988, were aimed at legally ensuring minority representation in 
Parliament, thereby seeming to strengthen the foundations of a multiracial soci-
ety (Aljunied, 2010). They established the criteria for a Malay candidate to be 
eligible for election as a Member of Parliament (MP) as “any person, whether 
Malay race or otherwise, who considers himself to be a member of the Malay 
community and who is generally accepted as a member of the Malay community 
by that community” (Aljunied, 2010:322).
Upon close scrutiny, this definition poses several problems and possibilities. 
First, it assumes that prior knowledge of the Malay community, with set bounda-
ries differentiating Malays and non-Malays, exists. Second, self-identification as 
a Malay is effectively ruled out, as the definition entails the authority of the 
“community” in determining a person’s identity. Finally, the phrase “Malay race 
or otherwise” implies that Malay identity is tied to both a hereditary and non-
hereditary criteria, as in the case of, for instance, a Singaporean citizen with 
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Chinese ancestry who is accepted by the Malay community as a Malay and is 
registered as one, who would then qualify to stand for election as a “Malay” MP 
(Aljunied, 2010).
The state’s attempt to define Malay identity through the strategies discussed 
above had a generally negative effect on its popularity among Singapore Malays. 
This was manifest in the 1988 general elections results, where a large number 
of Malays swung their votes to the opposition parties. Far from achieving its 
intended aims, “the long-term objective of forging a sense of nationhood through 
the introduction of a new interpretation of the Malay identity heightened the 
transnational sway of resurgent Islam and sub-ethnic particularisms in Singapore. 
Ethnic resurgence remained an entrenched feature of the Malay community in 
Singapore throughout the 1980s” (Aljunied, 2010:323).
On the other hand, Zuber (2010:35) argues that the definition provided has 
its strengths:
[S]ince a group’s identity is part of the group’s consciousness, it is accept-
able that the group’s identity will be understood by all within that group, 
either implicitly or explicitly and that the group has some form of common 
understanding of what is basic to the group’s identity. . . . [T]he Singapore 
Malays have long existed as part of a group. . . . [I]t can be expected that the 
Malays in Singapore intuitively know who they are. . . .
However, Zuber also points out that this legalistic definition “created a situ-
ation where the Singapore Malays had to expressively articulate the meaning of 
a Malay. . . . It was in light of this need that the Malay community had to con-
sciously put forth an expression of being Malay in Singapore, and articulate the 
traits of Malay” (2010:35). This task was undertaken by the Malay elite, whose 
expression of the Malay identity is steeped in the core identifiers of the Malay 
language, customs, and traditions and the Islamic religion (Zuber, 2010).
Over the years, conscious efforts have been made in Singapore to promote 
and iterate the consciousness of these identifiers. For instance, to promote and 
sustain the Malay language, events such as the bi-yearly Malay Language Cultural 
Month are held. When the 2010 Census Survey revealed that the use of the 
Malay language has declined, the Malay Language Council began to look into 
initiatives to improve the teaching of the language in schools. Also, in an effort 
to increase awareness of Malay customs and religions, the Malay Heritage Centre 
was established in late 2004.
Conclusion
Why are ethnicity and race used in Singapore’s public health genomic policy-
making? In the first part of this chapter, I suggest that the answer has to do with 
the Health Science Authority’s (HSA) concern with determining “who to give 
the drug to” in a cost-effective manner. I delineate the ways in which medical 
researchers and health economists typically think about “population” categories 
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in the context of public health genomic policy-making – for example, whether (or 
not) to subsidize certain drugs or testing – in the context of cost management 
concerns. For example, to restate some of the key remarks:
DR. RAJARATNAM: The prevalence of double heterozygotes (*6/*28) in Singa-
pore is 6.9 percent, 1.2 percent and 2.9 percent in Chinese, Malays and Indi-
ans, respectively. . . . [W]hat I meant was ethnic group matters . . . because 
this involves . . . regulatory bodies introducing the test. The FDA [in the 
USA] did not introduce *6 testing because it is totally absent in Caucasian[s]. 
Whereas [the] HSA introduced both *6 and *28 testing. That’s where eth-
nicity matters.
DR. BALLHEIMER: . . . The allele frequencies differ so the cost-effectiveness 
differs. . . . We need to do a model that’s representative of the popula-
tion . . . We just use allele frequencies based on what the government gives 
us. And they give us frequencies based on Chinese, Singaporean, Chinese, 
Malay, and Indian. So we just use it. If they gave it to us in a different way, 
we would analyze it in a different way. . . .
As such, it was shown that the social actors involved in decision-making take 
the current ethnic composition of the nation as given. While factors other than 
ethnicity can be used to sort data, existing routines for collection and easy 
availability of data categorized along ethnic lines make ethnicity a convenient 
choice.
Duster (2006:435) points out that “some African Americans have cystic fibro-
sis even though the likelihood of that is far greater among Americans of North 
European descent and, in a parallel if not symmetrical way, some American Whites 
have sickle cell anemia even though the likelihood of that is far greater among 
Americans of West African descent. But in the world of cost-effective decision-
making, genetic screening for these disorders is routinely based on commonsense 
versions of the phenotype.”
This chapter indicates that it is vital to identify limitations when researchers 
use ethnicity or race as a proxy in formulating public health genomics policies. 
I suggest that there are at least two types of potential harm with respect to the 
typical calculation of allelic frequencies or other genotype information along eth-
nic lines. At the very least, the interview data provide evidence that there is the 
conflict between public health policy guidelines couched in the ethnic distribu-
tion of genetic variants and medical doctors’ clinical ideal of delivering medicine 
based on an individual’s DNA analysis.
More significantly, as we see by examining a detailed history of the formation 
of the Malay category, the nature and character of ethnic identity formation is 
an ongoing project shaped by complex historical, political, and social forces. As 
such, when scientists, health economists, or public health officials use race or eth-
nicity as a surrogate for personal genetic information, there is an almost unavoid-
able risk of giving a false appearance of biological coherence to ethnic identities, 
which are actually fluid and historically contingent.
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Note
 1 Manickam (2009) provided a detailed example of a documented argument 
between three newspapers to illustrate her point on the Malay “race” being used 
for the writers’ own ends. In summary, one of the newspapers, Jawi Peranakan, 
was not appreciative of the analysis of Malays found in Bintang Timor, a Chi-
nese Peranakan-run newspaper, and responded from the position of one part of a 
Malay community reluctant to let “non-Malays” comment on its state of affairs. 
The issue was complicated further by an earlier exchange between Jawi Perana-
kan and Sekola Melayu, in which the latter newspaper addressed the authors of 
the former as non-Malays. Yet, the “Malayness” of Sekola Melayu’s writers was, 
itself, questionable; one was of Indian origin and had previously written for Jawi 
Peranakan.
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For most complex problems, the pursuit of perfect knowledge is asymptotic. Uncer-
tainty, ignorance and indeterminacy are always present.
– Jasanoff, 2007
Introduction
Genomic medicine is concerned not only with the acquisition and understand-
ing of knowledge regarding the human genome, but also judgments concern-
ing whether and how to translate knowledge into practice. In previous chapters, 
I have focused on how populations are constructed in the broader contexts of 
knowledge production concerning human genome variations and illustrated 
the ways in which populations become racially and ethnically labeled in various 
settings – transnational genomic science, the global pharmaceutical industry, and 
national genomic public health policies. Moreover, I have tried to problematize 
the relatively routine practice of using ethnicity/race as a proxy by pointing out 
that these ethnic and racial categories are intrinsically a function of the social 
dynamic known as “othering.” In this chapter, I turn to the clinical setting to 
describe the ideal of personalized medicine that most medical oncologists in Sin-
gapore hold, which involves using the molecular characteristics of individuals to 
improve prevention, detection, and treatment of cancer. These doctors, who are 
delivering health care on the front lines, articulated their serious concerns about 
using the ethnic or racial identities of patients as proxies in making decisions con-
cerning drug efficacy, drug toxicity, and preventive medicine for individual cancer 
patients. In other words, we suggest that there are limitations to racially and eth-
nically framed knowledge of human genome variation not only at the conceptual 
level but also at the practical level. This chapter identifies some of the social and 
economic conditions, which are seen as suboptimal by most, if not all, clinicians, 
under which the racial and ethnic identities of patients shape treatment decisions.
Using ethnicity or race as a basis  
of clinical decision-making
The oncologists interviewed were not explicitly critical of researchers using ethnic 
or racial categories in studying the human genetic or genomic structure; however, 
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they articulated problems in using ethnicity or race as a basis for clinical decision-
making. Specifically, ethnicity cannot be a substitute for genotype information in 
deciding how to treat a patient. In fact, once the relationship between genotype 
and the medical outcome has been identified, ethnicity is no longer relevant, as 
explained by Dr. Wang:
[C]ertain geographical regions and certain ethnic populations are more prone 
to certain diseases than others. Whether this is because of a genomic interac-
tion, or is it because of an environmental interaction, because of certain diets 
and practices. That is what we want to find out. But the ultimate [goal] should 
not be to use ethnicity as the means to deny or allow access to healthcare or 
certain treatment because of your race or because of your ethnic group.
In other words, researchers create proxies based on observations already framed 
in terms of popular, a priori taxonomies, such as geographic regions and ethnicity, 
and assume that there exist possible genotypic similarities that contribute to an 
ethnic group’s vulnerability to a particular disease. Ethnicity serves as an interme-
diate step for further research to identify the assumed underlying genetic factors. 
Once the genetic variants are known, ethnicity ceases to be of value, Dr. Wang 
continued:
. . . if you were to say it’s more common in Chinese, therefore Chinese 
patients with lung cancer should be treated with IRESSA, then you’ll be 
missing the patients who are Indians and Malays who have the EGFR muta-
tion, you see? That’s what I mean. So you have to use the ethnic group, to, as 
the basis of drilling down, what is the cause of this difference, and then based 
on that EGFR mutation, you treat every ethnic group the same.
If you have a particular genotype, does it behave [in a] similar manner in 
different groups? Yes. It should. And all the examples point towards this. So 
a Caucasian, Spanish, who has a EGFR mutant will respond [to] the same 
quantum and the same way compared to an Asian who has got the EGFR 
mutant lung cancer, when treated with IRESSA.
Thus, Dr. Wang presented the example of IRESSA being effective for patients 
with EGFR mutations regardless of race, despite the fact that IRESSA was ini-
tially discovered to work best in Asians, especially Chinese, female nonsmokers.
In a similar manner, Dr. Yuan reinforced the argument that ethnicity is used 
only as a transitional classification in order to move toward identifying specific 
genetics to improve treatment:
I was in Boston, presenting [on] our CTRG trials and ethnicity [i.e. clinical 
trials for prospective cancer drugs using ethnicity as a frame], when I was 
called a racist. This lady said, “in America, we’d never allow you to do this 
research, ‘Cause it’s racial profiling.” And I said “Look, we’re just look-
ing for signals, and once we find the [genetic/genomic] signature, ethnicity 
becomes redundant.”
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In other words, ethnicity is no longer of concern once specific genetics are 
known. Doctors do not administer medicine based on ethnicity, but on genomic 
status, such as EGFR mutation status. While it is understood that racial classifica-
tion is sensitive and deemed as discriminatory, Dr. Yuan shared his observation 
that researchers in such cases see racial profiling as a necessary short-term strate-
gic measure for further investigation.
Likewise, Dr. Wu discussed the difference between research and medicine: that 
ethnicity might be useful to stimulate further research, but should not be used 
once the specific genotype information is established:
One must distinguish between what is research-based and what is medi-
cine . . . you have to use the best knowledge that you have, and race and 
ethnicity is just one layer of information that is of less precision. If you do 
know what the variant is, and it’s been proven through research that it mat-
ters, then you should clinically adopt the variants and not the ethnicity. Eth-
nicity is when you don’t know [the genetic variant], and it just gives you 
something to consider.
A lung cancer medicine, for example, would benefit a patient of any ethnicity, 
as it targets the genetic variant, which remains the same across ethnic groups. 
Dr. Wu continued:
. . . EGFR mutant lung cancer is only ten percent of all adenocarcinomas in 
the Western world, but forty to fifty percent of all (such patients) in Singa-
pore . . . or in Asia. But if you carry the mutation, whether you’re a West-
erner or you’re Asian, you benefit fairly similarly from the drug. So there may 
be different frequencies of the alteration, but the meaning of the alteration, 
once it’s present, is probably similar.
This view is echoed by Dr. Deng, who stated that:
[W]hen it comes to molecular profiling, you move beyond ethnic and 
racial profiles because it doesn’t matter what race you come from, it is the 
tumor that is important. We believe that the tumors may have common 
characteristics regardless [of] whether you are Chinese, Malay, Indian or 
Caucasian.
Moreover, the physicians explained that there is no perfect correlation between 
ethnicity and genotype. That is, there is no gene variant that is present in only 
one ethnic group, nor is there an ethnic group whose members all carry the same 
gene variant. Hence, ethnicity should not be used as a proxy for the presence or 
absence of a gene variant. These points were articulated by Dr. Koh:
Based on all the data that we’ve seen so far . . . in terms of the distribution 
and frequency [of the genetic variant]? It’s very unlikely that you’re [going 
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to] find a population with an allele frequency of 99 percent. I mean, we’ve 
never seen anything like that.
Even if it’s 50 percent, if it’s 50 percent, you’re [going to] be wrong 
50 percent of the time! You can’t do that. You can’t be wrong 50 percent of 
the time, that’s unacceptable.
To these doctors, race/ethnicity as a proxy is acceptable only in research – but 
even then, it is used as a temporary category, which can only hint at the pres-
ence/absence of specific genetic variants involved. Drugs do not become effec-
tive because of a patient’s ethnicity; rather, it is the specific genetic mutations that 
cause a drug to work, as explained by Dr. Hsu:
The ethnic groups simply provide a pre-test surrogate of what the result 
would be. So if I see a Chinese, Asian, woman, non-smoker, I would say, 
before I test you, I know that you are 55 percent chance of being an EGFR 
mutant. But, after the test result comes out, the results speak for itself, right? 
Because at the end of the day, the drug recognize the [genetic/genomic] tar-
get. So it doesn’t quite matter, whatever color you are, whatever ethnic back-
ground, as long as the mutation is present. And this is proven, so . . . Italian 
patients with EGFR mutation respond very well to Iressa, just as Singapore 
Chinese women do. Same. So it’s the target that matter, I think drug is 
ethnic-blind.
In short, genetics are what matter in the end, rather than racial or ethnic cat-
egories. As Dr. Yeh emphasized:
So as long as you carry the EGFR mutation, regardless if you’re Korean or 
Japanese, Taiwanese, Singaporean, Indian, U.S . . . If you carry the EGFR 
mutation . . . you would treat with the drug! Absolutely. It is the driving 
mutation. It does not respect ethnic boundaries.
In other words, while the genotype may be presented in varying frequencies in 
different ethnic or racial groups, the doctors were against using ethnicity or race 
as a basis to preferentially select or exclude certain patients from genetic testing 
or medical treatment. Indeed, for the EGFR mutation, while it is prevalent in 
“Chinese” or “Asian” lung cancer patients, the doctors stressed that patients of 
other ethnicities should also be tested for it. As Dr. Poh put it:
Because it [i.e. the presence of the EGFR mutation] is [in] about 50 percent 
of our patients with NSCLC here. In Western Europe, in European popula-
tions, Caucasian populations, it is about 10–15 percent. You will still test it 
and the reason is because it makes such a dramatic difference so you don’t 
want to miss it.
If you don’t [conduct EGFR mutation testing], you will get sued. And 
you don’t want to miss it [the mutation status].
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Clinicians are legally bound and have a sense of duty to administer treatment 
according to a patient’s individual diagnosis, especially in prescribing genome-
based medicine. As Dr. Deng put it:
. . . you know EGFR mutations, more common in Chinese, less common in 
Caucasians, 10 percent in Caucasians, 40 percent in Chinese, but does that 
mean if you are Caucasian, you got lung cancer, you are not going to screen 
for it? You still are. Because for the individual patient, it is really really impor-
tant because it makes such a big difference in the outcome.
Just like having the EGFR mutation, just because it is more common in Asians, 
it doesn’t mean you can’t prescribe it to a Caucasian who’s got the mutation.
Likewise, Dr. Tang pointed out that assumptions about mutation statuses in 
patients should not be made on the basis of general observations and statistics 
reflected by populations:
. . . going to the genetic basis of it should be the criteria, because cer-
tain genetic changes found more commonly in [Asians] doesn’t mean it is 
excluded in other races. Because it is less common, but that doesn’t mean 
that you don’t do the test. You understand what I am saying? Like EGFR 
mutant lung cancer is found in Asians; but if it is found in Caucasians, they 
also respond to the drug.
Other shortcomings of using race and ethnicity as a proxy in clinical practices 
exist, including, but not limited to, the phenomenon of intermarriage, the con-
temporariness of such categories, and the uniformity of genetic structure within 
groups, as these doctors described:
DR. WEE: . . . My medic will help me call Mr. Chong Ah Kow. The person that 
enters my room is an Indian, looks exactly like an Indian, but (his name) is 
Mr. Chong Ah Kow.
[INTERVIEWER: You would have presumed that Mr. Chong was Chinese?]
“So your father is Mr. Chong?” [Dr. Wee asked the patient.]
“Ya, correct, (and) my mum is an Indian.” [The patient replied.]
So, so I guess . . . ethnicity is some kind of genetic information, but we realize 
that it has limitations.
DR. LIN: There are some patients with a Chinese father and a Caucasian mother, 
vice-versa.
DR. HSU: I think in medicine . . . races don’t really matter, right? Whether you’re 
Chinese, Indian or Malay, you will treat a heart attack the same way; likewise, 
for diabetes. There is no major need to treat one race differently.
The second thing about this is, how uniform is your group? How uniform is the 
(genetic structure) of the Chinese ethnic group? So when people say that 
Asians are more likely to have EGFR mutation for lung cancer, what does 
“Asian” mean, right?
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In the past the Indians were Asians; now we consider them as South Asian. So the 
definition of an ethnic group’s uniformity is always evolving. So if I tell you 
that Americans respond better to this drug than the Chinese, (you’d think,) 
“Americans what?” Jewish? Irish? Spaniard [sic]? You know, the world’s been 
highly globalized, and people are moving left and right of the geographical 
boundary, which may not correspond to the political boundary – which, in 
turn, may not correspond to the genomic boundary.
DR. LIANG: . . . the matter is not so straightforward, because of mixed marriages, 
alright? A person who looks like a Malay might be Chinese . . . so it is not so 
simple to look at the declared race. In fact, if you have read the newspapers 
not too long ago, some people don’t know what race to give themselves.
So – there’s Malay-Chinese, Chinese-Malay, [but] what if you have got some 
European blood, is it Eurasian or . . . ? [Race] is no longer reliable anymore, 
because people are intermarrying across races.
Sometimes, doctors may be forced to use the ethnic or racial profile of a patient 
to make clinical decisions under suboptimal circumstances. These include times 
when genetic testing is unavailable, or when the relationship between genotype 
and medical outcome has not been discovered. For instance, Dr. Yuan said:
[I]f we were a poor country, okay? I mean, to do these tests is a few hundred 
dollars. So let’s say I’m in a country where I don’t have the ability to do 
the test.
And I have a white patient and an Oriental patient with lung cancer. I can 
tell the white patient, look if I give you this drug, there’s a 10 percent chance 
it’s going to work, and I can tell the Oriental patient there’s a 50–70 percent 
chance this drug is going to work. That’s using ethnicity. But I would rather 
be a 100 percent certain, I’d rather do the test.
The doctors interviewed also made clinical observations of inter-ethnic differ-
ences in toxicities of the chemotherapy drug docetaxel (Taxotere) and have used 
ethnic background to guide the dosing of docetaxel, while no clear genetic expla-
nation has been offered in such scenarios. Dr. Hsu shared his observations:
Chemotherapy is also known to differ between ethnic groups. For example a 
drug called Taxotere. Taxotere is a very famous drug that is used for breast 
cancer and all kind of cancer. A common dosage in the West is 75 milligram 
per meter square, every three weeks, but we know that 75 milligram is not 
something that many Asian patients can take. So, as a result, NUH did the 
study I think four five years ago, that showed that a Chinese woman getting 
breast cancer treatment at 16 milligram per meter square achieved as good 
an outcome as Caucasian woman getting 75. So that knowledge of the eth-
nic background immediately allows you to adjust the first dose, straightaway. 
And in fact, if you give 75 milligram to Chinese woman first dose, some of 
them will die, because of the side effect, and also, it’s quite customary for 
104 Cancer genomics in clinics
all Asians to use a lower starting dose. In fact, Japan, the same drug, for the 
same indication, the official labeling is never 75, it’s 60. They already have 
imputed into their drug approval system that every time you see Taxotere, 
we drop by twenty percent. So in Japan, and maybe to some degree the 
Chinese in Singapore, we are quite in favor of reducing the dosage of certain 
chemotherapy drug, based on purely ethnic background.
Patients with dihydropyrimidine dehydrogenase (DPD) deficiency are more 
likely to have severe side effects from the chemotherapy drug 5-fluorouracil 
(5-FU). According to Dr. Teo, if DPD deficiency testing cannot be done, 
doctors may be compelled to use ethnicity as a factor to guide the dosing 
of 5-FU:
[Administering] 5FU . . . I am a little bit more nervous with Malay and 
Indian patients. Because the DPD deficiency test is not currently available 
routinely. It is only available in laboratory setting, in a very sophisticated lab, 
and we can’t do that routinely. So what we do is that when we see patients 
from Malay or Indian origins, I may reduce the dose a little bit by 10 per-
cent. But that’s based on intuition. It’s not based on science. It’s not based 
on protocol. It’s not based on any algorithm. It’s just based on intuition, 
cause that’s all I have available today. But there are no drugs that you can say 
“Oh Indian, take this drug. Chinese, take this drug. Malay, take this drug.” 
There isn’t anything like that. There isn’t.
Finally, there may be clinical situations in which a patient cannot afford the 
luxury of time. As Dr. Lin clarified:
The thing about lung cancer is you may not have a second chance. Some-
times the patients are very breathless with lung cancer. And by the time 
you realize takes weeks later that it doesn’t work or few weeks later, they’re 
dead, you know. . . . Non-trial situations are very complicated. Sometimes 
the patients don’t want [to have this particular treatment]. Sometimes it’s 
cost issues, sometimes it’s too breathless to wait. Sometimes we give both 
chemotherapy and IRESSA at the same time. Because there’s not much time 
to wait, to wait for one or the other to work.
To sum up this section, physicians are clear about using ethnicity: yes for sci-
entific research – but only with strict terms and conditions – and a resounding 
no for clinical practice. The use of ethnicity in research is acceptable only when 
it is used as a surrogate category that is assumed to lead to the discovery of 
concrete genetic characteristics. In clinical practice, race and ethnicity should 
only be considered as a last resort, if genetic test results are unavailable. In 
any event, all doctors interviewed unanimously agreed that it is the presence/
absence of genetic mutations that influences the drug efficacy of personalized 
medicine.
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Personalized medicine in clinical practice: drug efficacy
Scientific research and clinical trials seek to establish whether, in subjects under 
study, there is a relationship between the independent variable (e.g. presence 
of a genetic marker) and the dependent variable (e.g. responsiveness to a drug 
treatment). In a clinical setting, the doctor is making an assessment about an 
individual patient. A statistically significant relationship observed within a study 
population may not be applicable to the individual patient. As Dr. Lin explained, 
that is a major challenge for doctors in applying personalized medicine in a clini-
cal setting:
[W]hen you talk about personalized medicine, you are assuming that it has 
to be 100 percent accurate. It’s not a 100 percent accurate. Obviously, it 
can’t be. It’s just maybe more accurate in your selection versus other criteria!
It’s the same with this test. . . . Look, this is a graph. It divides the 
score, the recurrence. They don’t even give you right and left, yes and 
no. . . . They give you a continuous range! And they say this is low-risk, 
intermediate risk, high risk! That day I just tested this woman, is right in 
the middle here. So genomics, they can be informative, they can be help-
ful. It’s again how you use the information. In some situation, your clinical 
judgment and assessment can be as good and can still supplant without 
your genetic tests!
Doctors were interviewed about three key areas in which genetic testing could 
be applied to personalized medicine: drug efficacy, drug toxicities, and preventive 
medicine. Drug efficacy involves assessing the effectiveness of a particular drug 
therapy for an individual patient. Drug toxicity involves assessing the likelihood 
of an individual patient developing adverse drug reactions (ADRs) from a drug 
therapy. Preventive medicine involves assessing an individual’s susceptibility to a 
particular disease with a view of possible preventive measures or early treatment.
The doctors generally had positive views about applying genetic testing to 
assess drug efficacy, while pointing out limitations. Genetic testing has been help-
ful in formulating more treatments that are differentiated for patients and for 
avoiding costly drug treatment prescribed to patients who are unlikely to respond 
to it. One of the doctors, Dr. Wu, also noted that personalized medicine has 
made great advances in certain fields such as the treatment of colorectal cancer 
and lung cancer:
. . . in colorectal cancer for example, only patients who are, do not carry a 
particular mutation in KRAS or NRAS will benefit from a particular drug. 
So if you carry the mutation, there’re biological reasons, which have been 
shown in clinical studies, to show that you will not benefit from the drug, 
and you will save the cost, which is expensive – the drug is seven thousand 
dollars. To put this in context, the test for that is less than a thousand, often 
less than three hundred dollars, so it’s a dramatic difference.
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Genetic tests also shed light on a patient’s biological composition, such as the 
presence/absence of mutation; this is crucial to the decision-making process, 
as a suitable, cost-effective treatment can then be tailored for each patient, as 
Dr. Deng pointed out. Without this genetic test, the patient will undergo a gen-
eral treatment, which may see the patient taking several drugs to find a suitable 
one that is responsive. This process could be costly, and risky, if the drug(s) has 
side effects that could complicate matters. As Dr. Deng described:
I think lung cancer has been . . . it has really changed dramatically in the 
last five years. We previously used to very much just apply certain treat-
ment to patients with lung cancer, all non-small cell lung cancer would [be] 
group[ed] together, and now we actually wait for specific genetic test to be 
done and for the results that, before we actually decide which is the best 
initial treatment and at the moment we test for three common markers, 
EGFR, ALK, and ROS1, and each of these have got specific implications on 
the type of treatments that would be deemed most effective. So we actually 
wait, sometimes two weeks, for these results to come out before we start 
treatment.
Similarly, for Dr. Koh, advances in genomic medicine facilitate targeted treat-
ments that maximize the benefits patients may receive from a particular drug and 
minimize potential adverse drug reactions:
[I]t’s good for the patient, because they’re subjected to potentially more 
effective treatment by sub-selecting the groups that are most likely to ben-
efit from a particular treatment, and they’re less likely to be subjected to 
toxicity of the treatment that doesn’t work for them, so it’s good for them. 
It’s good for society, because it reduces healthcare costs and improves 
outcomes.
Genetic testing was thus perceived by these doctors as a beneficial develop-
ment that serves patients and society well, including its economic impact. Dr. Yeh 
shared his view:
So prior to the EGFR testing, we would put patients who fit the clinical phe-
notype, nonsmokers, adenocarcinoma, Chinese, or Asian. Into . . . to treat! 
But they would have to treat for maybe about a month or . . . 6 weeks. And 
pay maybe [over] 3000 . . . dollars? For that core amount of drug before you 
see whether there’s a response. Whereas now, you test ahead of time, you are 
going to spend 300 dollars, a tenth of that amount . . . and be able to decide 
whether you’re going to expose the patient to this drug or not.
According to scientist Dr. Huang, genetic testing can help a patient who is in 
the early stages of breast cancer assess whether he/she requires chemotherapy 
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after undergoing surgery. This helps the patient to save costs and avoid the side 
effects of chemotherapy:
We know that from retrospective studies, that 40 percent of patients with 
early stage breast cancer after surgery actually will not require chemotherapy. 
Meaning that, meaning that if you don’t treat them with chemotherapy after 
surgery, these patients will have very good 5 year survival. But 60 percent 
of patients after surgery will relapse. So those people require chemotherapy. 
What happens if you were a clinician? And you had a female patient . . . after 
surgery. Would you treat or not treat?
You treat! So the reality is that everybody gets treated. Which means that 
40 percent of patients actually get overtreated. So they incur the toxicity 
of the chemotherapy, they incur the costs. So there is actually a test that 
measures the expression levels of 70 genes. It’s called MammaPrint. This 
is not an Asian-specific test. This was developed in Europe. That you can 
send your patient to and they can analyze the breast cancer, and they can 
tell pretty accurately that, does it follow the 40 percent or does it follow the 
60 percent. And on the basis of that, you can synthesize that information as 
the doctor and you can decide if you still want to proceed [with] the treat-
ment or not.
Fundamentally, however, the relationship between genotype and drug effi-
cacy is still not completely understood. As Dr. Zhang pointed out, even with a 
gene variant that is established to be linked to drug efficacy, doctors have always 
encountered exceptions in their clinical practice:
There are many other factors that affect the outcome of the treatment or 
how a gene behaves in the body. We cannot say just because two patients 
have the same genetic mutation, they should behave and they should react 
similarly to the same drug. . . . There are many other things that affect 
the patient and the functioning or interaction of these drugs and genes. 
I don’t think we know enough to predict for sure how this will react. We 
can at best tell you 70 percent, 80 percent of patients will react to a certain 
degree.
The results of genetic testing offer important insights, helping doctors and 
patients to better evaluate a situation and relevant treatment options. However, 
these genetic test results are still probabilities. There is no certainty that a tar-
geted treatment will definitely work in all patients with specific mutations, nor is 
there a definite duration for which the drugs remain effective against a patient’s 
mutations. As Dr. Tang explained:
About 70 percent of the patients will carry that EGFR mutation. Of those 
patients who are EGFR mutation, you do expect that 80 percent of them 
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will respond to the drug so 20 percent that will not respond – meaning that 
they either remain the same or they may even grow with the treatment. And 
of those patients who respond, not all will respond in a durable manner to 
the drug; meaning that some of them will develop resistance to the drug 
within 6 months, some will have the disease controlled for much, much 
longer [than] that 2 years, 3 years; the longest I had is like 10 years. So 
the spectrum is really wide. Although majority of them will relapse within 
a year, so the main thing that we need to know is that why this variability 
in terms of response? . . . And if the patient develops resistance, is there a 
reason for that?
The doctors recognized not only the benefits of genetic testing, but also its 
limitations. Furthermore, as Dr. Xie pointed out, in clinical practice, there is no 
guarantee in any situation – even when a specific mutation is present, that does 
not mean that the drug will definitely work:
[J]ust because you have a EGFR mutation, you got a high chance of respond-
ing to it, but not all patients respond to it.
Moreover, new knowledge about the interactions between genes and drug effi-
cacy is constantly being developed. Hence, underlying genetic links for some pre-
viously unexplained cases may surface with further advances in medical research. 
Dr. Hsu shared his clinical experience:
I just tell you the latest development – for colon cancer, you know we do it 
for KRAS testing right? We do this testing because the KRAS is showing no 
mutation, we will use a drug called Erbitux, right? So if the tumor KRAS, 
which is a proto-oncogene, if the KRAS gene is mutated, we cannot use this 
drug. Quite the opposite from lung cancer. Before 2008, we don’t even test, 
we just give this drug. After 2008, we test this drug, KRAS, as a matter of 
routine, standard – every colon cancer Stage 4 we test, alright? So if they 
have mutation, can’t use the drug; no mutation, we use the drug. Every-
body’s happy right? Until last month. Last month’s data have shown that 
even the KRAS no mutation, inside, 18 percent of them have a separate type 
of mutation that’s not captured by the KRAS. So now we’re doing NRAS, 
so now, it’s very complicated, from six years ago, we don’t test; last six year 
we do KRAS, everybody’s so happy – then they found that 18 percent of 
the KRAS is not truly sensitive to the drug. Why? Because there’s a second-
ary mutation, it’s called NRAS. And after they found NRAS, they go to a 
third one called BRAF. So nowadays for colon cancer we’re doing so many 
molecular profile, until the big colon cancer group is now split into five or six 
different subtype. So this movement is moving at a rapid pace.
In summary, physicians generally did not see any ethical problem with genetic 
testing to assess drug efficacy. The testing is for somatic mutation in the cells 
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in the tumor area. Somatic mutation is nonhereditary, and, hence, there is no 
concern about how the genetic information would implicate a patient’s biologi-
cal descendants. By contrast, genetic testing for preventive medicine (to be dis-
cussed later in this chapter) could pose concerns, as it typically involves testing 
for germline mutations, which could be passed on to descendants. As Dr. Wu 
pointed out:
Somatic alterations [are] in the tumor, whilst germline are something that’s 
inherited, which is inherited in your genome from your parents. For somatic, 
I don’t think there’s much ethical considerations, because it’s very clear-cut 
that you get the benefit from the treatment and you therefore reduce the 
expense and side-effects of unnecessary treatment that wouldn’t have ben-
efited you.
There is, thus, little or no ethical concern about genetic testing for somatic 
mutations as the results from the tests concern only the individual patient 
involved, unlike germline mutations, which affect future generations. Further-
more, genetic tests for somatic mutations will facilitate better decision-making 
for the most suitable treatment for the individual at that point in time. According 
to Dr. Deng:
. . . I think, the community is generally comfortable with somatic testing, 
because that’s the cancer genome, it’s very specific thing that we’re testing 
for, with a very targeted objective, which is to try to see what therapies a 
patient may be eligible for.
Hence, it is broadly agreed that genetic testing for somatic mutations is mor-
ally and medically acceptable. However, the same cannot be said for genetic test-
ing for germline mutations, whereby future generations would be genetically at 
risk, as well. Thus, genetic testing for somatic mutations is largely supported by 
the doctors. As Dr. Xia put it:
[F]rom the medical viewpoint . . . because these are somatic mutations. They 
are not inherited. So there is no implication for the next generation. These 
are just random mutations that happen in the lifetime of someone. There is 
no risk involved [in] testing for these things.
With respect to somatic mutations, these doctors agreed that genetic tests assist 
them in advising on treatment options for individual patients, based on the indi-
vidual’s genotype information, facilitating personalized medicine. At the same 
time, they recognized that the genetic mutations being tested are only strongly 
correlated – not definitively causative – with the efficacy of the drugs. However, 
genetic tests for preventive purposes seemed to be less welcomed by these doc-
tors. This will be discussed in greater length in a later section, “Personalized 
medicine in clinical practice: preventive medicine.”
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Personalized medicine in clinical practice: drug toxicities
In contrast to their attitudes concerning drug efficacy, doctors had more reser-
vations about the usefulness of genetic testing in assessing drug toxicities. For 
Dr. Xie, the vast amount of data necessary to verify claims and difficulties in 
offering a clear definition of toxicity present huge obstacles in using genetic tests:
I think the problem is that you need huge amounts of data to validate any 
marker you think may be predictive of toxicity because you’ve got to ask 
yourself, how do you define your toxicity, there is a whole spectrum of toxic-
ity. Is it very bad diarrhea, moderate diarrhea?
There may be very subtle differences in one particular polymorphism in 
the gene that predicts for this particular toxicity versus the other one that 
predicts a less toxicity. And then you got to study a thousand patients to give 
you a validated perspective, so it is very difficult to validate.
There is no single, unanimous definition of toxicity. There are shades of toxic-
ity intensity, as discussed previously – ranging from mild to detrimental. These 
terms are subjective not only to doctors but also to patients as well. Hence, evalu-
ation of genetic testing to reduce toxicities would be vague. Moreover, doctors 
can directly adjust dosage based on patient feedback, as shared by Dr. Hsu:
The data [on toxicity] is somewhat immature, so the immaturity of the sci-
entific translation, is the barrier for the SNPs testing. And, some of the clini-
cians will say that why do you need the SNP test? You just give the drug, 
any side effect you just adjust the dose. So this skepticism will make SNPs a 
somewhat a nice concept, but it won’t be widely adopted.
Moreover, according to Dr. Chong, some existing genetic tests of drug toxici-
ties suffer from a lack of specificity and sensitivity:
[F]or predicting drug toxicity, I know there are tests out there to predict for 
toxicity to Irinotecan [and] to 5-flurouracil . . . none of it has been robustly rep-
licated and proven to be highly specific and sensitive, so it’s not in common use.
The clinicians that were interviewed remained, thus, somewhat unconvinced 
about toxicity tests. These tests are, for the moment, not as scientifically rigorous 
and statistically meaningful as drug efficacy tests; not many clinicians use them 
today. As Dr. Koh said:
There are lots of patients who have that certain polymorphism, but don’t 
have toxicities. . . . So the predictive power is not as strong as we would like 
for it to be. We’re definitely doing the genetic testing for efficacy . . . but 
for toxicity, because it’s still somewhat controversial, and the utility is still 
limited, we’re not using it. It’s not standard of care right now.
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Because the tests are not as useful and are open to diverse interpretations, they 
are largely put aside. Therefore, for Dr. Zhang, many of the decisions made in 
clinical practice are based on the doctor’s judgment:
Toxicity . . . yes there are some tests but many people, some tests, many peo-
ple still think that it is not very specific nor is very sensitive. So, we can’t use 
these genetic tests to see if a patient should or should not receive a particular 
drug. A lot of time it is still based on our clinical judgment.
Drug toxicities, similar to drug efficacy, are also affected by nongenetic fac-
tors. Warfarin is an anticoagulant that is used in the prevention and treatment 
of thrombotic disorders. Two genes, CYP2C9 and VKORC1, are known to 
influence the body’s metabolism and sensitivity to Warfarin. Excessive dos-
age of Warfarin can cause fatal bleeding. It is suggested that the profiles of 
these two genes could potentially guide doctors in determining the dosage of 
Warfarin to administer to a patient. However, Dr. Zhang pointed out that an 
adverse reaction (i.e. bleeding) to Warfarin could be caused by many nonge-
netic factors. Thus, Dr. Zhang described clinical vigilance and patient manage-
ment as more important than genetic testing in mitigating the adverse effects 
of Warfarin:
For example, a certain kind of herbal tea, even simple like chamomile tea, 
will affect the coagulation of warfarin. So we can’t tell patients that you must 
not eat this and that . . . there are 1000 of things (to avoid). If patient has 
cough and cold, and went to see a GP (General Practitioner) and get some 
medicine. That interferes with Warfarin, and you run into trouble.
So one way is to do that [genetic] test and use it to assess how much 
Warfarin to give. But even with that test . . . we still have to monitor the 
Warfarin, titrate the dose by looking at the clotting duration or the clotting 
time. . . . So without Warfarin, maybe 12 seconds, with Warfarin, maybe 
24 seconds. So this is our target. Anybody who is on Warfarin will do the 
clotting test and make sure that their blood clot within 24 seconds. If it takes 
longer than that, it is considered high dose . . . excessive. If it is too fast, we 
increase the dose. Now you have this genetic test, does that mean that you 
don’t have to do the clotting test? You still need to! So with or without this 
genetic test, we still need to do the observation test. But this [genetic infor-
mation] helps you predict which patient, when you start Warfarin, [is] more 
likely to run into trouble.
Even if genetic testing suggests that a patient might potentially have adverse 
reactions to a drug, clinicians like Dr. Xie pointed out that sometimes the drug 
may be the only treatment option available. In such cases, it might be better for 
the patient to tolerate the drug toxicities than to have no treatment. A case in 
point is Irinotecan, a chemotherapy drug used to treat colorectal cancer. Studies 
have shown that patients with certain variants of the UGT1A1 gene are more 
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likely to develop adverse effects such as diarrhea from Irinotecan treatment. 
However, doctors may still prescribe Irinotecan if this is the best (or only) treat-
ment option and then try to manage the side effects by adjusting the dosage. As 
Dr. Xie put it:
I agree that [patients with variants in] the UGT1A1, who take certain drugs 
will get much worse diarrhea, get very toxic and very unwell. But the ques-
tion is whether or not it applies to everyone, what is the option [if not taking 
the drug]. If you then develop toxicities, is it manageable? I mean, how bad 
is the diarrhea? If you tell the patient, “if I give you this drug, there is a risk 
that you might develop really bad diarrhea; but if you are willing to take 
that risk, we can see what happens.” If subsequently the patient does well, 
responds to treatment, they might accept that they are having diarrhea ten 
times a day – that it is worthwhile.
Even though Irinotecan results in toxicities, the doctors would still prescribe it 
if it is deemed the most suitable treatment option for a patient at a given point in 
time. To deal with the toxicities, genetic testing is not really necessary as the dos-
age can be adjusted based on the patient’s feedback along the way. As Dr. Chong 
described it:
We just sort of bite the bullet and use it [anyway]. This chemotherapy, Iri-
notecan, is not used that commonly, but sometimes . . . we need to use it, 
because it’s the only option. You know what I mean? So sometimes we use 
a bit of clinical discretion; we start off at a bit of a lower dose and see if it 
goes well. . .
The example of Irinotecan illustrates that genetic testing for toxicities is thus 
not really helpful, as, in reality, patients can be in trying circumstances with lim-
ited treatment options. Even if they are going to suffer from toxicities, the doc-
tors would advise the treatment if it is the only viable attempt to help them. As 
Dr. Xia pointed out:
In actual fact, Irinotecan can be given in several ways, can be given once 
every 3 week or can be given on [a] weekly basis and if given on a weekly 
basis, you have an even better handle on the toxicities. And also, in a con-
text of nothing else to offer for that particular patient, for whatever rea-
son, you know you have exhausted everything else, you are going to try, 
anyway.
Another example is carbamazepine (CBZ), which is used to treat epilepsy and 
other conditions, including diabetic neuropathy, trigeminal neuralgia, and bipo-
lar disorders. The Singaporean Ministry of Health has issued an advisory that 
the use of CBZ should be avoided in patients who are found to be positive for 
the HLA-B*1502 gene allele due to the risk of adverse side effects. Nonetheless, 
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according to Dr. Liang, doctors may still have to use the drug for such patients if 
there is no other treatment available:
[T]he problem [of CBZ’s adverse side effects] was thought to be significant 
enough that the study was done. Some economic projections suggest that 
it may be worthwhile doing the screening, so Ministry accepted it and sent 
out the circulars to all doctors. But it is not mandated, in the sense that the 
doctors still have the freedom to decide whether he thinks it should be done 
or not, because sometimes, we may have no other choice, meaning besides 
this medicine, you don’t have any other choices.
Though some genetic tests for toxicities are highly recommended, as in the 
case of CBZ, whose adverse side effects are widely recognized as significantly 
harmful, in most cases such tests are not as useful as those for efficacy. Two com-
mon reasons for this stand out among all of the doctors interviewed: (1) the 
degree of toxicity is subjective for both doctor and patient, and (2) in clinical 
practice, patients sometimes do not have another choice than to use the drug 
anyway because of limited options or because it is the only treatment option. 
Hence, even if the toxicity test discourages the use of a drug (citing a patient’s 
vulnerability to side effects), the treatment has to be given, albeit at a lower dos-
age if necessary, for the patient’s benefit.
Personalized medicine in clinical practice:  
preventive medicine
The application of genetic testing in preventive medicine is a double-edged 
sword. On the one hand, early identification of susceptibility to certain diseases 
enables early intervention to manage the disease or even prevent it from occur-
ring at all. On the other hand, unlike drug efficacy testing, which is for somatic 
mutations (and nonhereditary), preventive medicine involves testing for ger-
mline mutation. As germline mutation is hereditary, the information affects 
not only the individuals being tested but also other people related to them by 
blood.
To begin with, the doctors generally agreed that genetic screening is more 
appropriate when the subject already has a family history of the disease in ques-
tion, as Dr. Chong described:
[S]o genetic testing on healthy subjects . . . I think the common ones would 
be like breast cancer, if you have strong family history of breast cancer, you 
check for BRCA, you can do just a check for Lynch Syndrome, so I would 
say healthy subjects only if there’s strong family history.
At present, there are a few genetic tests that can be done for preventive 
screening. However, as Dr. Koh explained, such tests are only encouraged if an 
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individual has a family history of certain cancers, suggesting that the relevant 
hereditable mutations might be present, putting the individual at risk:
There has to be a reason to do the testing, it has to be a good reason. So 
for example, I mean, patients who have very heavy family history of breast 
cancer that span across generations, affect multiple family members, well, of 
course we’re concerned that they have certain mutations that increase the 
risk for breast cancer.
. . . there are patient who’d come in and ask us to do genetic testing 
for this cancer or that cancer. I say, look, your history doesn’t warrant that 
because you have no history of this in your family, or you have a history of 
another cancer, which is not relevant to this test at all.
The link between genetic profile and disease propensity is only a probabilistic 
relationship and not a definitive one. In some cases, as Dr. Wu explained, such as 
between a BRCA gene and the risk of breast cancer, the statistical relationship is 
perceived as strong. But, in other cases, scientific research has only established a 
weak relationship, which would have limited value for clinical purposes:
[F]or very specific, well-described phenomenon, where the penetrance of the 
disease is very high, such as BRCA, and cancer. . . . But not . . . when you’re 
looking at the GWAS result, where it tells you that the risk is 1.3 times, or 
1.2 times, I mean, how does that actually impact human health?
I guess it’s a matter of effect size. . . . [T]he number of genes where the 
odds ratio is more than five, or whatever, is really limited. . . . [M]ost of these 
variants are at less than odds ratio of 2. So how does a 1.8 times or 1.7 times 
risk matter?
There’s . . . I mean, there are very clear causative variants that . . . such as 
BRCA and all that, where the odds, the penetrance is like 80 percent or so, 
and that is very clear. Those are clear-cut causative.
Unless the causative relationship between the incidence of the disease and the 
specific gene mutation is proven to be significantly conclusive, the test results 
would not have practical concerns for the doctors interviewed. After all, accord-
ing to Dr. Xie, given that the human genome is huge, such findings can be com-
mon and clinically insignificant:
There are some genes where the penetrance is very high, where you know 
that if you got this underlying mutation, you are very likely then to develop 
this cancer, like the BRCA mutations for example. . . . [T]hese patients then 
go ahead and have their prophylactic mastectomy and oophorectomy. The 
problem is that there are probably a whole host of other genes that people 
have done these big studies on what we call SNP studies, single nucleotide 
polymorphisms studies. So they found that this particular polymorphism in 
a particular amino acid, in a particular exon, or promoter region or even a 
non-coding region of the gene, predisposes you to a risk! So how do you 
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resolve that biologically and the thing is we don’t understand that much at 
the moment.
The doctors interviewed pointed out that the public may not understand the 
full picture – that gene mutations only suggest probabilities of developing cancer 
and do not precisely determine the emergence of cancer. Dr. Liang pointed out 
that, without proper counseling by medical professionals, genetic testing runs the 
risk of creating unnecessary anxieties:
[E]ven Angelina Jolie – doesn’t mean she will get breast cancer. She has a 
very high chance, that’s all. There is a chance that she might not even get it. 
You know, but the public, some of them don’t understand this thing about 
probability and chances.
The problem with genetic counselors is that they can only counsel from a 
very statistical viewpoint. They don’t know the disease. They cannot know so 
many diseases. He may know in terms of understanding from the probability 
perspective, what it means and the risks of inheritance.
Quoting the prominent case of Angelina Jolie who underwent mastectomy and 
oophorectomy because of the presence of the BRCA1 gene mutation, Dr. Koh 
explained that the presence of the specific gene mutation implies only a high 
probability of suffering from the cancers in the future, but nothing is definite. 
Healthy subjects might be subjected to health scares, with statistically significant 
predisposed genetic risk shown, especially if genetic counselors provide guidance 
mainly based on statistics reflected in the reports, with minimal or no knowledge 
of the diseases in question. Dr. Koh continued:
You can tell someone, [taking the genetic test] will help you to understand 
that your chance of developing a disease is twenty percent higher than a 
person who is negative for that polymorphism, or even twice – but the prob-
lem is that, they don’t explain to people, before they are tested, that the 
frequency of this problem is one in ten thousand, and so your risk of hav-
ing this if you test positive is two in ten thousand. I mean, that’s not really 
meaningful, right?
That’s not really meaningful to people, because, people will be walking 
around thinking, oh, I have twice the risk of developing Parkinson’s disease. 
Well, yes, but Parkinson’s disease is not that common!
The risks reflected are not always clinically meaningful, as the probabilities of 
getting the disease might not be as high as the statistics appear to show, especially 
after taking into account population statistics. As Dr. Wu noted, these results 
could lead to unnecessary apprehension and would not serve anyone well, as 
there is no guarantee that the subject will suffer from the disease:
I think there are two things to balance, the sin of omission and the sin of com-
mission, which is, the patient knowing it will allow them to go for screening, 
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or go for certain risk-reduction strategies, and that will benefit them and 
potentially save lives. But if you tell them the wrong information, it will cause 
unnecessary anxiety and possibly in certain rare cases, overtreatment.
The results of the genetic tests for preventive purposes can be highly detri-
mental to a healthy subject’s psychological health. He/she could become highly 
insecure and paranoid, and if there is a family history, other family members could 
be affected as well. As Dr. Hsu pointed out:
. . . you may actually get results that impose psychological stress to the 
patient. Once they know that they’re a carrier of the gene, every time you 
have a stomach pain, you think that cancer is back; every time you feel a 
lump in the breast, you think that cancer has come. So the psychologi-
cal cloud over you is very devastating. And more importantly, you’re also 
transferring that psychological pressure, to all your blood relations. Every 
woman in your family, every sister gets the same stress (with breast cancer 
as an example), so that’s very devastating.
Doctors like Dr. Koh emphasized the necessity of support mechanisms to help 
subjects understand the implications of their genetic profiles and also manage 
anxieties that may arise:
. . . so we ask them to do testing, but we explain to them why we think 
that they’re likely to have the mutation, we explain to them what the muta-
tion testing involves, we explain to them what the possible implications are, 
including, loss of privacy, potential loss of employment, insurance, if that 
data were to become available to third parties, all those things you really have 
to explain to patients.
The data from genetic testing are sensitive, highly personal, and require rele-
vant professionals and experts to provide an explanation of the results. Individual 
patients without the necessary knowledge might not understand the outcome 
properly and may not be able to deal with the situations that could arise. As 
Dr. Xie put it:
I think we need to agree that they should at least understand what is being 
tested, what are the implications to them if something positive is found, 
especially if it is a germline mutation that predisposes . . . them [to] a high 
risk of developing of a particular condition and how to deal [with] that con-
dition. So suddenly you do a test and you got an 80 percent [chance of] 
Alzheimer’s disease, or you got Huntington disease. How are you going to 
deal with all that? So I think . . . there will need to be healthcare professionals 
that are trained specifically to deal with these issues of molecular testing and, 
and sequencing in order to de-convolute the complexities of these issues for 
the patients.
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On top of the need to have health care professionals to assist individuals in 
understanding their test results and consequent decision-making, Dr. Xia warned 
that other general issues, such as health insurance concerns and data privacy, 
should be considered, as information on predisposed biological risks might prove 
to be too much of a liability:
There are other implications, you know such as insurance. . . . Because if 
let’s say her daughter [i.e. the patient’s daughter] were to buy health insur-
ance in the future, the family history is often asked about. Then she would 
have to say that her mother has breast cancer and of course the question 
on whether you should then offer and volunteer the information that your 
mother has a BRCA mutation. I mean the mother could choose not to tell 
the daughter right? Okay, then in which case, that’s the point the daughter 
is not burdened with this information . . . should you or should you not tell 
your relatives that you are a carrier.
Thus, for subjects who are found to have gene variants that are associated 
with increased risk of a certain disease, there is then the difficult question of 
what the clinical response should be. Apart from more frequent screenings, 
which in themselves could generate anxieties, should highly invasive medical 
procedures be considered to further reduce risk? For example, if a subject has a 
mutation in the BRCA1 and BRCA2 genes, should she undergo a mastectomy 
to eliminate the risk of developing breast cancer? Dr. Hsu shared his clinical 
observation:
. . . once you know the results of the test, it leads to two adverse outcomes. 
Number one, you need to do mutilating surgery to yourself – if you have 
BRCA1 and BRCA2, you need to remove both breasts, both ovaries. If 
you’re found to have FAP gene, you need to take out the entire large intes-
tine, at the age of below twenty-five. So, we’re talking about doing mutilat-
ing surgery, to people who haven’t got the cancer, but they have a high-risk 
of getting the cancer. So you’re doing mutilating surgery to young people 
before they even get the disease. Very hard to accept.
Consequent actions that individuals have to consider or act upon after being 
informed of their predisposed genetic risks are usually surgeries to remove rel-
evant body parts where the diseases in question might develop. The effects of 
these surgeries are permanent, and, hence, such preventive measures require 
much consideration by both the doctors and individuals. Dr. Zhang wondered 
how doctors should advise patients on preventive measures based on genetic test 
results that reveal the probability of developing a particular disease:
As for susceptibility, yes we know it predicts susceptibility but the level of pre-
diction is still not very high. In other words, the person who has a particular 
mutation, the chance of them developing cancer is still not 100 percent. So, 
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we probably can’t use that to guide us in our treatment. We can at best tell 
patients to be more careful and to do more frequent screenings.
Genetic testing for preventive purposes seems to have more adverse implications 
than benefits based on these doctors’ accounts. First of all, such data are not eas-
ily comprehensible. Second, these tests only indicate the likelihood of disease but 
provide no definitive answers. This could potentially cause much distress for indi-
viduals, and even for family members, particularly since the germline mutations in 
question are heritable and would affect future generations. Lastly, there are limited 
measures that individuals can adopt to reduce biological risks and prevent the dis-
eases in question. Thus, doctors generally agreed that these genetic tests in relation 
to preventive medicine should be done in the context of a strong family history.
Conclusion
This chapter highlights the tensions between racial and ethnic categories con-
structed in the contexts of global genomic science and the pharmaceutical indus-
try, and national public health policies and practice at the clinical level. The 
physicians interviewed explained that these endeavors are not helpful in their daily 
practice of personalized medicine. The reservations from the physicians were not 
so much concerned with research methodologies and the deployment of racial/
ethnic categories in genome science and medical research, but the usefulness of 
such information because there is no perfect corrleation between ethnicity and 
genotype. For example, even though the prevalence rate or the frequency of the 
EGFR mutation may be higher in the “Asian” or “Chinese” population, this does 
not mean that doctors do not offer genetic testing to an “Indian” or “Caucasian” 
patient. Indeed, they emphasized that EGFR mutation testing should be done 
for each lung cancer patient, irrespective of ethnic identity. This chapter lends 
support to what Cooper, Kaufman, and Ward (2003:1167) point out: “if you 
really need to know whether a patient has a particular genotype, you will have to 
do the test to find out.”
Moreover, the applicability of such racially/ethnically framed knowledge about 
human genetic structure seems weakest in the case of preventive medicine, as 
compared to treatment decisions related to either therapeutic efficacy or toxic-
ity. That is, even if the penetrance rate of the BRCA gene, associated with breast 
cancer, may be particularly high in a given population, the doctors still think that 
such genetic testing for disease susceptibility should only be recommended when 
the individual has a strong family history of suffering from the disease. There 
are complicating factors such as the fact that there is no consensus regarding the 
definition of high penetrance, the context of each disease might be different, 
and the percentages and/or effect size of a particular genetic variant changes 
as a function of shifting boundaries of ethnically and racially labeled popula-
tions. Ultimately, what the research studies and genetic tests offer are probability 
statements. Through genetic tests, and being informed about whether a specific 
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mutation is present or absent, certain treatment options will be preferred, as these 
treatments are “probably” going to work better than others.
Genetic tests are not available for all types of mutations or all diseases. Thus, 
given the availability of selected tests, clinicians have to balance treatment options 
and discuss them with patients. If the desired treatment against one particular 
mutation does not work in sync with another treatment for other mutations or 
diseases, clinicians have to restrategize. Additionally, drugs may not have been 
developed to work against particular mutations. As genetic testing is becom-
ing more prevalent in the clinical setting, and more and more genetic tests can 
be developed at a faster pace than drugs can be developed, clinicians may find 
increasing numbers of “orphan patients” without medical treatment.
Last but not least, given the limitations noted in this chapter – such as limited 
or lack of access to genetic tests, the immaturity of scientific research on genet-
ics and disease causality or drug response – clinicians might still rely on existing 
racial/ethnic categories of patients to prescribe medicine, a practice that they 
criticize. To put it differently, the overwhelming consensus among the practicing 
clinicians interviewed is that race/ethnicity is a specious proxy for individual gen-
otype. Given this, we need to be wary of the increasing bifurcation of the clinical 
care where race and ethnicity is used, unfortunately, as the poor man’s genomic 
test. In other words, the overwhelming consensus among the practicing clinicians 
interviewed is that race/ethnicity is a specious proxy for individual genotype. 
Given this, we need to be wary of the increasing bifurcation of the clinical care 
where race and ethnicity is used, unfortunately, as the poor man’s genomic test.
In line with this discussion, I will also suggest that this production and utili-
zation of genetic knowledge involves an ethical dilemma, which will be further 
explored in the next chapter.
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“If living were a thing that money could buy, you know the rich would live, and 
the poor would die . . .” All My Trials (traditional folk song)
Introduction
This chapter highlights lessons learned, primarily from medical oncology, in terms 
of challenges and limitations of interventions at the molecular, as opposed to the 
environmental, level when addressing the complex disease of cancer. Interview data 
suggest that the unique feature of genome-based personalized medicine is that it 
is expensive but not curative. Given this characteristic, we focus on various ethical 
dilemmas of personalized medicine provision from the perspectives of physicians. 
For example, doctors struggle with questions of whether to recommend genetic 
testing and, after testing, whether to recommend certain kinds of genome-based 
personalized medicine. Given that socio-economic resources are finite, should a doc-
tor provide all available information or only information as needed by the patient? 
This chapter describes the different ways oncologists handle these ethical dilemmas 
and potential challenges to their resolutions. Finally, some medical researchers and 
oncologists raise the question of whether personalized medicine should be the pri-
mary way to fight cancer, particularly when “estimates based on a range of scientific 
evidence indicate that more than 50 percent of cancers can be prevented” by inter-
ventions at the environmental level (Colditz, Wolin and Gehlert, 2012).
Genome-based personalized medicine is effective but not 
curative; moreover, it can be prohibitively expensive
Concerted efforts to promote personalized medicine could lead to patients and 
the general public having unrealistically high expectations, thinking that many 
previously incurable diseases could now be treated with personalized drugs. 
Dr. Zhang (public hospital) noted the need to manage the expectations of 
patients and the public:
I think one of the things that we have to be careful [about] is the patient’s 
expectation, the expectation of the society, of the community. There are 
actually very few blockbusters, very few real big breakthroughs in the last 
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thirty years. Things like Penicillin is one breakthrough. Beyond Penicil-
lin . . . there’s hardly any new breakthrough in medicine. Because all these 
new molecular [therapies], they are not curing the patient.
Oncology is the field of medicine that has seen the most extensive application 
of personalized medicine. However, personalized drugs rarely cure cancer – even 
if they have the promise and potential to prolong the lifespan of the patients by 
several months and perhaps also to improve quality of life during those months. 
Dr. Zhang said:
Just prolonging, so in the past it’s maybe from 6 to 9 months, now from 
9 months to 12 months and later on from 12 months to 18 months. So it’s 
longer. So we tell patients, say, this drug helps to . . . reduce the risk of death 
by one third, prolong the life by double. To patients, of course, reduce one 
third, very good. Double, of course it’s very good but the absolute differ-
ence is actually minimal.
Effective but it is not curative. We don’t cure the patient. If we use this 
effective drug, patient live longer. The conventional chemotherapy with 
a lot of side effects . . . patients live shorter. The difference is probably 
6–12 months . . . many more thousand dollars per month.
. . . It is effective because it is targeted therapy; it only hits the cancer cells, 
and sparing the normal healthy cells. There [is] a lot of chemotherapy that 
ends with NIB or NAB. NAB is all the antibodies, all these costs probably 
$5000–8000 a month, this one more expensive. The outcome of patients 
treated with this therapy [referring to NAB] is a lot better – they live longer 
than patients who just received treatment using conventional, old-days 
chemotherapy. But, unfortunately, most of these patients are still not cured. 
So using all these expensive NIB and NAB, maybe they live one and a half 
year, two years, three years; whereas those who use the conventional therapy 
maybe live one year, 14 months. So there is a difference.
Indeed, Dr. Zhang went so far as to say that, if he had cancer, he would not 
want to undergo expensive personalized medicine treatment just for the sake of 
prolonging his life by a few months.
I believe that if I have cancer, I will not want to waste my money to using 
such expensive (Cetuximab) chemotherapy to prolong my life for just one 
year. I will be happy just with conventional chemotherapy – whether type B 
or type C are good enough, just control my cancer and let me live 6 months 
longer – 1 year longer to do what I need to do.
Dr. Tang shared a similar observation that genome-based personalized medi-
cine is not a cure:
At this point in time, the majority of the patients, their response is not 
durable.
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Genomic medicine, as a representation of progress and advancement in scien-
tific knowledge, also has its limitations. A recurring theme discussed by multiple 
doctors is the myth that personalized medicine “cures,” while, in fact, most of 
the time it offers only temporary relief. Moreover, doctors are voicing serious 
concerns about the high and growing costs of personalized medicine for cancer 
patients (Pfister, 2013). As Aronson (2015) explains:
If precision medicine can distinguish patients who will benefit from a treatment 
from those who will not, in principle, care should become more efficient and 
less costly. But the converse can also be true: treatments become more expen-
sive as the costs of development must be distributed across smaller populations.
Furthermore, while drug development and related research are costly, Pfister 
(2013) suggests that “what the market will bear” seems to be a central pricing 
consideration and priority among pharmaceutical companies. The high prices of 
such drugs inevitably call affordability for patients into question.
Should the cost of a cancer drug be  
part of the treatment decisions?
Personalized medicine is a nascent field and is at different levels of maturity 
for different diseases. Nonetheless, as personalized medicine represents a “new 
frontier,” some doctors may be pressured to employ its techniques, especially in 
terms of ordering genetic testing, even though clinical benefits may be uncertain. 
Dr. Xia argued:
We must order FoundationOne1 for all our patients. Because we have talked 
about this in this meeting . . . and such [organizations] have already endorsed 
this, so sometimes the squeakiest wheel gets the most grease, right. But it’s 
like advertising. . . . Do you really understand what is being said and on what 
basis? You have to think critically . . . and you must have the knowledge of 
science to actually judge and interpret yourself, whether it is all fluff, and 
just another way for companies to make money or it really does make an 
impact on your clinical practice. And I actually suspect that there are a whole 
lot of clinicians that don’t understand it . . . [and] therefore they are very 
taken, they are very easy to get swept off their feet, with brilliant pictures, full of 
colors . . . [emphasis mine]
Genetic testing is currently, to some extent, a medical trend. However, looking 
beneath the surface, the test results might not be useful for clinical practice. As 
implied above, what is the relevance of a genetic test if the patient cannot afford 
the specific drug afterward? Dr. Zhang illustrated this point:
Once upon a time, I told our colleague, if you have a patient who has colon 
cancer after operation, just to do that test, is $400. So if I think I don’t want 
to use this drug, no need to test, don’t waste my money. Now EGFR is also 
Socio-economics and ethical dilemmas 123
very expensive. All these are expensive. But my colleagues looked at me and 
laughed. They said, “you are an old dinosaur. In this era, everybody must 
have that test.” So now it becomes a standard test . . . anybody who has gone 
for the operation will have that test, whether you want to use that drug or 
not, it doesn’t really matter. Some patients are so frail and weak that they 
didn’t have the chance to take even simple chemotherapy, but they have that 
[genetic] test done.
Because science has moved to a new era that everybody will have that test. 
So that we can tell our foreign colleagues, we can tell other countries that 
in Singapore, we have X percent of patients who have this test done and X 
percent who have this positive, X patients who have [been] treated [with] 
this [targeted therapy]. . . . This is [a] standard test, nobody has a choice. 
You don’t have a choice.
Indeed, even if the genetic test sheds light on a specific treatment to maxi-
mize patient outcomes, such results are of no value if the patients cannot afford 
the specific drugs. However, genetic tests are still often advised, or may even 
be binding, as the first step forward in cancer treatment. Patients sometimes 
unknowingly have their choices restricted by a medical trend that has increasingly 
engulfed their trusted doctors. Dr. Zhang pointed out:
A good example is . . . a patient being offered a treatment that cost $6000 
a month. Now, this patient is a recent migrant; she didn’t have much of 
savings. This is a tailored personalized treatment because the cancer has a 
certain mutation that can be treated with this new drug. . . . But this patient 
cannot afford [it]. Are you going to tell her, “sorry, we have a medicine 
but since you can’t afford [it], we can’t treat you”? [pause] On the other 
hand, we also have other drugs for this kind of cancer. The result is not as 
good as the new molecular targeted therapy, which cost[s] $6000 a month. 
Our standard, basic chemotherapy for these patients probably cost[s] about 
$1500/$1200 per cycle or for a month. In terms of outcome, yes, the tar-
geted therapy has less side effects, they live a little bit longer. The cheaper 
therapy . . . more side effects and the survival is a little bit shorter. But [con-
sidering a] patient’s [difficult] social and financial situation, probably the 
basic old treatment is more applicable. But because of the emphasis and the 
need to brand our targeted personalized therapy, patients were very often 
given only one choice [of the $6000 a month treatment].
Having said that, while the “new norm” in cancer treatment may be to order 
genetic tests and to prescribe genome-based therapies, doctors also pointed out that 
most genetic tests are not mandatory. In principle, doctors and patients have the lib-
erty to decide whether to perform genetic testing, as Drs. Xia and Hsu pointed out:
DR. XIA (PRIVATE CLINIC): Testing for BRCA mutation in a patient with breast 
cancer is not a problem. You know that, of course, patient herself, make the 
decision as to whether she wants to test it or not.
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DR. HSU (PRIVATE CLINIC): So for the tumor profiling, in fact, all the profil-
ing the patient will pay, insurance company will pay, and they are not very 
expensive because each test of the tumor profiling is about a few hundred 
dollars. They are only specific, commercially-provided tests, the Oncotype 
DX, these two tests, one for breast, one for colon, they cost about four 
thousand dollars each. That one is quite hefty, I’m not sure whether all 
insurance [companies] will pay. But for the other tests, which are only two 
hundred dollars, three hundred dollars, the patient will pay out of pocket 
without difficulty. So the payment is not much an issue, therefore adoption 
is widespread, because the data is very important to the therapeutic, and 
the cost is only two three hundred dollars, most patients are willing to do 
the test.
In other words, compared to the therapeutic (drug) aspect of personalized 
medicine, the diagnostic (genetic testing) aspect may appear less costly and is 
probably not much of an issue for patients who can afford private health care in 
the first place.
However, for poorer patients, a genetic test costing hundreds or even thou-
sands of dollars is still a significant financial burden, as Dr. Xie noted:
Some patients [would say] . . . if you are telling me that . . . I should get this 
drug, but only if this test is positive, but I can’t afford the drug, so why waste 
my time? I’m not going to have the test. The test itself is expensive.
Similarly, Dr. Hsu was concerned about the accumulated costs, and he added 
the problem of “orphan patients”:
Even a research assistant can find a new gene, you know, very easy to find, 
and very easy to translate that into a test. The cost is very low. The genomic 
testing nowadays, molecular or immunohistochemistry, very easy to do. So, 
truly, the laboratory advances, there is no barrier, there is no barrier, they 
can move very fast. Every few months you have a new gene that comes 
out, and, nowadays, all the clinical trials store specimen, so they’re able to 
go back to the archive to take out a specimen to test, so they can correlate 
between what is in the lab, and what is in the specimen. So, this movement 
is very quick.
The problem is, who is going to pay for all these additional tests? Each 
test is about three four hundred dollars, so to put things in perspective – 
previously, we do KRAS number 2, now we know there’s KRAS 3 and 4. 
And then now we do NRAS 2,3,4. So, in other words, previously we do 
one test, which cost two hundred and twenty-five dollars. Now there are 
six tests. That becomes a thousand plus dollars. And if we see this we’re not 
happy, we can do the BRAF, which is 11 and 15. So there are eight tests to 
do. So this rapid explosion, there’s no limit for it, because people feel that 
being able to be more targeted allows less wastage of drugs. So as a result 
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of that, there is insatiable desire to keep taking out [a] new gene, and try to 
narrow [it] down. But this makes therapeutic[s] a bit complicated, because 
for those groups of patients that don’t fulfill the very narrow group, what 
do you treat them with? So, more and more patients are excluded from 
drugs which previously they would receive. So the complexity of such an 
approach is that, number one, a lot of costs will go into the testing; num-
ber two, some delay, in terms of treatment; number three, more and more 
people are disqualified, from treatment, because the treatment is becom-
ing more and more targeted, you see. So you have a lot of orphan patient. 
Orphan without parents right? So orphan patient. Because there [is] no 
drug to treat them, because oh, by this criteria, excluded, by this criteria, 
excluded. By the time you split everything, all the good drugs cannot be 
used anymore.
In the context of limited economic resources (such as public hospitals), oncolo-
gists sometimes assess the financial background of their patients and recommend 
treatment that is affordable rather than the most cutting edge. This is partly to 
save patients and their families from having to confront face-to-face the morally 
difficult question of how much an extra few months of life are worth. Dr. Zhang 
pointed out:
Here, when I see a patient in [a] public hospital, we don’t tell them “look, 
this drug is $10,000. You can have Drug A. Or, otherwise, you can choose 
Drug B, $3000. Or, you can have Drug C at $1000.” If I say this in front of 
patient’s children, “Here are 3 drugs for your mother, you can have $10000, 
$5000, $1000, which one do you want?” How do you expect the daughter 
to answer this question?
So here, we roughly assess and look at the patient’s and family’s financial 
background, and we make our own decision: “look, I think that 6 months 
extra life is not worth putting in all this money. Don’t sell your house. Don’t 
borrow money from relatives.” If I think using this drug is good enough, 
I will treat this patient with this drug and I will not escalate . . . if necessary, 
we will keep it around that level.
In Singapore, the Standard Drug List (SDL) is based on the World Health 
Organization’s (WHO) Essential Drug List, but is ultimately determined by the 
Drug Advisory Committee (DAC) and MOH (Ministry of Health, 2011). As 
Appendix E indicates, in Singapore, many of the PM drugs are not on the Minis-
try of Health’s Standard Drug List and hence not subsidized by the government. 
The SDL has been split into two components, SDL I and SDL II (Khalik, 2011). 
The former covers an array of cheaper generic drugs, while the latter covers some 
more expensive targeted and branded therapies (Khalik, 2011). The SDL lists, 
I and II, appear to be collectively compiled on the MOH website (Ministry of 
Health, 2015). The state’s decision to publish this list is relatively new as well. 
As recently as 2011, in Singapore’s Parliament, the Worker’s Party (WP) asked 
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if the SDL was public record, as even health care professionals appeared unsure 
of what drugs were actually on the lists (Ministry of Health, 2011). The state’s 
justification for not publishing them, as was reported in Today Online, rested in 
the fear that “Big Pharmacy” would exploit the lists and lobby for their products 
to be included (Lim, 2013).
Drugs on the SDL II list are subsidized at a rate between 50 and 75 percent of 
their retail cost (Ministry of Health, 2012). To qualify for the higher 75 percent 
subsidy, however, patients must come from a low-income family, earning no more 
than a monthly SGD$1,500 household per capita income (Ministry of Health, 
2012). Of the 18 personalized drugs listed in HSA’s database, only two are on 
the SDL. They are trastuzumab (known as Herceptin) and letrozole (known as 
Femara) (Ministry of Health, 2015). The remaining 16 drugs, however, may 
be covered under the Medication Assistant Fund (MAF). The MAF subsidizes 
expensive drugs that have not been included on the SDL, but are deemed neces-
sary to treat patients (Ministry of Health, 2012). Indeed, in response to a query 
made concerning the availability and cost of afatinib, a personalized drug used 
to treat non-small-cell lung cancer with an EGFR mutation, the National Cancer 
Centre noted that, though the drug is not currently on the SDL, the MAF could 
be extended to cover it (Toh, 2014).
Even with state subsidies, however, doctors interviewed pointed out that for 
patients who are of fewer means and who are also not covered by private health 
insurance, personalized medicine drugs are simply out of reach, or they would 
involve depleting savings, borrowing, or selling property to raise funds. Dr. Xie 
pointed out that:
[I]n this economy . . . everyone is a paying patient, the cost of health-
care is quite an issue that we don’t tend to consider, in terms of genomic 
medicine – even if the patient has got [an] EGFR mutation, and you say that 
look you’ve got to spend $3000 a month, to pay for this drug, and you got 
18 months of expectancy, it means that you survive for 18 months versus 
six months, the guy might say, okay, so for the extra year, I’m [going to] 
spend a heck of a lot of money for something that is ultimately going to kill 
me. So why don’t I save the money and give it to my kids for their educa-
tion? Okay, so there’s, at the end of the day itself, there is the opportunity 
cost as well, for individual patients. And, in the end, it is beyond genetics, 
it is also a social issue, alright? Socio-economic issues. I mean the guy who 
can afford anything, it doesn’t matter what they’re doing, $3000 a month 
is like a job promotion, but for the average uncle, he can’t afford to pay for 
his rent. . . . I am sorry, your genetic test or not, I am still not being able to 
afford my treatment.
But, the other question is . . . an overall survival benefit is not that 
huge . . . so the question is how much are you willing to pay for an extra year 
of life? How much are you willing to pay for extra two years of life? [I]t looks 
like in the country where there is no national health service, health provision 
is primarily provided by patients, then it very much depends on whether you 
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have insurance or not. If you don’t have insurance, then unfortunately that a 
lot of these things are beyond your means.
The accessibility of PM drugs being closely linked to socio-economic circum-
stances can be especially disturbing in cases where the PM drug is the only treat-
ment option available, as Dr. Teo described:
[I]f a cancer patient comes to us; we don’t want to deny care to them. So 
[you] can imagine a person with liver cancer, and he lives in a two room 
flat, Jurong West, and he’s a low cost labourer, for example, and he has liver 
cancer. And [the doctors] say “Uncle, it’s going to cost you $8000 a month 
to get sorafenib.” You know what I mean? It’s crazy. And that’s the only 
approved drug for liver cancer.
Doctors have found themselves caught in a dilemma. On the one hand, they 
feel compelled to prescribe genomic medicine as it is deemed as the “new norm” 
of medical advancement. On the other hand, they have to confront situations in 
which patients are unable to afford the cost of such medical acceleration.
As oncologists grapple with the issue of whether to order genetic testing and 
prescribe genomic medicine for the general public, they have pointed out the 
necessity of opening up a difficult discussion regarding priorities in allocating 
finite resources for public health care deliveries. More specifically, this entails 
intensive deliberations on moral and social dilemmas. When asked to allocate 
limited resources (thus involving valuing one population group over the other), 
doctors found themselves torn between making a financially sensible decision or 
an emotional one. Dr. Zhang asked:
How do I tell patients that the difference is about a year, or a year plus and 
do you think this is affordable? If I have money, I pay $8000 a month and 
I live 3 years. If I can’t afford, I use cheap chemotherapy, I live 1.5 years. 
The patient says how can you measure lifespan, human’s life with money? 
That’s why, last week, there was a complaint letter in Straits Times column 
about patients. The starting statement is “My mother is 84 years old” and 
the last statement is: “This drug cost $4500 a month, how come [the] 
government doesn’t subsidize [it]?”2 You are the tax payer, you [have got 
to] ask do I want to use my money to subsidize the care of a patient at 
84 years old, who has an incurable cancer using something [for] $4500 
a month? Can I use this money to help children get better nutrition and 
education?
Although uncomfortable, an open discussion and debate regarding the pri-
orities of allocating public resources is vital in answering important questions: 
who are the stakeholders, and how are they affected? It appears that, in response 
to these questions, one is made aware that eventually the cost may have to be 
passed on to the citizens, either in terms of higher insurance premiums or higher 
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taxes. With this awareness of sharing costs, what other repercussions will arise? 
Dr. Zhang answered “wastage”:
So in America, everybody gets Cetuximab upfront. Anybody [who is a colon 
cancer patient] who has Kras wildtype will get Cetuximab upfront. Here, 
I do not give Cetuximab. We use conventional chemotherapy. In [a] private 
hospital, in [the] U.S., everyone gets Cetuximab upfront. Here, no. So if 
you have money/savings, that’s fine, carry on. But if [the] health insurance 
[company] knows that everybody who has colon cancer gets Cetuximab, 
next time they will jack up the premium for everyone. So in the U.S., every-
one is paying $400–800 a month for health insurance. . . . But if I buy health 
insurance, am I going to spend money on [a] premium to subsidize other 
people so that they can get Cetuximab – something that I myself will not 
want to waste my money on? [pause] And if [the] government steps in and 
say that we will fund everyone, then my income tax will be used to pay for 
other people’s Cetuximab treatment when I myself will not want. And when 
you go into health insurance and government full subsidy, it is okay if you 
use the money to pay for effective treatments wisely. But the trouble is that 
once you get into that mode, people become very wasteful. . . . [E]verything 
I want, I bring home first, whether I use it or not, never mind . . . since it 
is free. So if everybody takes everything, premiums have to go up and taxes 
have to go up.
Nonetheless, doctors have noted the health care expenditures borne by patients 
are disproportionately high in Singapore compared to other jurisdictions in Asia 
at a comparable stage of economic development, such as Hong Kong and Tai-
wan. Dr. Teo said:
I think there is still a lot of out of pocket payment for patients. . . . I just came 
back from Hong Kong and a Singaporean spends 58 cents of every dollar 
on healthcare . . . and that includes Medisave. In Hong Kong, it is less than 
10 cents. If I am not wrong, it is about 10 cents. Can you imagine? A Hong 
Kong citizen who falls sick only spends 10 cents for every dollar of health-
care. But here they spend 58 cents. I think the government knows that and 
is rolling out more and more healthcare subsidies for this year’s budget. But 
we felt that for the longest time, it was just too low. Some of us see it that 
way. And . . . in Taiwan, it is national health insurance.
Doctors pointed out that Singapore government policies restricting the use of 
Medisave to cover expenses for genetic testing and counseling are obstacles to 
using PM not only in therapeutics but also in preventive medicine. For instance, 
if a patient tests positive for a gene variant that predisposes him or her to a par-
ticular type of cancer, then the patient would need regular screening (such as 
MRIs) to monitor whether he or she actually develops the cancer. Such preven-
tive screening, however, cannot be reimbursed under Medisave. Therefore, for 
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a patient with an average income, this begs the question of, what is the true 
purpose of developing or bringing in PM when the patient’s hands are tied by 
the steep cost of treatment and the inability to get any subsidies for it? Dr. Liang 
(public hospital) asked:
If [the] government sends me for this test, and I can prevent these illnesses, 
why can’t I pay Medisave for it? These questions will come, you see? . . . . 
[T]hen the next thing is that now that I have the test done, when I go and 
consult a geneticist, do I get subsidies when I consult?
The issue of state subsidies also surfaces in the area of recommending genetic 
testing as a preventive measure. Chieng and Lee (2006) note that, since 2003, 
patients could qualify for a 100 percent subsidy for the BRCA1/2 mutation 
screening if they were clinically deemed to have a 30 percent chance of having the 
mutation. But the extent to which state subsidies cover other types of predictive 
genetic testing is not clear. As Dr. Neo (public hospital) pointed out:
We have no insurance reimbursement, we have no Medisave revenue; let’s say 
we have a mutation, and you need time to [have an MRI screening]. . . . So, 
if you can imagine, if I talk to a patient, and I tell them, based on your fam-
ily history, you have a very high chance of having a mutation. I am going to 
offer you screening. Screening is $4000. It has to come out of your pocket. 
And sometimes, they will think about it and they will say okay, fine, because 
of my family history, I would like to know. They do the testing but even if 
they’re positive, subsequent to that, there is still no reimbursement for the 
screening measures to keep them free from disease. So that’s something that 
I am hoping to change.
In summary, several challenges were raised in discussing the cost of prevention 
and treatment using PM. First, the introduction of PM left doctors running on 
a medical treadmill. Yet, this cutting-edge development (i.e. genetic testing) is 
limited in both long-term benefits and value, particularly for patients unable to 
afford follow-up genomic therapies. Doctors thus found themselves caught in a 
difficult situation: since a reasonable conclusion would be that adoption of such 
genomic medicine corresponds to economic resources, should they even cre-
ate the awareness of the availability of costly drugs for lower income patients? 
Eventually, we may observe a scenario in which PM serves only a small, privi-
leged group of people who can afford it. Second, the adoption of PM inevitably 
implicates a wider population beyond the patients and their family members. 
Ideally, insurance and/or government subsidies should assist in making PM 
affordable for those in need. Realistically, such practices will encounter an uphill 
battle in convincing the general public to contribute higher premiums/taxes, 
particularly when the pricing of PM is unlikely to come down in the near future. 
Ultimately, we may see that the high costs of PM may serve as a negative factor 
in effectively (re)distributing health care resources.
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Who should be expected to interpret genetic tests when 
cancer is a “context-dependent manifestation”?
In addition to the matter of high costs of personalized medicine, there is also 
marked concern about knowledge gaps. That is, the question arises of whether 
doctors are sufficiently knowledgeable about genetics to be able to competently 
interpret test results in order to inform their clinical decisions. Dr. Xia described 
this situation as follows:
I think that a lot of clinicians, not that I’m trying [to make them look good] 
or to blacken their names. But I think they don’t truly understand the sci-
ence behind all [this] molecular testing. They take a lot on trust. What I kind 
of fear, is the formulation of treatment recommendations, that [are] based 
on what their scientist friends tell them. You know what I mean? Because 
they may not have the capacity to actually delve into the scientific data and to 
truly understand, what it all means but rather they are taking it on the basis 
or on the recommendation of their scientist colleagues. I actually fear that.
[T]his edges upon the age old thing about how much of a clinician should 
you be and how much of a scientist should you be. Of course, in an ideal world, 
you understand everything, but that’s not the case. In reality, there are actually 
a lot of clinicians who don’t understand the scientific basis of a lot of the stuff.
Existing studies have found that nongeneticist physicians are not well equipped 
with the knowledge to interpret complex clinical sequencing reports and com-
municate results to patients (for example, see McGowan et al., 2014). This 
observation is likely to be relevant to Singapore’s context due to the very nature 
of medical specialization. Dr. Liang, who specializes in palliative care and does 
not practice in the field of oncology, admitted that he does not have in-depth 
knowledge about genetics:
Honestly, sometimes the doctors themselves do not know the exact infor-
mation. Just ask me about [the] BRCA gene, I really don’t know very much 
about it. I know it is a source of cancer but I can’t tell you what is the proba-
bility, and I can’t tell you what are the other factors that may affect it. . . . So, 
it becomes more and more difficult for the doctor to have that amount of 
knowledge with them.
Due to the hype about personalized medicine and the enormous amount of 
information available on the Internet, better educated patients could investigate 
on their own. They could ask their doctors questions that the latter may not have 
up-to-date knowledge of to answer competently. This could put doctors in a 
dilemma: appear ignorant in front of patients or risk providing incomplete or inac-
curate information. This concern was addressed in a candid manner by Dr. Liang:
For example, if let’s say you have an interest in [the] BRCA gene, after  reading 
an article, you may have read up more. But let’s say I am working with the 
elderly, I don’t care about [BRCA] genes, then suddenly if you ask me, I really 
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don’t know. I must go and check. . . . And sometimes, the doctor can be caught 
unaware about some things and doctors don’t like to look stupid, that they 
don’t know about it. . . . And that’s the danger because it’s better to say I don’t 
know than to say something that you think is right but actually you are wrong, 
without knowing it. And the patient thinks that you told them the right thing.
Since most physicians receive limited training in genetics, could the knowledge 
gap be filled by genetic counselors? Dr. Liang expressed reservations about this 
idea because genetic counselors, who are not trained as physicians, would not 
have sufficient knowledge about different medical conditions:
The problem with genetic counselors is that they can only counsel from a 
very statistical viewpoint. They don’t know the disease, they cannot know so 
many diseases. It’s like I can advise you on elderly-related diseases, even if it 
is genetic. [But] I cannot advise you on pediatrics conditions. I cannot advise 
you on cancers. So very much it is still the expertise of the individual groups, 
I can’t see a geneticist, knowing all the conditions. He may know in terms of 
understanding from the probability perspective, what it means and the risks of 
inheritance. That, the geneticist will be quite good at. So, it’s a bit complex.
To further complicate matters, personalized medicine is developing at a rapid 
pace with new drugs and new diagnostics being regularly launched by pharma-
ceutical companies. It is difficult for doctors to individually digest the plethora of 
information (including clinical research findings) about these products and then 
to decide which ones should be applied in a clinical setting. Dr. Liang suggested 
that greater professional support from within the medical community would be 
helpful in bridging the knowledge gaps of individual doctors:
To my mind, there should be some panel of experts to advise. So, I would expect, 
say, in Singapore, the Chapter of Oncologists. [Which] will then advise what 
drugs might be suitable for what, and give their position statements. . . . These 
are [also] international guidelines. This cancer should be treated this way. I am 
following the guidelines. It’s when I veer away from the guidelines, I got to 
justify. . . . So that’s helpful because there’s some international experts coming 
to say this is the way to go, then the doctor won’t be faulted.
The logical conclusion from the above discussion seems to be that there is an 
urgent need to incorporate genomics into the training of new doctors as well 
as into the curriculum of medical education. In response to this need, medical 
schools are starting to address personalized medicine, in particular pharmacog-
enomics, in their curricula (Cornetta and Brown, 2013). However, as Dr. Wee 
pointed out, cancers are “context-dependent manifestations,” and scientists need 
to know that genetics is not everything:
I suspect that the medical school kind of training that we go through, is often 
not geared towards equipping us to interpret genetics results. So I guess then 
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there may be people who sub-specialise, become medical geneticists, perhaps 
certain not so straightforward types of results and interpretations will need 
to be handled by the medical geneticists. But on the other hand it is true 
that . . . the scientist needs to probably also appreciate the other side of the 
world, [which] is that genetic[s] is not destiny. It is not destiny because 
there are always modifiers. . . . That’s why I start off by defining what is 
penetrance, it is the probability of getting the disease given the genotype. 
So this probability can be, is a continuous scale, can be 0 to 100. And it is 
very rarely at the extremes, it is often somewhere in the middle and there 
are modifiers. We have known of people who have mutations – you thought 
sure to have certain [disease] conditions but they don’t have. I mean, there 
is context dependent manifestations.
(The Swiss Academy of Medical Sciences (SAMS), 2012:7)
In short, due to medical specialization, physicians normally lack the breadth 
and depth in genomics whereas genetic counselors lack sufficient knowledge of 
various medical conditions.
Direct-to-consumer genetic testing
To further complicate the issue of knowledge gaps and correct readings of genetic 
testing results, there are now many commercial offerings of genetic testing for 
clinical purposes. Many of these are widely publicized. Questions have been raised 
about the benefits of such testing, especially direct-to-consumer (DTC) testing. 
DTC testing refers to genomic analyses that are marketed directly to consumers 
without involving health care professionals. Such tests usually claim to identify 
an increased or decreased risk of certain diseases. Regulators and medical profes-
sionals are critical of DTC testing. For instance, the Swiss Academy of Medical 
Sciences (SAMS, 2012:7) expresses strong criticisms:
The availability of “predictive” tests of this kind is apt to discredit PM in its 
entirety. Such genetic tests are offered on a direct-to-consumer (DTC) basis 
by well-known companies, operating internationally. . . . The real problem 
revealed by these unscientific offerings is that, in the PM sector, a market 
has become established which cannot be controlled or regulated. In Swit-
zerland, DTC tests of this kind – not ordered by a physician – are essentially 
prohibited. . . . [H]owever, prohibitions are of little use, as they are so easy to 
circumvent in a globalized world. . . . A number of national and international 
professional bodies have already adopted clear positions, issuing warnings 
about these services [emphasis mine].
Dr. Liang expressed similar objections:
There are companies, internationally, that do that [offering DTC testing]. 
They send your blood, they come and tell you you have this, this, this, this, 
this. Your risk is this, this, this, this, this. Okay? Should that be done or not? 
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Should the public be given that or not? Should the public have access to all 
their own information or not? So that’s now a new challenge. . . . Recently, 
[the] FDA, just a few months ago, ordered one of their companies, . . . to 
stop offering those free cheap kits for genetic testing. . . .
What Dr. Liang was referring to was the US FDA ruling, in November 2013, 
that a company called 23andMe stop selling its DTC product “The Saliva Col-
lection Kit and Personal Genome Service” until it obtained FDA “marketing 
clearance or approval.”
One of the key concerns with DTC testing is that, without the advice of medi-
cal professionals, the general public is not equipped with sufficient knowledge 
about medicine and genetics to be able to comprehend the implications of the 
test results. Dr. Liang, who was comfortable undergoing one of these DTC tests 
himself because he was knowledgeable about it, cautioned that it would create 
anxiety for a layperson:
So I sent in a kit to them, they sent it back, I just went to [the] website . . . they 
tell me that, I have a higher risk of these kinds of conditions. . . . Some 
I already know, so it’s okay. . . . And based on probability, they say these are 
my risks. They also try to explain why, what’s the background behind these 
risks. Because I think I am knowledgeable enough, I am not worried about 
what I see. Some things they say I’m at risk, but I am not worried, no big 
deal, can wait and see. . . . But a lay person sees it, what happens? [Inter-
viewer: He brings to the doctor.] Correct. Then the doctor also doesn’t 
know what’s happening, or the doctor might know. [In any case] [h]e cre-
ates a lot of anxiety and problems as well.
Scientists and medical professionals have “expressed concern about the inabil-
ity of many patients with cancer to adequately comprehend the purposes and 
complexities of pharmacogenomics testing, especially the potential psycho-
social implications of germline and somatic genetic testing” (McGowan et al., 
2014:189). Dr. Liang pointed out, in particular, that the public, in general, does 
not understand that genetic testing merely reveals a probabilistic indication of 
disease likelihood. He felt that the story of the actress Angelina Jolie undergo-
ing a mastectomy because she had the BRCA gene mutation presented an overly 
deterministic message about genetic testing:
It’s a probability thing. And this is where it can be very complicated because 
if a patient goes for genetic testing, he is likely to want to know an answer 
that is yes or no. Will I get cancer or not? But the doctor actually says you 
have a higher chance of getting cancer. Does it mean you will? Even Angelina 
Jolie – doesn’t mean she will get breast cancer. She has a very high chance, 
that’s all. There is a chance that she might not even get it. You know, but 
the public, some of them don’t understand this thing about probability and 
chances. . . . So the problem is the message to the general public is that you 
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got this gene, you better go and get your breasts operated. And commercial 
people . . . plastic surgeons . . . will be very keen.
The same concern of lack of genetic counseling was expressed by the SAMS 
(2012:7):
Some DTC services are certainly valid, such as the detection of mutations 
in genetic disorders with a dominant or recessive pattern of inheritance (e.g. 
Huntington’s chorea). But users receive the results in a direct, unfiltered 
form, without the necessary additional information or appropriate coun-
selling. This practice cannot legitimately be defended by invoking peo-
ple’s . . . right of freedom to obtain information. In fact, what is involved 
is an ethically unacceptable omission, since the “information” in question 
concerns complex medical matters which require careful interpretation.
Indeed, even for genetic testing that has to be ordered through doctors, the 
same question of benefits has to be raised. While such costly testing will reveal a 
whole wealth of information about mutations present in the patient, the informa-
tion itself does not indicate any treatment. As noted by Dr. Xia:
Actually there are plenty of companies that will offer to investigate your tumor 
and they will interrogate like a whole genome worth of mutations. . . . You 
pay a lot of money. You pay a lot of money for information that is for what? 
I mean what is the purpose? I mean there isn’t a matching treatment to go 
with that particular mutation. Then what is the point?
Many companies offering genetic testing may be based overseas and not sub-
ject to the regulation of local health authorities. According to Dr. Liang, there 
are also potential concerns about the quality of their services:
And the first question would be, how reliable is that data? It is also 
between the different labs, is there good correlation, how do I know if 
this company offering this test is doing it the right way? . . . But suppose 
you send your blood overseas to do a test, Singapore government cannot 
be responsible for that. Do we assume that if you send anywhere in the 
world you will be okay or not? What are the standards there? How do we 
know that that particular company in their own country has actually been 
regulated well?
Commercially available genetic tests fall into two different categories. The first 
category (i.e. direct to consumer genetic testing) may not only be the result of 
an uncontrollable or unregulated market but could induce unnecessary anxiety 
in patients due to the lack of an expert opinion on the implications of disease 
risk. Issues with the second category (i.e. genetics tests ordered through doctors) 
may sometimes overlap with the first. First, the lack of corresponding treatments 
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puts the utility of having the genetic test in question, and, second, there is an 
absence of quality assurance due to the lack of stringent validation by local health 
authorities.
Privacy concerns and the potential for genetic 
discrimination at the level of the individual  
and the group
Patient confidentiality is a key pillar of ethics in medical practice. The profes-
sional ethics mean that health care providers are required to keep a patient’s 
personal health information private unless the patient consents to releasing 
it to other parties. Information obtained from genetic testing is part of a 
patient’s personal health information and its confidentiality should be pro-
tected. However, germline mutation is inheritable, and, hence, such informa-
tion has implications for not just the patient being tested but individuals who 
are biologically related to him or her. If the test reveals that the patient carries 
a gene variant that predisposes him or her to a certain disease, should the 
information also be made known to the biological relatives so that they might 
consider undergoing genetic testing themselves? Dr. Koh explained this ethical 
dilemma as such:
[W]hen that data becomes available, who should have access to it? . . . right 
now, only the individuals have access to it, because of privacy issues, only 
the individual has access to it, but, someone may make the case that family 
should have access to it, because the families could be involved, right? The 
families, as in biological families, who are related to that individual, cause 
they could have inherited the same mutation, if it’s an inheritable mutation. 
So those things are all very . . . very tricky, in terms of who should have access 
to this kind of data.
In the case of communicable diseases, there are public interest grounds for 
limited disclosure of a patient’s information without his or her consent to prevent 
the spread of the disease. Should the same principle apply with regard to genetic 
information? Dr. Liang was uncertain about this:
[E]ven communicable diseases, in many places, even that information is also 
protected; in Singapore, the protection is a little bit less, and there’s more 
skewed toward protecting the public, but nevertheless, it’s along that line of 
spectrum, . . . I mean, predisposition doesn’t necessarily have to do with sort 
of public health issues, but it can affect other individuals.
On the other hand, there is the “right not to know” argument. There are 
individuals who prefer not to know whether they are predisposed to certain dis-
eases, so that they do not have to live with anxiety for the rest of their lives. If 
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an individual chooses to undergo genetic testing for a germline mutation, and 
the test results have implications for his or her relatives, should the relatives be 
consulted and be provided with genetic counseling as well? Dr. Chong explained 
that ultimately the patient’s autonomy should be respected:
[At] the end of the day it’s patients’ autonomy. They may not want to know. 
Okay, my mum’s got [the] BRCA mutation, I don’t want to know, I don’t 
want to mastectomise myself, I don’t want to remove my breasts, I want to 
live my life happy. If I get breast cancer, so be it, I die. I don’t want to live 
under this cloud, I don’t want to live under this cloud of going around with-
out what I deem to be an important part of my body. It is legitimate. So to 
me, at the end of the day, there is a completely private dimension to this, but 
unfortunately, the private clashes with [the] commercial, with the reimburse-
ment, with payment. That’s when all the conflict starts.
A further complication to the issue of “right not to know” is that of what is 
termed “incidental (unintended) findings.” For example, an apparently healthy 
subject has his or her DNA tested as part of a GWAS, but the test reveals that he 
or she possesses a genotype that is associated with elevated risk of developing a 
completely different disease. Should the information be revealed to the subject? 
Dr. Wu explained the moral dilemma:
[W]hen you do a larger, broader panel, you may find things that you didn’t 
expect to find. . . . [W]e may find a genetic germline syndrome that’s not 
expected – these are the incidental findings. The incidental findings like you 
see someone, who’s old, and has got breast cancer, you wouldn’t have sus-
pected it, but then you’ve picked it up incidentally because it’s part of your 
genetic testing panel that you do, either in a research setting or in a clini-
cal practice setting. And how do you handle that. I think there needs to be 
certain frameworks and guidelines that are out there. . . . Cause there are 
many extremes [positions] that’re taken, there’re ethical views that [if] this 
is done in a research setting, you do not need to inform the patient, and also 
you’re not sure whether your result is right, or wrong, and you may cause 
unnecessary anxiety. There is also the ethical counterpart which says that 
because you’re doing it in a research setting, but you have a possibility that 
the patient has got a particular genetic syndrome, you are obliged to inform 
the patient of that possibility.
Dr. Chong’s point above about “private clashes with [the] commercial” brings 
us to the issue of genetic discrimination, a situation in which an individual is 
treated less favorably than others because of an apparent or perceived genetic 
variation from the normal human genotype. Areas with high likelihood of genetic 
discrimination are employment and insurance.
Most importantly, potential discrimination can be exercised not only against the 
individual, but also against racialized groups. As Dr. Chong wisely pointed out:
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INTERVIEWER: [I]n the clinical trials, sometimes the patients sign away their 
rights. . . . [D]o they know what they sign away?
DR. CHONG: When the trials are being crafted up, the Ethics Board will say you 
must have all these security measures to make sure the data is kept intact and 
everything, but you see, what happens is, like what you mentioned, we do the 
trial in Singapore, and suddenly we find that a lot of “Indians” happen to have 
this gene, that predisposes them to a certain cancer at a very young age, then 
what have we done? We say, no we’ve done good, we will now screen Indians 
at [an] earlier age for this cancer, and all that, but we may also open the Pan-
dora’s box! Employers may say that, if you’re Indian, before we employ you, 
go for this genetic test. On the one hand we have raised the awareness, we 
look after their health, on the other hand, we have also made them a possible 
target for prejudice and stigmatization. So is it a benefit, is it a risk?
In the scenario that Dr. Chong sketched, employers may decide to make 
genetic screening mandatory for all potential “Indian” employees. Moreover, it 
is not unreasonable to hypothesize that the “Indians” who refuse to get tested, 
and those who get tested and happen to carry that gene, will automatically be 
denied the employment opportunity. Yet, this gene can be present in individuals 
from other ethnic groups, even if it is statistically less likely. Moreover, as articu-
lated by PuruShotam (1998), “who is an Indian” is already a problem to begin 
with. Similarly, Leong (1997:86) puts it this way to explain the official labeling 
and simplification of ethnic categories:
The CMIO categories were convenient labels for bureaucratic functions of 
form-filling and rational administration, but the British recognised much 
finer distinctions in census surveys. In the census of 1881, forty-seven ethnic 
groups were named; these increased to fifty-six in the 1921 census (Puru-
Shotam, 2000). The reduction of ethnicity to four categories and the use 
of these narrow classifications in official policy began when Singapore was 
granted sovereign and independent status on 9 August 1965.
The “Indians” today were comprised of Bengalis, Dogras, Gujeratis, Mharattis, 
Marwaris, and so on during the colonial period. Even then, the elaborate list of 
ethnic categories was itself socially constructed (PuruShotam, 1998).
Dr. Chong painted a worrying possibility that might materialize with advance-
ments in genetics research:
I think we will come to a point in the future, I don’t know when, especially if 
the GWAS data for healthy people becomes very robust, for certain cancers, 
common cancers, insurance, employers, may even ask you to go for a test, 
before you are hired or enrolled onto an insurance plan. Heaven forbid that, 
but there’s still a point that I can’t rule out.
. . . [I]f you genotype cancer patient[s] and you find that it’s something 
potentially transmissible, in terms of genetics, to the next generation, then 
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that would actually be causing a lot of problems for your kids, your siblings, 
because, again, insurance may wise up to the fact and ask, [have you had this 
test done]? Maybe they’ll say all policy buyers have to go for [a] BRCA test 
first, or you’ll be loaded.
[T]his is where people’s personal agenda, and business clash. If this was 
just a matter about you knowing whether or not you have the gene, and 
therefore your risk of your siblings and your children having the gene, then 
it’s just that. But it’s now tying in with the economics of healthcare – who 
pays? Third party pays, [but] third party doesn’t want to pay, third party 
wants to carefully select who they insure – they only want to insure the best 
that they can insure so it’s free money to them. So this is why the collision 
happens, right?
It is a personal thing, the collision only happens when it ties in with 
reimbursement or remuneration, in the sense of if your mother has BRCA, 
and now, you are going to be hired by a multi-national corporation, are 
you supposed to declare that? Because if you develop breast cancer due to 
the BRCA from your mum, the multinational company is off the hook for 
your bill.
Some countries have put in place legislation to prevent genetic discrimina-
tion. The United States enacted the Genetic Information Nondiscrimination Act 
(GINA) in 2008. The GINA prohibits health insurers from requesting genetic 
information from an individual or from the individual’s family members and from 
using this information to make decisions regarding coverage, rates, or preexisting 
conditions. The GINA also prohibits most employers from using genetic infor-
mation for hiring, firing, promotion, or making employment decisions. However, 
GINA’s nondiscrimination protections do not extend to life insurance, disability 
insurance, or long-term care insurance (U.S. Department of Health and Human 
Services, 2009). It should also be noted that this legislation does not completely 
eliminate concerns about discrimination – patients in the United States are still 
worried about sharing their genetic information with their employers and insur-
ance companies despite the GINA (McGowan, 2014).
A cursory review of application forms for health or life insurance in Singapore 
suggests that the insured are required to declare details of genetics test results that 
suggest predispositions for disease. Since insurance companies are in the business 
of pricing risks, it is likely that someone who declared that she has a BRCA muta-
tion will be charged a higher premium or have breast cancer excluded from cover-
age. Below are examples of clauses found in application forms:
Have any of your immediate family members (parents or siblings only) suf-
fered from cancer of any form or any known hereditary disease or disorder? 
[emphasis added]
Any other ailment, impairment, Bodily Injury, Accident, condition(s), 
medical investigations, or Hospital treatments not mentioned above? 
[emphasis added]
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I/We are aware and acknowledge that the failure to provide all relevant 
details in each of the Sections of this Application Form may prejudice any 
claim(s) that may be made by Me/Us in the future. [emphasis added]
It soon becomes clear that this awareness of disease predisposition may entail 
discriminatory practices in society, specifically in terms of purchasing insurance 
or getting a job. In view of this, should one be open about results when such 
personal data can potentially be used against oneself?
Should genome-based pharmaceuticals be  
the primary approach to treating cancer?
In 2014, Dr. Christopher Wild, Director of the International Agency of Research 
on Cancer (IARC), pointed out that “despite exciting advances . . . we cannot 
treat our way out of the cancer problem.” According to Anand et al. (2008):
Only 5–10 percent of all cancer cases can be attributed to genetic defects, 
whereas the remaining 90–95 percent have their roots in the environment 
and lifestyle. The lifestyle factors include cigarette smoking, diet (fried 
foods, red meat), alcohol, sun exposure, environmental pollutants, infec-
tions, stress, obesity, and physical inactivity. The evidence indicates that of all 
cancer-related deaths, almost 25–30 percent are due to tobacco, as many as 
30–35 percent are linked to diet, about 15–20 percent are due to infections, 
and the remaining percentage are due to other factors like radiation, stress, 
physical activity, environmental pollutants etc.
However, despite the understanding that cancer is a product of both genetics 
and the environment, it seems that the idea of “personalized medicine” is almost 
synonymous with genome-based pharmaceutical products, with significantly 
much less emphasis on environmental causes and prevention, and some doctors 
are voicing their concerns, including Dr. Neo:
So Polaris3 is happening . . . again they are taking the approach for more 
common stuff . . . yes I agree with the overall approach that we need to 
raise the infrastructure so that when we find out what mutation it is, patients 
can have targeted therapy. But my question is these are all patients with 
developed cancers, stage three, stage four. . . . I am saying that it is equally 
important, Polaris attends to the group where there is genetic predisposition 
to cancer, whether the pediatric group, or the adult population.
Indeed, identifying environmental risk factors is important, as research has 
shown that more than 50 percent of cancers can actually be prevented. At the 
same time, such environmental interventions also bear more extensive benefits 
than cancer drugs, as they not only improve quality of life but also target a broad 
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spectrum of cancers and chronic diseases rather than just a specific organ (Colditz, 
Wolin, and Gehlert, 2012; Sze, 2010). Yet, several push and pull factors have 
contributed to the current trend of focusing on genetics and treatment over envi-
ronment and prevention. One significant factor is the potential financial gain that 
pharmaceutical products can bring. Dr. Soh argued:
[Pharmaceutical companies] will naturally design drugs, to run the trials in a 
population where they are going to make money. That’s all, they are a private 
company.
At the same time, the uphill task in isolating environmental sources may serve 
as a deterrent to research in this area. For instance, gathering DNA data is seen as 
relatively easy, while the environment is perceived as constantly in flux, and epi-
demiological studies require large databases of personal information, as Drs. Xie 
and Wee pointed out:
DR. XIE: The environment is actively changing . . . the PSI [Pollutants Standard 
Index], tomorrow, you know . . . again, different.
DR. WEE: Our genes are the same from the day one we are born . . . it’s actually 
[an] easy task to measure the gene, the genetic information. But environment. 
Today I drink soya bean, tomorrow I drink coffee, so it’s . . . ever changing. . . .
As Dr. Tang put it, although prevention is a well-established and cost-effective 
method of reducing cancer incidence, it is difficult to incorporate it into personal-
ized medicine without first knowing the root cause:
So if we don’t know what the cause is, how do you prevent? There is no way 
to prevent. So that is the most challenging one to achieve. Finding a more 
effective treatment for established cancer is not easy, but it’s not as difficult 
as trying to find ways to prevent the lung cancer.
So, most of the efforts are now concentrated on treatment rather than 
prevention. For simple reasons because they know that finding the etiologi-
cal agents is near to impossible that’s the current thinking, but I don’t think 
it is totally impossible.
These inherent complications of research on environmental causes and difficul-
ties in obtaining results have resulted in a lack of financial support. Dr. Murphy 
shared how he is caught between a rock and a hard place:
I think it’s harder now to get funded to study the environment and lifestyle, 
and that’s because it’s very difficult to do. It’s very expensive and it’s very 
difficult; whereas genetic studies are actually much easier now.
To further complicate matters, the environment and biology are always inter-
acting with one another, and such interactions make it even more difficult to 
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differentiate and categorize observations as effects of purely biological or environ-
mental causes. Dr. Yuan drew an analogy between understanding cancer and the 
English language to highlight the interplay between biology and the environment:
I think that the first step is trying to understand the alphabet . . . so sequenc-
ing the human genome and then sequencing the genome of different cancers 
is just the beginning of the alphabet.
Once you’ve got the alphabet, you need to try and string it into sentences 
that are meaningful. And then once you string things into a sentence, you 
then have to see whether it fits into the paragraph. Because all three can be 
taken out of context [i.e. the environment].
Moreover, Dr. Yuan pointed out, while the current state of personalized medi-
cine tailors cancer treatment based on the expression of molecular signatures, 
looking exclusively at the molecular signature based on a single test/sample can 
also be misleading:
[D]epending which part of the tumor one samples, there could be differ-
ences. . . . And then to cap it all off, one feature of cancer is that cancer 
spreads. . . . [B]etween the original tumor removed from the patient’s breast, 
and later if it spreads to say, the lung or the liver, up to 20 percent of the 
metastasis can have a different signature.
In a similar thread, Dr. Hsu warned against overlooking the effect of the pas-
sage of time:
[T]he primary and secondary tumor may be different. The chance of the 
discordance is 15 percent . . . therefore your so-called testing and all that is at 
one frame in time, but there is a longitudinal dimension that is not captured.
However, even if the personalized treatment matches the molecular signature, 
each individual’s response can still be affected by the cumulative effect of his or 
her body’s health status and lifestyle choices, as Dr. Yuan described:
[Our] livers may be built differently, and our kidneys may be built differently. 
And we may have different underlying diseases.
. . . [A]bout 10 percent of the oriental population, if we, if we don’t have 
the vaccination program, are Hepatitis B carriers. . . . That means 1 in 10 
people have potentially abnormal liver. And we put the drug, the way the 
drug is metabolized is different.
. . . [I]f patients have underlying kidney dysfunction. . . . And if, so if the 
kidney is also affected because of some childhood illness that goes on to 
adulthood. Again the ability to clear. . . .
Well, it’s diet and the whole issue of supplements . . . anything that you 
take has an effect . . . anything that we take by mouth has to go to the liver 
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has to go to the kidneys. And there are numerous examples whereby what 
you take will interfere with the drug. So you give chemotherapy and you get 
a side effect, and you don’t know what it’s due to.
Even though we know that “we cannot treat our way out of the cancer prob-
lem,” there is less emphasis on prevention for a variety of reasons. They include, 
but are not limited to, financial gains from pharmaceutical products noted in 
Chapter 3 and the strong belief in the relative ease in “controlling the genetic 
variable” as compared to environmental factors.
Conclusion
Socio-economic factors are, ultimately, related to ethical issues. And it’s precisely 
this relationship that this chapter highlights. A relatively unique feature of per-
sonalized medicine is that it can be prohibitively expensive; but, at the same time, 
it is not curative. Contrary to popular expectations, generally, the new genome-
based medicine serves only to prolong the patient’s life for a few months or years. 
As such, doctors have raised a number of concerns. They have articulated that, in 
some instances, prescribing genomic medicine has become a new norm. In some 
cases, genetic tests are routinely being ordered regardless of whether patients can 
afford the medicine. Thus, these doctors wonder whether they should take into 
account the high cost of the medicine when deciding on treatment. In particular, 
when faced with patients from economically disadvantaged backgrounds, doctors 
have found themselves pondering questions of how or if they should tell a patient 
that all of this is available. It becomes a judgment call based on professional 
knowledge, but it also presents an ethical dilemma.
Physicians have different ways of resolving or handling these ethical dilemmas. 
Some may think, No, I would not tell the patient. I would look at the situation, 
and I would not tell them. This is because they do not want to put the burden on 
the patients to struggle with this issue. Given awareness of such expensive short-
term treatment, the patient or the patient’s loved ones may begin to ask: “Should 
I sell the house? Should I borrow from relatives to come up with 50,000 dollars 
or 200,000 dollars to prolong life for six months to one year when one eventually 
will die?” However, this consideration from the doctor may not be appreciated by 
patients and their loved ones. There may be loved ones who feel that $200,000 
or $600,000 over one year is completely worthwhile, just to be with this person 
for one more year. Who is to decide what the most appropriate way is of handling 
such a dilemma?
These are common questions that doctors struggle with, and have to think over, 
because their decisions can potentially be challenged by patients and patients’ 
families. Their compassionate decision to withhold such information “because 
it’s costly” may become problematic if patients happen to be informed about the 
available medicine and demand: “There is all of this medicine. Why didn’t you 
recommend it? Aren’t you supposed to save my life? Why didn’t you recommend 
this medication?” On the other hand, potential users may also find themselves 
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caught in an ethical dilemma. For example, should the patient sell the house in 
order to acquire such medicine? Answers to these tough questions do not come 
easily for doctors or patients and their loved ones.
Beyond creating an awareness of genetic tests, oncologists have raised addi-
tional concerns such as who should be expected to interpret and conduct genetic 
tests (i.e. whether direct-to-consumer testing should be available) and how 
much emphasis should be given to genetic testing vis-à-vis environmental factors 
(i.e. since cancer can be a context-dependent manifestation).
The ethical dilemma exists not just for doctors, patients, and patients’ families, 
but for governments and societies as a whole (in deciding what to pay for through 
government subsidies/taxes). As noted in this chapter, some ask why the govern-
ment cannot subsidize these treatments or why few subsidies exist in their county 
compared to others. However, if the government does subsidize these expensive 
treatments and tests, where does it end? Should the public subsidize a very costly 
medicine that will prolong an 85-year-old grandmother’s life for 3 months or a 
year? How about subsidies for genomic medicine pertaining to other diseases 
such as heart failure or diabetes? And, if all of these subsidies are approved, how 
would the government raise sufficient funds to deliver what is promised?
A downstream implication of genetic testing involves addressing issues of 
patient confidentiality and potential discrimination against an individual or a 
racialized group in areas of employment and insurance. For example, how should 
insurance companies use genetic information about a particular person or group? 
Should they require potential customers to go for a test? Should all people above 
a certain age, or belonging to a racial/ethnic group, go for specific kind of genetic 
testing when they acquire medical insurance or seek employment? If one has the 
genetic propensity for a particular disease, why should the insurance company 
raise the premium for everyone? Should results of genetic testing be available 
only to the individual or not? Who should have access to such personal genetic 
information?
Having confronted such a variety of dilemmas in relation to adoption and 
implementation of genomic medicine, some physicians have taken a step back 
and questioned the validity of focusing only on genes in addressing the complex 
problem of cancer. Focus should also be placed on the other side of the story – 
that is, on understanding environmental factors that contribute to cancer inci-
dence in the first place (Sze, 2010). These physicians have suggested that research 
focusing on nongenetic factors should be funded as well in order to devise pre-
ventive strategies that will ultimately benefit everyone, regardless of wealth.
Notes
 1 FoundationOne is a commercially available molecular diagnostics test for all solid 
tumor types, which analyzes routine clinical specimens for somatic alterations in 
relevant cancer-related genes. The test costs US$5,800. Nanos, Janelle. 2014. 
“Google To Offer FoundationOne Cancer Tests to Employees.” BetaBoston, 
November 15. Retrieved December 15, 2015. (http://www.betaboston.com/
news/2014/11/05/google-to-offer-foundationone-cancer-tests-to-employees/).
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 2 The Straits Times, February 14, 2014, “No Stock of Cancer Drug.” For the reply 
from the National Cancer Centrem Singapore, see The Straits Times, February 14, 
2014, “Stock Limited as Drug Is New.”
 3 The POLARIS (Personalized Omic Lattice for Advanced Research and Improv-
ing Stratification) is a program established in 2013 to pilot the application of 
clinical genomics in the treatment and diagnosis of medical diseases in Singapore 
and the region. Retrieved April 2, 2016. (https://www.a-star.edu.sg/polaris/).
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Following the sequencing of the human genome in 2003, the curtains of a new 
century of medical advancement opened to reveal the development of a person-
alized medicine or precision medicine (PM) paradigm. In the words of Willard 
(2013:5), genome-based personalized medicine refers to:
[A] rapidly advancing field of healthcare that is informed by each person’s 
unique clinical, genetic, genomic, and environmental information. The goals 
of personalized medicine are to take advantage of a molecular understand-
ing of disease to optimize preventive healthcare strategies and drug thera-
pies while people are still well or at the earliest stages of disease. Because 
these factors are different for every person, the nature of disease, its onset, 
its course, and how it might respond to drug or other interventions are as 
individual as the people who have them. In order for personalized medicine 
to be used by healthcare providers and their patients, these findings must be 
translated into precise diagnostic tests and targeted therapies. Since the over-
arching goal is to optimize medical care and outcomes for each individual, 
treatments, medication types, and dosages, and/or prevention strategies may 
differ from person to person – resulting in unprecedented customization of 
patient care.
According to Trent (2012:32), “the US President’s Council of Advisors on Sci-
ence and Technology reported in 2008 that interest in personalized medicine stems 
from its potential for: 1. Improved patient care; 2. Disease prevention; 3. Reduction 
in health costs, and 4. Stimulating new drug development.” In this book, I note 
that effective treatments for a few types of cancer – lung, colorectal, and liver are 
prominent examples – has been improved by genome-based personalized medicine.
At the same time, this book suggests that the construction and identifica-
tion of racially and ethnically labeled populations have become integral parts in 
the development of the aforementioned aspects of personalized medicine. For 
example, with respect to stimulating new drug development, I demonstrate in 
Chapter 3 that in order to identify patients likely to participate in clinical tri-
als and to maximize the chances of a successful trial, pharmaceutical companies 
routinely seek information (such as prevalence rates of a specific genetic variant) 
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among racialized and ethnicized populations. Moreover, while the economic 
impact of pharmacogenomic interventions and associated companion diagnos-
tics at the macro-level remains unclear (Shabaruddin and Payne, 2014), I draw 
attention in Chapter 4 to cases such as those in Singapore, in which the con-
struction and identification of the prevalence rates of a specific genetic variant 
among local ethnic populations is a key component in cost-effectiveness studies 
of pharamacogenomics.
Indeed, as noted in the introduction, “while contemporary genomic research 
promises personalized medicine (or measures of risk) targeted at the individ-
ual, it is primarily the comparison of groups and populations that drives human 
genome research” (Hinterberger, 2012:74). As such, I pay particular attention 
to claims-making and potential contradictions between the goals of “individual-
ized medicine” and the continuing search for population-related genetic markers 
and regions.
The key argument this book advances is that while ethnic and racial categories 
emerge as a result of social processes of (self-)othering, in the process of creating, 
marketing, and regulating genomic medicine, such categories have come to be 
believed by some scientists to indicate the biological existence of racial and ethnic 
groups. Specifically, in the pursuit of personalized medicine, some scientists and 
medical researchers building the reference population datasets and/or conduct-
ing population-based genetic studies use race and ethnicity as proxies for human 
genetic diversity, or to calculate allele frequencies or to interpret the significance 
of any genotype information. This problematic usage occurs even when the sci-
entists themselves articulate the social nature of such categories. Ironically, it 
undermines biologists’ own understanding that there is only one race: the human 
race. Moreover, one of the key questions that this book addresses is, what are 
the consequences of the molecularization of race and ethnicity for personalized 
medicine in Asia and beyond? The interviews with physicians (mostly oncolo-
gists) suggest that there are serious issues and ethical dilemmas in translating such 
racialized and ethnicized knowledge about human genome variation at the level 
of clinical practices of PM. Thus, in sum, the evidence in this book suggests that 
race/ethnicity is a specious proxy for both human population genetic/genomic 
diversity and for individual genotype in clinical decision-making.
While this book focuses on personalized medicine for cancer, the lessons 
learned could potentially be useful for the development of personalized medicine 
for other diseases. As the World Health Organization announced:
[C]ancer figure[s] among the leading causes of morbidity and mortality 
worldwide, with approximately 14 million new cases and 8.2 million cancer 
related deaths in 2012. Moreover, the number of new cases is expected to 
rise about 70 percent over the next two decades to 22 million new cases. 
More than 60 percent of [the] world’s total new annual cases occur in Africa, 
Asia and Central and South America. These regions account for 70 percent 
of the world’s cancer deaths
(Stewart and Wild, 2014).
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The estimated toll of cancer on human lives highlights the importance of look-
ing into the benefits and potential ethical, legal, and social issues involved in the 
fight against cancer in this postgenomic era. In the sections that follow, I begin 
by summarizing that the definition of population in population-based genetic/
genomic studies is not only context-dependent but fluid and arbitrary. The fact 
that definitions of race and/or ethnicity are in a perpetual state of indeterminacy 
should make us worry about the emergence of ethnically and/or racially based 
medicine, billed as “personalized medicine.” Specifically, I emphasize again the 
regional racialization of genetics/genomics and the molecularization of ethnici-
ties in Asia. Finally, I identify some ethical, social, and legal issues raised by the 
findings, and the challenges of treating and preventing complex diseases, such as 
cancer, in an era of postgenomic medicine.
The definition of population in population-based  
genetic studies is context-dependent
In the context of a global pharmaceutical industry, as described in Chapter 3, 
I found that the population categories that matter are racial (e.g. Asian and Cau-
casian) and ethnic (e.g. Chinese). How do these racial/ethnic categories mat-
ter? Pharmaceutical companies do not, generally, make ethnic-specific medicine 
because they prefer drug indications to be as broad as possible, so that medicine 
can be sold to as many people as possible. However, it is revealed that companies 
do actively seek knowledge regarding distributions of allele frequencies and other 
genotype information among ethnically or racially labeled population groups as 
a strategy to deal with potential failures of multi-billion-dollar investments in 
drug development. The story of IRESSA serves as a prime example: the only way 
forward in “salvaging” the drug was through racializing clinical trials – Asians vs. 
Non-Asians. Even though further analysis found that it was EGFR mutations 
that contributed to the responsiveness to the drug, the spotlight was already on 
IRESSA as an “Asian-focused” medicine for lung cancer patients. As Dr. Chong 
pointed out:
I mean, you know, especially in [the cases of] all these very costly targeted 
drugs like IRESSA and everything, it’s best to enrich your population for 
those [for] whom you will see a response, so whilst it’s not Chinese and non-
smokers per se, rather EGFR, but there is a very close association between 
the two, so by first purifying your population with these non-genetic tests, 
i.e. check[ing] gender, check[ing] race, you make it more likely that your 
trial will produce meaningful results.
But of course, there are some of these trials nowadays where, to get reg-
istration in China, they are obliged to recruit x number of patients from 
China. There’s one particular trial that we’re involved in now, they opened 
it up to Singapore only because they needed to get non-Mainland Chinese 
into the trial. So there’s all these overlapping things, politics and business, 
you know, you’re trying to get registration with the drug.
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I further show that two population groups – “Asians” and “Caucasians” – are 
of particular interest to pharmaceutical companies, as they seek to maximize prof-
its by channeling resources to the increasing affluence of the “Asian” market and, 
later, to the perceived core (i.e. “Caucasian”) market. Despite apparent problems 
in defining racial categories, the population categories of “Asian” and “Cauca-
sian” were found evident in all four phases of clinical trials, including Phase IV, 
post-marketing surveillance (PMS). Drawing on extensive interview data, I sug-
gest that concerns about winning regulatory approval and greater access to over-
seas markets propel drug companies to naturalize socially constructed concepts 
of race and ethnicity into biomedically relevant objects.
In the context of a globalized genome science, geneticists in Asia also play a key 
role in marshaling big datasets and defining population categories along racial and 
ethnic lines. In particular, I suggest that a closer examination of how the HUGO 
Pan-Asian SNP Consortium (in Chapter 2) constructed population categories 
illuminates the emerging regional racialization of genomics and molecularization 
of ethnicity in Asia. First, the Consortium was established primarily to address 
gaps found in international genomics projects, such as the use of only Chinese 
and Japanese DNA as “Asian” samples. In an effort to address this problem of 
a lack of representativeness of samples, and to counter the perceived hegemonic 
scientific authority of the West, the HUGO PASNP Consortium members gath-
ered to take control of the definition of “Asian” genome variation. Second, host 
and guest nations collaborated and shifted the supposedly disease-oriented study 
into one concerned with population migration. Moreover, Consortium members 
used contemporary ethnic categories as population sampling frames and prox-
ies for genetic diversity in studying migration histories. As Duster (2005:1050) 
notes, “particular groups of individuals chosen to represent each region of the 
world are often chosen because of their convenience and accessibility,” and this 
is no less true in Asia. Finally, even though political, logistical, and financial (i.e. 
nonbiological) factors contributed to this shift from a study of disease susceptibil-
ity to a study of migration history, “scientific” or biological claims with serious 
epistemological and medical consequences for the development of therapeutics 
were being made based on ethnic and racial differences between and among 
Asians.
Cancer is the leading cause of death in Singapore, with about 30 percent of 
deaths attributed to it (Ministry of Health, 2015). In the context of national pub-
lic health policy-making, I show that the categories that matter are current cen-
sus ethnic categories of Chinese, Indian, Malay, and Others (CMIO). How and 
when do such categories matter? In Chapter 4, I demonstrate that they are key 
elements in cost-effectiveness studies aimed at promoting optimal management 
of scarce public health resources. There are certainly valid reasons for making 
use of genetic data calculated at the population level, such as controlling cases of 
adverse drug reactions and cost-benefit analysis of various genetic tests to decide 
which drugs to subsidize and screening programs to fund. However, the use of 
genetic data calculated based on prevailing CMIO census population categories 
remains questionable. As Loveman (2014) demonstrates, census racial categories 
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are a function of the shifting agendas of the ethnoracial and economic elites who 
do the categorizing.
The case of Irinotecan, discussed in Chapter 4, is an example of how imple-
mentation of personalized medicine is associated with the CMIO categories. 
Past research on personalized medicine found that patients with two variants 
of UGT1A1*6 and UGT1A1*28 are at an increased risk of adverse reactions 
to Irinotecan. This information was taken one step further by population-based 
research to include the statistical prevalence of these two gene variants across dif-
ferent ethnic groups in Singapore – a move toward creating aggregate data for 
cost-effectiveness analysis. The key issue lies here: why was ethnicity adopted as 
a population category when aggregated data can be conceptualized and analyzed 
in various ways that have been associated with toxicity (such as utilizing cat-
egories based on weight range, types of diet, etc.)? Further prompting revealed 
that distribution of risk alleles based on ethnicity was adopted due to existing 
administrative routines and convenience of such categories for data collection 
and analysis. In other words, it was the availability of categorical data (i.e. CMIO 
categories) – as opposed to biomedical considerations – that prompted the use 
of ethnicity in assessing whether a patient is likely to suffer from toxic effects in 
taking Irinotecan. Moreover, the reliance on race and ethnicity as frames for cal-
culating risk-allele frequency is consistently illustrated through a review of cost-
effectiveness studies of drugs such as IRESSA, Irinotecan, and carbamazepine in 
selected countries in Asia.
In short, as is demonstrated in Chapters 2, 3, and 4, the kinds of popula-
tion categories that matter in population-based genetic studies are context- 
dependent. Moreover, while Bliss (2012) illustrates “antiracist racialism” – that 
is, that racialization in genomic science in the United States is primarily a func-
tion of geneticists’ good intentions to include racial and ethnic minorities in their 
research – the interviewees in this study did not explicitly voice social justice 
concerns. Rather, I draw on interview data to argue that the usage of racially 
and ethnically labeled population categories serves multiple purposes, includ-
ing getting studies published in the highly competitive scholarly community, 
working with pharmaceutical companies’ capital investments, and saving public 
health care costs. Furthermore, as is shown in Chapter 5, in the interviews with 
clinician-scientists in Singapore, many, in fact, explained that the usage of race 
and ethnicity in research settings stems from clinical observations, and that the 
use of these as proxies for genetics is not ideal and is merely a temporary tool, 
a means to the end of finding a molecular target. Once the molecular cause of 
disease susceptibility or drug response is identified, racial and ethnic identifica-
tions are mostly irrelevant in the clinical setting – indeed, the interview data sug-
gest that using race/ethnicity as a proxy for administering drugs is a last resort 
only in cases in which other options are limited. One scenario might be when 
genetic testing is unavailable or unaffordable, or when the relationship between 
genotype and medical outcome is not clear. If genetic tests are unavailable, physi-
cians sometimes take race/ethnicity into account based on prior clinical obser-
vations of inter-ethnic differences in terms of drug responses and/or toxicities. 
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However, such clinical observations and decisions are not based on science but 
on what Dr. Teo called “intuition.” Furthermore, such “intuition” is generally 
used only initially, because in some cases, patients cannot afford the time to take 
genetic tests and wait for results when their conditions are severe and require 
more immediate treatment.
Despite the limited and problematic usefulness of racial and ethnic identifi-
cations in clinical practice, the CMIO census categories continue to be widely 
used as population categories in genetic/genomic research projects in Singapore, 
while “Asian” and “Caucasian” continue to be popular categories used in studies 
at the international level. Evidently, however, the persistence of the usage of race 
and ethnicity to construct and identify human populations in genomics is due to 
non-biological reasons, including, but not limited to, convenience sampling, sci-
entists’ intuition, bureaucratic inertia, and the multiple political-economic pur-
poses highlighted earlier.
The definition of a population is not only context-
dependent but also fluid and arbitrary
Definitions of population categories rely on more than just “others” observed 
through a “Western”-centric lens. With the advancement of medical science in 
Asia, there is a growing prominence of scientists and clinician-scientists from 
previously marginalized scientific communities taking steps toward the construc-
tion, reinforcement, and circulation of an “Asian” identity. This serves to counter 
the perceived Western ethno-centrism and, in turn, introduces a cycle of self-
othering processes, which, ironically, reproduce cognitive categories generated 
in the West.
To begin with, scholars have produced a vast and growing literature that docu-
ments race as a social/historical/cultural construct: a system of ideas, identities, 
and material relations that emerged slowly in the context of Western European 
imperialism and colonial expansion beginning in the fifteenth century. The first 
laws designed to establish and patrol racial boundaries and hierarchy did not 
appear until the middle of the seventeenth century (Smedley, 2007). As indi-
cated in the first chapter of this book, racial and ethnic categories emerge out of 
the othering/social-boundary-making process, as an “ongoing strategic effort to 
make a difference in space among the movements of people, money or products” 
(van Houtoum and van Naerssen, 2002:126). During the colonial era, race/
ethnicity was a product of colonial administration: artificial boundaries were cre-
ated to meet the exigencies of daily rule. For instance, as Spaan, von Naerssen, 
and Kohl (2002:163) write, “the colonial economy marked the origin of the 
Malaysian multi-ethnic society” – a person of each “race” had certain character-
istics or mannerisms that made him “suitable” to be working in certain occupa-
tions in the eyes of the colonial administrators, and “real or imagined attributes 
such as language, customs, religion and indigenousness (were codified)” (Spaan, 
von Naerssen, and Kohl, 2002:163). Similarly, Loveman’s (2014:44) study 
shows that in Latin America the census in the colonial era functioned to justify 
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“orderly extraction of agricultural, mineral and labor resources” by indigenous 
and imported slave laborers for elites from and in Spain and Portugal.
The Swedish naturalist Carolus Linnaeus published the tenth edition of Sys-
tema Naturae in 1758 and classified human beings as part of the animal king-
dom. Linnaeus designates four basic races of humans – American, European, 
Asian, and African, and his influence on racial thinking remains obvious today 
(Goodman, Moses, and Jones, 2012). Gissis (2011) argues that two modes of 
discourse and visualization played a significant role in the emergence of “race” 
as a new scientific category during the eighteenth century: one involving society, 
civility, and civilization (as found primarily in the travel literature), and the other 
involving nature (as found in natural history writings, particularly botanical clas-
sifications). That is, the European colonizing enterprise resulted in an extensive 
flow of new objects at every level. Visual representations of these new objects 
circulated in the European cultural world and were transferred and transformed 
within travelogues and natural history writings. Over the course of the century, 
the discourse on society, civility, and civilization collapsed into the discourse on 
nature. Humans became classified and visually represented along the same lines 
as flora, according to similar assumptions about visible features.
In addition, the advent of the nation-state necessitated the formation of the 
“native” and the “other.” States trying to create “nations” require the creation 
of a myth of being, and who-we-are-as-a-nation is always relational (Göl, 2005). 
I provide an example in Chapter 2 of the historical and political construction of 
the “Japanese.”
From historically othered to contemporary self-othering
At the same time, it must be added that the “othered” takes part in the othering 
process. For instance, as previous chapters show, social actors in contemporary 
times uncritically have adopted the notion of “Asian” and reinscribed it at the 
molecular level. In particular, there are at least three ways in which the notion of 
“Asian” – “regionally-Asian” (Chapter 2), “geographically-Asian” (Chapter 3), 
and “nationally-Asian” (Chapter 4) – is constructed by social actors participating 
in the creation and development of genomic medicine in Asia. Moreover, ethnic 
categories created during the colonial era have been taken for granted and rein-
scribed in the twenty-first century. For instance, Chapter 4 illustrates the forma-
tion process of the “Malay” category during the period of British colonial rule. 
Soon, this constructed identity – that stood out against other groups like Chinese 
and Indians – was internalized by the people. The definition of being Malay, 
however, is different from that in Malaysia just across the causeway in Singapore: 
being Malay in Singapore is not limited to those having a “Malay” ancestor, but 
acceptance by the Malay community. This case study points again to the fluid 
definition of race and ethnicity.
Thus, I suggest not only that definitions of populations are context-dependent, 
but that they are fluid and arbitrary. How does it play out in genomics in Asia? 
In the following paragraphs, I reiterate some of the main examples. For instance, 
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the definition of Caucasians is contested, as is evident from the following quotes 
from researchers:
DR. ZHAO: Well, I think in this sort of study done in Asia . . . I think it’s just basi-
cally anybody from European heritage or American heritage.
Dr. Tang further added that geography does not really contribute to the defi-
nition of who is Caucasian and who is not Caucasian. Interestingly, he briefly 
pointed out that physical appearances matter and can serve as differentiation 
markers:
INTERVIEWER: What about Europeans?
DR. TANG: Those that are in Europe. Australians are considered to be of European 
descent. . . . [U]sually, it’s more of the racial thing rather than . . . geography.
INTERVIEWER: How [are] Western European[s] different?
DR. TANG: Caucasian appearance.
INTERVIEWER: Not location based?
DR. TANG: No. Like Chinese migrants who migrate to Europe or [the] US will 
not be considered . . . Western European. They will still be called East Asian 
in [terms of] their ethnicity.
There are clearly no objective criteria or processes to define and identify one’s 
race or ethnicity. Dr. Rajaratnam stated that he would use identification cards to 
directly check on race and ethnicity, though he had other concerns as well:
Verbally asking them, and by their IC [i.e. national registration identification 
card]. Because that is their national identification. So that’s the only proof 
we have.
One thing I am very careful of is with Indonesians. Indonesians, they may 
have Malay names, but they can be Chinese, they can be Indians. But all of 
them, their names are Malay. So I am very careful. If the Indonesian patient 
is clearly a Chinese, I mean, you can also see.
I am very careful, unless I can get at least two people to verify for sure 
that that person, that Indonesian is a Chinese or Malay, [and] Caucasians 
also. . . .
Names, however, may not match how researchers and/or doctors expect a 
patient to look. Dr. Wee brought up an example similar to Dr. Rajaratnam’s 
attempts to be careful with racial/ethnic identification:
I always shared this joke that, during my reservist military service, one day 
I was running a clinic in an army camp. Then my medic would help me call 
Mr. Chong Ah Gow. The person [who] came in [was] an Indian. ‘Cause his 
mum is an Indian. He looks exactly like [an] Indian, but he is Mr. Chong Ah 
Gow. [Interviewer: You would have thought he is Chinese]. So your father 
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is Mr. Chong? Ya. Correct, my mum is an Indian. But he looks exactly like 
[an] Indian.
Such situations arise precisely because race and ethnicity are social and 
fluid constructs. There is no essence in “being” “Caucasians,” “Asians,” or 
“Malays.” However, in using them in research and analysis, researchers some-
times act as if these categories are unproblematic and coherent. Dr. Poh, for 
instance, said that he identified who was “Caucasian” based on what his col-
league told him:
Because one of my colleagues is from Germany . . . and he gave us samples. 
Normal German, Caucasians. . . . They tell us.
Additionally, the category of “Caucasian” is often used in comparison with the 
category of “Asian.” However, definitions of both categories remain vague and 
contested. This can be seen in this particular example: Dr. Huang suggested a 
geographical gauge for what could be included under “Asian,” though eventually 
he gave up on coming up with a precise definition:
. . . so anything that is 6 hours flight from here [Singapore]. . . . I mean 
I think that the easy ones are easy. Thailand is Asia. South Korea is Asia, then 
you get . . .
. . . I would consider Japan Asia . . . maybe not South-East Asia. So . . . I 
would say anything that’s not Western Europe or North America. . . .
. . . Is Russia Asia or not? That becomes a bit of a blurry line. So it’s a, it’s 
a nice title to have [for a scientific paper presentation]? But obviously, where 
does Asia end? Is Australia part of Asia, I don’t know [laughs].
In the case of Singapore, Dr. Zhang defines “Asian” based on existing racial 
categories: Chinese, Indian, and Malay.
DR. ZHANG: Okay, our “Asian” probably refers to Chinese, Indian, and Malay.
INTERVIEWER: So if a Caucasian lives in Singapore, which is part of Asia, he/
she is not Asian?
DR. ZHANG: [He/she]’s not Asian.
Other researchers define “Asian” similarly in their studies, with respect to the 
specific races:
DR. ZHUANG: [T]he category of “Asian” is very heterogeneous. [S]o . . . although 
we generally put down “Asian” . . . in our patient selection criteria, we would 
have to define [it] . . . to the specific races. Whether we’re talking about Chi-
nese, we’re talking about Malay, we’re talking about Indian. We tend not to 
group them together. So, when we do an Asian study, that study may include 
Chinese, Malay or Indian, or sometimes just Chinese alone.
Conclusion 155
Undoubtedly, neither “Asia” nor “Asians” is objectively defined nor delineated. 
“Mapping Human Genetic Diversity in Asia” (HUGO Pan-Asian SNP Consor-
tium, 2009) is a high-impact publication that has informed and lent support to 
“Asians” being conceptually “one people” after the mapping of genetic varia-
tions and migration patterns of 75 populations from 10 countries: Japan, Korea, 
China, Taiwan, Singapore, Thailand, Indonesia, Philippines, Malaysia, and India 
(excluding Australia). Definitions of ethnic groups in the study, however, were 
left to the scientists’ discretion. This is problematic as it glosses over the fact that 
these ethnic categories are historically, politically, and socially constructed. An 
analysis of the emergent and fluid nature of the label “Japanese” in Chapter 2 
serves to remind us of this point. Two additional categories used in the study are 
Han and Korean. Here are how these ethnic populations are subjectively defined 
by Consortium members:
Han Chinese:
DR. CHUA: We use . . . three generations. So this is for HUGO Pan-Asian. And 
also our definition of Han Chinese. In all my studies when we talk about Han 
Chinese, this is the definition. For us, [it is] difficult to get . . . 4 generations 
because nobody knows . . . 4 generations. Difficult to find. I mean . . . you 
know your parents are Chinese, your parents will know whether their parents 
are Chinese, but your grandparents may not be there to know the fourth 
[generation]. . . .
Korean:
DR. KANG: The way we define the Koreans [was] at that time, people who had 
three generations of knowledge that they have been in Korea, no external 
influence, and people who are from two cities, one called Ansung, the other 
one Ansan. . . . We took the original samples from a previous study in Korea, 
Korean Study, so they collected this. So essentially they just defined geo-
graphically, these two cities.
The problematic usage of these racial/ethnic categories in human genetic/
genomic studies has been carefully examined due to their wide- and far-reaching 
implications, including, but not limited to, how such categories become molecu-
larized in labs and then packaged to be sold to the uninformed public. Dr. Raja-
ratnam pointed out that use of statistics on the prevalence of certain alleles in 
relation to race and/or ethnicity is also part of public health decision-making 
rubrics:
The prevalence of double heterozygotes (*6/*28) in Singapore is 6.9 per-
cent, 1.2 percent and 2.9 percent in Chinese, Malays and Indians, respec-
tively. . . . [W]hat I meant was ethnic group matters . . . because this 
involves . . . regulatory bodies introducing the test. The FDA [in the USA] 
did not introduce *6 testing because it is totally absent in Caucasian[s]. 
Whereas [the] HSA introduced both *6 and *28 testing. That’s where eth-
nicity matters.
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Upon closer inspection, race and/or ethnicity is used for data analysis because 
existing data is already provided and defined by the government along those 
lines, as Dr. Ballheimer said:
70 percent of Singaporeans are Chinese. We need to do a model that’s repre-
sentative of the population. . . . We just use allele frequencies based on what 
the government gives us. And they give us frequencies based on Chinese, 
Singaporean, Chinese, Malay, and Indian. So we just use it. If they gave it to 
us in a different way, we would analyze it in a different way. . . .
Definitions of ethnicity in Singapore are not entirely consistent across all doc-
tors and/or researchers interviewed. There is, however, a tendency to use self-
identification and the identifications of three generations (the individual, his/her 
parents and grandparents) to categorize an individual. As Drs. Yuan and Wang 
explained:
DR. YUAN: When we do studies, if ethnicity is involved, we usually ask for three 
generations. So okay that’s how we define. So . . . you know, how did your 
parents define themselves, how did your grandparents define themselves? So 
if the grandparents, parents and, and the patient, or the human subject, all 
declare themselves as Malay, then the person is classified as Malay.
DR. WANG: In these studies, the definition of Asian, definition of ethnic group 
is based on three generations. And what is written on the national registra-
tion identity card of these patients. So it’s more or less a self-declared ethnic 
group. And of course we excluded those individuals that . . . we’re a bit 
uncertain of. In other words, if the patient were to say that my mom and 
my dad are Chinese and my grandparents are Chinese, we are okay. You’re 
Chinese. If my mom and dad are Chinese, my grandparents one of them is 
not a Chinese . . . okay, you are not a Chinese.
In short, the definition of any racial or ethnic group, whether “Caucasian,” 
“Asian,” or “Han,” is not based on biology and is never static. Different social 
actors can define a racial or ethnic group differently and verify such identification 
in various manners.
The regional racialization of genetics/genomics and  
the molecularization of ethnicity in Asia
At a ceremony announcing the completion of the first draft of the human genome 
in 2000, President Bill Clinton declared: “I believe one of the great truths to 
emerge from this triumphant expedition inside the human genome is that in 
genetic terms, all human beings, regardless of race, are more than 99.9 percent 
the same” (The New York Times, 2000). I suggest, however, that in the process 
of creating, marketing, and regulating genomic medicine, such categories have 
come to be believed by some to indicate the biological existence of racial and 
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ethnic groups. As Duster (2005:4) points out, “by accepting the prefabricated 
racial designations of stored samples and then reporting patterns of differences in 
SNPs between those categories, misplaced genetic concreteness is nearly inevita-
ble.” Such an insight can also be applied to situations in which molecular geneti-
cists use ethnicity as a proxy – that is, now there is misplaced genetic concreteness 
of ethnic categories. For instance, HUGO PASNP member scientist Dr. Sato 
said, “one of the biggest findings from the Pan Asian Consortium is just [that] 
ethnic classification corresponds to the genetic classification very well,” and 
HUGO PASNP member scientist Dr. Lee remarked, “What is the implication of 
demarcation? Well, ethnic populations are genetically different. It’s true. Right, if 
you talk about even Koreans and Chinese, you can still see difference, the point is 
how different [when] you talk about on the world scale” [emphasis mine].
Scientists should not really be surprised to find interracial or inter-ethnic dif-
ferences in genetics due to historical discriminatory practices against particular 
groups (TallBear, 2013) and the practice of endogamy. More importantly, as 
Feldman and Lewontin (2008:93) put it:
[I]t must be borne in mind that the taxonomic problem cannot be inverted. 
That is, while clustering methods are capable of assigning an individual to a 
geographic population with a high degree of certainty, given that individual’s 
genotype, it is not possible to predict accurately the genotype of an indi-
vidual given his or her geographical origin. . . . There are gene alleles that 
appear only in one group . . . but there does not exist any gene for which 
one major geographical cluster includes 100 percent of one genotype while 
another major geographical cluster has 100 percent of another genotype.
Furthermore, as noted earlier:
When researchers claim to be able to assign people to groups based on allele 
frequency at a certain number of loci, they have chosen loci that show differ-
ences between the groups they are trying to distinguish.
(Duster, 2006a:434)
“Race is best understood as a relationship and, more specifically, a relation-
ship between social groups in conflict over resources,” writes Duster (2002:549), 
“Serbs and Croats become white when they get to New York, Capetown or 
Melbourne, but when they return to the Balkans the salience of their whiteness 
recedes, even dissipates.” Having gathered the interview data with social actors 
in different settings, I suggest that clinician-scientists and molecular geneticists 
exhibit different levels of faith and considerations concerning the genetic basis of 
fundamentally historically and socially constructed racial and ethnic categories. 
At one end, some researchers believe that there is definitely a genetic basis to 
race, and, at the other, some believe that there is absolutely no such basis. Many 
researchers in Singapore repeatedly emphasized that race and ethnicity identifi-
cations will become irrelevant once the molecular target affecting the disease or 
158 Conclusion
drug toxicities or drug effectiveness is found, suggesting that they do not believe 
that there is a genetic basis to race/ethnicity. Indeed, one clinician-scientist who 
studies inter-ethnic differences and drug responses, Dr. Wang, actually lamented, 
“I think the BiDil story is a very sad one. Shouldn’t have happened. It’s kind of 
one drug company, Nitromed, trying to make some money.”
That said, I have presented data to suggest that the molecularization of race 
and ethnicity is occurring when researchers use such categories as proxies or 
calculate allele frequencies or interpret the significance of any genotype informa-
tion for various purposes, regardless of whether they actually believe that there 
is a genetic basis to race. In addition, as Tallbear and Bolnick (2004)’s article on 
“Native American DNA tests” suggests, “now that genetics carries such cultural 
power, we face several pressing questions: Will Native American identities and 
rights that have been reckoned through a combination of kinship ideas, law, and 
policy now be reckoned increasingly through DNA? Will DNA tests be required 
in law and policy? Will prevailing cultural notions of kin, race, and genetic ances-
try undermine tribal notions of kin that emphasize a close cultural connection 
to the tribe? How will the focus on DNA affect ongoing U.S. negotiations with 
tribal nations? Tribes need to consider these possibilities carefully.” One can 
raise such questions with respect to the molecularization of ethnic groups in 
Asia as well.
The specter of ethnic medicine
Through extensively describing the political and regulatory landscape at the time, 
Kahn (2013) explains how the social-political landscape was the driving force 
for the racializing of BiDil. He focuses particularly on patent laws and elucidates 
that “patent law is supposed to promote the invention of new and useful prod-
ucts. In the case of BiDil, patent law did not spur the invention of a new drug, 
but rather the recharacterization of an existing therapy for a particular segment 
of society – in short, the repackaging of the drug as ethnic” (Kahn, 2013:66). 
Kahn further points out that, “while clinical trials and drug development may 
sometimes look at an array of factors, including social and economic variables, 
they also frequently look only at biomedical variables. . . . When a drug’s efficacy 
or safety is correlated to racial or ethnic categories, it opens the door to reifying 
those categories as genetic” (Kahn, 2013:68) [emphasis mine].
As noted above, race and ethnicity are used as surrogates for genetics, but there 
are differences in opinion regarding whether race/ethnicity serves as a “good” 
surrogate. For instance, Dr. Chong said: “this [i.e. race/ethnicity] is just a lousy 
surrogate for a genotype. So at the end of the day, you have to drill down to the 
genotype, you know. I don’t think anyone is going to start prescribing medi-
cine that says that ABC is the preferred choice for Chinese, high blood pressure 
patients.”
While Dr. Chong and many of his colleagues suggested that it is not possible 
for drug prescriptions to be based on race/ethnicity, the existence of IRESSA in 
Asia and BiDil and the history of sickle-cell anemia screening made mandatory 
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for African Americans should serve as stern reminders for what may develop in 
the future with the advent of racially/ethnically labeled population-based genetic 
studies (Wailoo, 2001; Duster, 2003; Kahn, 2013).
Cancer genomics in the clinic
Genetic testing and genome-based personalized medicine have been adopted 
across three dimensions of clinical decision-making: drug efficacy, drug toxicities, 
and preventive medicine. In line with the view of personalized medicine as a ben-
eficial development, interviewees generally agreed that such targeted treatments 
not only maximize therapeutic benefits and minimize potential adverse drug 
reactions for patients, but also can reduce health care costs for society as a whole.
At the same time, interviewees continually emphasized that laboratory science 
and clinical practice are different worlds. The former seeks to investigate a clear 
relationship between an independent variable (presence of a genetic marker) and 
dependent variable (responsiveness to a drug treatment or susceptibility to a par-
ticular disease), while the latter requires an overall assessment of a patient beyond 
this proposed parsimonious relationship. This partially explains why the statisti-
cally significant relationship observed within a study population might not be 
applicable in a clinical setting.
It seems to us that “probability medicine” is a more accurate term than “pre-
cision medicine” or “personalized medicine.” To begin with, clinicians have 
pointed out that genetic mutations tested are strongly correlated with – but not 
precisely determinative of – a drug’s efficacy and toxicity. That is, even if a drug 
has been shown to be effective against a particular mutation, the targeted drug 
does not work effectively for everyone with the particular mutation. As noted in 
Chapter 5, Dr. Tang explained: “About 70 percent of the [local] patients will 
carry the EGFR mutation. Of those patients who [have the] EGFR mutation, 
you do expect that 80 percent of them will respond to the drug [IRESSA], so 
20 percent that will not respond – meaning that they [the tumors] either remain 
the same or they may even grow with the treatment.” As far as drug toxicities 
are concerned, the situation is similarly complex. For example, genetic testing 
for two genes, CYP2C9 and VKORC1, serves to help determine the appropriate 
dosage of Warfarin to be administered to a patient. However, an adverse reaction 
(i.e. bleeding) to Warfarin could also be caused by many nongenetic factors (i.e. 
drinking of herbal tea) that genetic testing may not account for.
Ogolla describes race-based medicine as synonymous with personalized medi-
cine (Ogolla, 2010). He further suggests that categorizing groups “on the basis 
of race and ethnicity to benefit their health is desirable” (Ogolla, 2010:47). How-
ever, the interview data suggest that oncologists believe that clinical medicine 
cannot profitably use race/ethnicity as a proxy in the administering of medicines to 
diverse ethnic and racial populations. Hence, I argue that using race/ethnicity as a 
framework to make clinical decisions about genomic medicine is not desirable and 
may actually cause harm for several reasons. First, as the doctors’ consensus seems 
to indicate, when information on particular genetic variants/mutations have been 
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identified, patients’ race/ethnicity becomes irrelevant. It might be useful at the 
research stage if variants are not known. However, a drug that effectively targets 
a mutation should work similarly across all patients, regardless of ethnicity. As 
Dr. Yeh put it: “It is the driving mutation. It does not respect ethnic boundaries.”
Results from a clinical trial that uses race/ethnicity as a framework may reveal 
the probability, for example, that patients from a particular ethnic group face a 
higher chance of having a mutant/variant gene. However, such a probability state-
ment is not very helpful in guiding treatment decisions because it is only when the 
patient actually goes through genetic testing that he/she knows whether he/she 
carries the mutant/variant gene. Likewise, even if trial results show that a particular 
ethnic group is less likely to carry a particular mutant/variant gene, this does mean 
that there is not a chance that a particular patient of that ethnicity does carry that 
mutant/variant gene. Thus, the frequency of a mutation within a particular ethnic 
group does not matter; all patients should go for genetic testing because there 
is always the chance that a patient might have the specific mutation. To proceed 
without genetic testing because of race-based probability statements could result 
in medical misdiagnosis or treatment (Witzig, 1996; Anderson et al., 2001; Gar-
cia, 2004; Barr, 2005; Braun et al., 2007; Acquaviva and Mintz, 2010; Megyesi, 
Hunt and Brody, 2011). The interviews with oncologists suggest that, for exam-
ple, even though the prevalence rate or the frequency of the EGFR mutation may 
be higher in the “Asian” or “Chinese” population, this does not mean that the 
doctors should not offer EGFR genetic testing to an “Indian” or “Caucasian” lung 
cancer patient. In fact, the physicians interviewed emphasized that EGFR mutation 
testing should be done for each lung cancer patient, irrespective of ethnic identity. 
Thus, the finding lends support to what Cooper, Kaufman, and Ward (2003:1167) 
point out, “if you really need to know whether a patient has a particular genotype, 
you will have to do the test to find out.” To reiterate, we need to be wary of situ-
ations, where race and ethnicity is used, unfortunately, as the poor man’s genomic 
test. As far as preventive measures are concerned, interview data suggest that race- 
or ethnicity-based estimates are less convincing than a patient’s family history, and 
there is a need to discuss what is meant by clinically relevant risk percentages.
Bioethics in practicing personalized medicine
The reality of genome-based personalized medicine, particularly in oncology 
where it is most extensively applied, is that personalized drugs offer the potential 
to prolong patients’ lifespans but not to cure their diseases. When personalized 
medicine becomes heavily promoted, patients may be led to mistakenly expect 
that it will cure them. Thus, it is important to manage expectations about per-
sonalized drugs. In the first place, as Roberts (2011:165) puts it, “when patients 
hear about a drug indicated specifically for their race, they may assume that it is 
‘just right for me.’ ” Next, one serious concern about these drugs involves high 
costs. Therefore, patients need to be clear about the fact that, should they opt for 
personalized drugs, they will be paying a very high cost not to be cured, but to 
prolong their lifespans.
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The high costs of personalized medicine create a dilemma for doctors in terms 
of how they ought to work though treatment decisions with patients. While 
genetic testing is increasingly a norm in clinical practice, test results may not 
be useful, particularly in cases in which patients are unable to afford the specific 
drugs to be taken. First, although the cost of each genetic test seems low, for 
lower income patients, the cost is still financially significant. Moreover, as more 
and more different genetic tests become available, the total cost of genetic test-
ing also grows. Some interviewees suggest that physicians should instead assess 
the financial backgrounds of their patients and recommend treatments that are 
affordable, rather than the most advanced (and, therefore, costliest), so that 
patients and their families will be spared the moral question of the value of the 
extra months of life. Even with state subsidies, personalized medicine remains 
very expensive for low income patients and those who are not covered by private 
health insurance. Thus, doctors feel pressure to prescribe genomic medicine, as it 
is the “new norm” in medical advancement, but they also face situations in which 
patients are unable to afford such advanced treatment. Should it be the physi-
cian’s right to withhold treatment information out of good intentions in order to 
handle such an ethical dilemma? What if a patient’s family was willing to find the 
means to pay the steep cost for a few more months with the patient, but was not 
informed about this possibility?
Making genetic testing and genomic medicine equally affordable for all patients 
entails a difficult discussion of how finite resources for public health care should 
be distributed and how various stakeholders are affected. As it is, it would seem 
that citizens would end up bearing the bulk of the cost through higher taxes and 
higher insurance premiums, and to convince the public to accept this would be a 
challenge. Even if they are agreeable, what about subsidies for diseases other than 
cancer? It appears to be a challenge for governments to fund all subsidies.
Another issue is that doctors sometimes lack the latest knowledge about genet-
ics to properly interpret genetic testing results that will ultimately inform their 
clinical decisions. In situations in which patients ask about areas about which a 
doctor is unsure, should he or she hide ignorance or risk providing incomplete 
or inaccurate information? Moreover, given the rapid rate of development and 
launching of new drugs and diagnostics from pharmaceutical companies, doc-
tors find it challenging to continuously process all of this information and decide 
which drugs should be applied in the clinical setting. It has been suggested that 
studying genomics could be incorporated into the curriculum of medical educa-
tion, and perhaps a cohort of doctors could become medical geneticists who 
specialize in this area in order to be able to interpret more complex test results, 
such as those for direct-to-consumer (DTC) genetic testing products.
There are also serious concerns about privacy and potential genetic discrimina-
tion against individuals or particular groups that the literature on “citizen science” 
has alluded to. Technically, genetic testing results are personal information to be 
kept confidential. However, in cases of germline mutations, which are inheritable, 
such information has implications for both the patient and his or her biological rel-
atives. Should these relatives be given such information so that they might consider 
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undergoing genetic testing themselves? What if individuals prefer not to know if 
they are predisposed to certain diseases to avoid having to live with anxiety? Or, 
for healthy individuals who go through genetic testing, if it so happens that a test 
reveals a certain predisposition for developing a disease other than that which the 
test was intended to find, would the doctor need to reveal this information? Such 
awareness of disease predisposition might also entail discriminatory practices in 
society. For example, employers and insurance companies may ask individuals or 
individuals belonging to a particular ethnoracial group to go for genetic testing 
before employing them or enrolling them in insurance plans. Let’s hypothesize 
that it is found that the Malays as a population group have a higher proportion 
of a manifesting tendency toward certain kinds of diseases – say 60 percent of the 
“Malay” as compared to 30 percent of the “Chinese” group. This information pro-
vided to an insurer, if what is said about Malays is uncritically accepted, could lead 
to consequences for individuals identified as “Malay”: (1) not being able to enroll 
in a particular insurance plan, (2) enrollment in an insurance plan that excludes cov-
erage for any expenses related to diseases they are supposedly predisposed to have, 
and (3) enrollment in an insurance plan that also insures against such diseases but 
charged a higher premium. In general, the revelation that one has a predisposition 
to a certain disease might result in denial of job opportunities or higher insurance 
premiums. So, should individuals be open with such information? Should employ-
ers or insurance companies be entitled to such information? Why or why not?
Lastly, cancer is a complex disease and has genetic, environmental, and lifestyle 
causes. According to Anand et al. (2008):
[O]nly 5–10 percent of all cancer cases can be attributed to genetic defects, 
whereas the remaining 90–95 percent have their roots in the environment 
and lifestyle. The lifestyle factors include cigarette smoking, diet (fried 
foods, red meat), alcohol, sun exposure, environmental pollutants, infec-
tions, stress, obesity, and physical inactivity. The evidence indicates that all 
cancer-related deaths, almost 25–30 percent are due to tobacco, as many as 
30–35 percent are linked to diet, about 15–20 percent are due to infections, 
and the remaining percentage are due to other factors like radiation, stress, 
physical activity, environmental pollutants etc.
Some cancers may also result from interactive effects of genes and the environ-
ment. Yet, in the postgenomic era, the focus seems to have been placed on “cur-
ing” cancer through genome-based pharmaceutical products, sometimes under 
the banner of “personalized/precision medicine,” as opposed to preventing can-
cer through tackling environmental and lifestyle causes.
While genetics, not race/ethnicity, should be the basis on which precision 
medicine should be developed, I caution against genetic determinism. As one 
interviewee, Dr. Wee, put it, “genetics is not destiny,” and the fact that even tar-
geted medicine is not always effective further attests to this statement. Environ-
mental problems, diet, and certain lifestyle practices can be detrimental to health, 
and, thus, the context of cancer as a multifactorial disease is significant.
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I warn against the dangers of seeing race as a biological/genetic concept, as 
this legitimizes racial discrimination (which has health consequences) and, on a 
broader level, treads into the dangerous territory of genetic determinism ( Nelkin 
and Lindee, 1995). Moreover, the focus on pharmacogenomics has overshadowed 
our collective ability to better understand the role of modifiable and preventable 
nongenetic/environmental factors, which have a strong potential to result in inter-
ventions that actually benefit all individuals regardless of socio-economic status.
To fully capitalize on the potential benefits of genomic medicine, in-depth 
interdisciplinary discussion is vital for the proposal and implementation of com-
plementary and/or alternative solutions. In the following section, I raise the 
importance of interdisciplinary collaboration and discussions among different 
social actors, particularly at the initial stage when scientists are formulating the 
variables, including that of “population,” in their human genetic or genomic 
studies (Kaplan, 2014).
Upstream engagement and regulatory guidance
To help elucidate the processes of naturalization of socially derived concepts 
of race and/or ethnicity, Duster (2006b:1) recommends that social scientists 
“turn greater attention to an analysis of data collection at the site of reduction-
ist knowledge production.” Through illustrating how molecular geneticists use 
racial and ethnic categories, one can penetrate the logic there and then help shed 
light on the internal debates and arguments among molecular geneticists dur-
ing the process of such knowledge production. In the pages of this book, a few 
researchers’ responses also reveal their dilemmas, as on the one hand, they rec-
ognize that race and ethnicity are constructed socio-culturally, but on the other 
hand, they believe in certain technologies, such as Ancestry Informative Markers 
(AIMs), to analyze race/ethnicity biologically. Several studies serve as models for 
how social scientists can work with molecular geneticists to provide a fuller pic-
ture of the process of scientific knowledge production and the “molecularization 
of race” in labs (Fullwiley, 2007, 2008; Fujimura and Rajagopalan, 2011; Shim 
et al., 2014). For instance, insofar as AIMs are concerned, Fullwiley (2008:706) 
concludes:
It should be clear by now that the very continents and people chosen for this 
product [ancestry determination] were selected due to their perceived prox-
imity to what we in North America imagined race to be. . . . In other words, 
the assumed bounded groups on which the AIMs draw (African, European, 
Native American and Asian) correspond to American cultural ideas of race, 
which, in the case of many scientists, also ends up shaping where across the 
globe they collect the DNA of “populations.”
In the absence of clear professional statements from molecular geneticists 
and/or medical researchers that race/ethnicity is not a genetically or biologically 
determined category, an interdisciplinary research team is even more necessary 
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in order to delineate systematically the discussions and possible impacts of both 
using and not using race/ethnicity as a proxy in genomic science.
With respect to clinical practices, according to Guttmacher et al. (2010:164):
[I]dentifying information that may be of clinical significance to the individual 
patient will be impracticable without the use of automated systems and clear 
guidelines. There are not enough clinical geneticists to help patients inter-
pret whole-genome sequencing results, and research shows that primary-care 
physicians lack the knowledge and expertise to help patients understand even 
single-gene genetic test results; they certainly are not prepared for whole-
genome counseling.
Good sampling methodologies and management of data require foresight that 
can be aided by interdisciplinary dialogue. Moreover, critical assessment of the 
presentation of data is important, for example, in the framing of data to highlight 
the significance of a particular study, or in assigning factors as either the “cause” 
or the “effect” in a cause-and-effect relationship, as both can drastically impact 
the outcome and perception of importance/implications of studies. For instance, 
in the case of hypertension, as Duster (2007:703) notes,
Michael Klag and his associates showed that, in general, within the African- 
American community, the darker the skin colour, the higher the rate of 
hypertension. Klag argued that the correlation between skin colour and 
hypertension was not biological or genetic in origin, but biological in effect 
due to stress-related outcomes of reduced access to valued social goods, such 
as employment, promotion, housing stock, etc.
In addition, states and relevant authorities (including research governance 
bodies) have important roles to play in terms of regulations because guidelines 
influence the actions of scientists and doctors. Jasanoff’s (2003) comparisons 
of regulations concerning biotechnology in Britain, Germany, and the United 
States lead her to argue that “regulatory choices invariably affect the degree to 
which publics can unpack and deliberate on the underlying purposes of innova-
tion.” Lee (2003) criticizes the lack of bureaucratic/governmental guidance and 
support (e.g. FDA, HUGO Ethics committee), asserting that current regulation 
“further embeds race and race thinking into the research process”:
The [USA] federal government has sidestepped critical examination of these 
local meanings of race.
[The draft guidance by the US FDA] cites its sister institution . . . and empha-
sizes the need for administrative continuity. Without consensus on the defini-
tions of the census categories, much less their validity as scientific variables. . . .
While [The HUGO Statement in Benefit-Sharing] reflects increasing con-
cerns over the impact of genetics research on social justice, these guidelines 
lack legislative enforcement.
Conclusion 165
I further note in Chapter 3 that these US FDA regulations – the Demographic 
Rule (CFR 314.50 d(5)) in 1998 and a guidance document in 2005 on col-
lection of race and ethnicity data in clinical trials – have problematic global 
consequences. That is, as pharmaceutical companies try to get their products 
registered with the US FDA, these administrative rules can inadvertently give 
rise to the development of race-specific or ethnic-specific medicine via non- 
Western routes. In order to avoid such pitfalls, regulations need to be informed 
by the concerns and controversies surrounding the usage of race and ethnicity in 
biomedical settings.
As Lee (2003:389) points out, although race is a “socially and historically con-
tingent concept [that] should not be eliminated from medical research,” there 
is a need for multidisciplinary dialogue and the creation of policies to address 
the role that race should play in scientific research in order to distribute benefits 
equitably. As Lee, Mountain, and Koenig (2001:47) add:
The ever-changing taxonomy of race is a reminder that any research utilizing 
the concept of race and/or ethnicity must include an interrogation of the 
economic, political, and cultural factors that inform the struggle over how 
these categories are defined and used.
Should using race/ethnicity as a temporary proxy be unavoidable, for exam-
ple, in the absence of better proxies and an understanding of probable molecular 
causes of disease susceptibility and drug response, or when necessary data were 
collected in the past using race/ethnicity as categories, the public needs to be 
informed that such categories were adopted due to methodological convenience 
and accessibility. If the adoption of an automated system is the future, then it 
seems that it would be instructive to further investigate whether, how, and why a 
patient’s ethnicity/race is included in such an electronic health care system. This 
study has focused on the key actors in the biomedical industrial complex (e.g. 
geneticists, clinician-scientists, pharmaceutical companies, public health policy-
makers, etc.), but it is also important for future researchers to understand how 
patients and their significant others (families, friends, etc.) receive, interpret, and 
act on the results of genetic testing.
What I have attempted to describe is a nuanced and complex situation con-
cerning the development of so-called “personalized” or “precision” medicine 
in cancer prevention and treatment. In the (post)genomic era, will medicine be 
“personalized” according to an individual’s unique genetic makeup, or will medi-
cine be developed and administered in relation to an individual’s racial and ethnic 
identities? While their primary intention is to develop drugs to treat various types 
of cancer and alleviate the physical suffering of cancer patients, but in the process 
of coming up with personalized genomic medicine, many molecular geneticists, 
cancer geneticists, and physicians do not realize the unintended consequences of 
their actions regarding the molecular reinscription of race and ethnicity.
Moreover, it seems that “precision medicine” or “personalized medicine” 
could be misleading terms, and actually it may be more accurate to call “precision 
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medicine” “probability medicine,” as a patient’s genetic information only pro-
vides clinicians with an additional layer of information to make probability state-
ments. Furthermore, the interview data in Chapter 5 show that it is largely not 
advisable for race/ethnicity to be used as a proxy for administering drugs. Such 
a framework is considered appropriate only as a last resort when options to treat 
patients are limited. Many of the doctors interviewed did recognize that races/
ethnicities are categories with social origins. Additionally, the doctors under-
stood that the labeling of someone as a member of a certain race suggests social 
and cultural elements, such as certain dietary preferences. Thus, they knew that 
ethnic/racial information is not equivalent to genetic information, and that the 
racial/ethnic proxy is very limited in its usefulness in clinical decision-making 
about genomic medicine. Finally, due to the high cost of genome-based per-
sonalized medicine, there is a double-risk for individuals living in middle- and 
low-income countries: they may be enrolled in clinical trials, but they cannot 
afford the medicine that eventually comes out of such trials. While individuals 
in resource-poor settings and marginalized groups do need adequate medical 
attention to ensure that their health status is optimized, I suggest that race- and 
ethnic-specific medicine is not the way to go. Instead, we should embrace the fact 
that cancer is a complex disease. Funding sources need to support research to 
advance our knowledge of both its genetic and non-genetic causes, rather than 
nudging researchers to yield to the molecular imperative even in the context of 
gene–environment interaction research (Darling et al, 2016). While we cannot 
escape categorization and classification, in the context of genomic science and 
medicine, we need to pay attention to the questions of why the categories of race 
and ethnicity are used as the population sampling frame, and who gets to define 
race and ethnicity and with what possible dire consequences.
As an era of genome-based personalized medicine dawns upon us, and as 
the processes of molecularization of race and ethnicity unfold, it is of utmost 
importance that the public, policy-makers, clinicians, and scientists under-
stand this: that race and ethnicity serve as a dubious proxy for human genetic 
diversity in population-based genomics research and for individual genotype in 
clinical decision-making, and that there is no genetic basis to racial and ethnic 
identities.
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Appendix A
A brief socio-history of  
ten societies in Asia
Governance prior to 
Colonial Times











India Company Rule (East 
India Company) 
[1757–1858]
British Crown Rule 
(1858–1947)
1947
Indonesia Company Rule  







Japan Shogunate (Feudal 
Society)  
(1192–1867)
Imperial Rule [The 
Empire of Japan] 
(1868–1945)
1947
Korea Japanese Protectorate 
(1905–1910)
Japanese Colony  
(1910–1945)
1948





Philippines Spanish Colony  
(1521–1898)
American Colony  
(1898–1946)  
[Japanese Occupation,  
1941–1945]
1946




Singapore by the 
British since 1819]















Japanese Rule  
(1895–1945)
1911




Work in the research 
lab and/or clinic?
First name Last name
Satoshi Hiro Public Research lab
Eugene Lee Public Research lab
Kenneth Cheung Public Research lab and clinic
Jun Wei Yeoh Public Research lab
Paul Lin Private Research lab and clinic
Jun Park Public Research lab
Daniel Yeh Public Research lab and clinic
Jerome Yuan Public Research lab and clinic
Wei Sheng Zhuang Public Research lab and clinic
Wei De Wang Public Research lab and clinic
Jun Yuan Chua Public Research lab
Josiah Huang Public Research lab
Frank Ballheimer Public Research lab
Jun Jie Liang Public Research lab and clinic
Zheng Wei Teo Public Research lab and clinic
Aaron Zhao Public Research lab
Yi Jun Wee Public Research lab and clinic
Jun Hao Hsu Private Research lab and clinic
Wei Jie Zhang Public Research lab and clinic
En Quan Tang Public Research lab and clinic
Zhi Hong Poh Public Research lab and clinic
Vijay Rajaratnam Public Research lab
Christina Neo Public Research lab and clinic
Michael Wu Public Research lab and clinic
Wei Yang Koh Private Research lab and clinic
Claire Xia Private Research lab and clinic
Desmond Deng Public Research lab and clinic
Han Wei Soh Public Research lab
Alex Xie Public Research lab and clinic
Gabriel Chong Private Research lab and clinic
Cong Ming Sim Public Research lab
Appendix B
Key characteristics of the scientists 
and clinician scientists interviewed
Japan
The idea of “eugenics” and eugenic movements first surfaced in Japan in the 
Meiji era (1868–1912) (Matsubara, 1998; Kato, 2009). According to Robertson 
(2002:195):
[E]ugenics, coined by Francis Galton in 1883, was translated into Japanese 
as the [R]omanized yuzenikkusu and as the neologisms yuˆseigaku (sci-
ence of superior birth) and jinshukaizengaku (science of race betterment). 
These terms were used synonymously with two terms coined a little earlier: 
“race betterment” (minzoku/jinshu kairyo) and “race hygiene” (minzoku/
jinshu eisei).
In addition, there was the belief in the concept of “pure blood” as a criterion of 
authentic “Japaneseness” in the 1880s (Robertson, 2002). The eugenicists were 
keen on preserving the “Yamato blood” that was deemed a superior substance 
due to its association with the imperial household and ability to dominate other 
racial groups (Robertson, 2002).
The Japanese practiced eugenic marriages, which meant that a “pure-blood 
Japanese” selected a partner who was healthy physically and psychologically for 
the sake of the nation (Robertson, 2002). Eugenic marriage counseling cent-
ers were set up in Japan, with the first opening in Tokyo in 1927. While center 
staff advocated mixed blooded marriages among the “white” and “yellow” races, 
they discouraged some. For instance, center staff tried to prevent marriages 
between Japanese women and Korean men who were working as laborers fol-
lowing Korea’s colonization (Robertson, 2002). The words of one survey report 
filed in 1942 read, “the Korean [male] laborers brought to Japan, where they 
have established permanent residency, are of the lower classes and therefore of an 
inferior constitution. . . . By fathering children with Japanese women, these men 
could lower the caliber of the Yamato minzoku” (Robertson, 2002:205). Caprio 
(2014) elaborates on how some medical scientists, such as Kubo Takeshi, used 
“scientific inquiry to biologically define Koreans.”
To make a long story short, the racial Eugenic Protection Bill was drafted 
(Morita, 2001; Kato, 2009). It should be emphasized that the proposal was 
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specifically made under the influence of the German Sterilization Law of 1933, 
as the Japanese considered Germans to be dominant in the field (Morita, 2001; 
Kato, 2009). The initiation of the bill can also be attributed to the pro-German 
atmosphere following Japan’s military pact with Germany in 1937 (Matsubara, 
1998). However, little scientific justification for such policies was provided to the 
public.
This bill, which aimed to sterilize persons with “hereditary diseases,” was 
introduced as the National Eugenic Bill and passed as the National Eugenic Law 
(NEL) in 1940 (Matsubara, 1998; Morita, 2001). The law articulated the legal 
procedure for eugenic sterilization surgery for people with mental and physi-
cal “hereditary diseases” to prevent them from reproducing (Kato, 2009). All 
“undesirable features,” including behaviors such as “alcoholism, rape, narcotic 
use and robbery,” which were considered to be bad for society, were associated 
with the concept of “heredity” and included as reasons for eugenic sterilization 
(Matsubara, 1998; Kato, 2009).
With the fall of Japan in World War II, the country was in economic and 
industrial ruin and facing a baby boom (Matsubara, 1998; Kato, 2009). This led 
Japanese leaders to believe that the “racial crisis” was much more urgent than 
before; some criticized the NEL as too mild and the sterilization procedures as 
too troublesome, rendering the law ineffective. They advocated for a powerful 
eugenic policy as the only option for Japan’s reconstruction. They also asserted 
that the protection of mothers’ health and keeping families small were important 
to enhance the health and well-being of offspring.
As such, the Eugenic Protection Law (EPL) was enacted in 1948. The objec-
tive of the law was similar to that of the NEL, with the addition of protecting life 
and health of the mother (Kato, 2009). However, “inferior descendants” were 
defined as not only descendants of patients with hereditary diseases, but also 
those with infectious diseases such as leprosy. In other words, nongenetic diseases 
and other mental diseases were included. In 1953, the Eugenic Protection Law 
was enforced by the Ministry of Health and Welfare; a eugenic operation could 
be performed against the patient’s will if the council judged it necessary.
In 1996, the EPL was revised again to remove all eugenic aspects, and its name 
was changed to the Maternal Protection Law (Robertson, 2002).
Korea
According to Shin (2006), as noted previously in this chapter, the “Korean nation 
was ‘racialized’ through a belief in a common prehistoric origin,” of being the 
purest descendants of the mythical figure Dangun. Even today, pure bloodism 
(sunhyol) – a pseudoscientific ideology – is justified as “defensive nationalism” 
(Pai and Tanherlini, 1998) and functions as a key resource in Korean politics and 
foreign relations. Recently, Shin’s (2006) study on national identity revealed that 
93 percent of survey respondents believed that “our nation has a single bloodline.”
In 2007, the United Nations Committee on the Elimination of Racial Discrim-
ination (UNCERD) asked South Korea not to use the myth of pure blood and to 
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“prohibit and eliminate all forms of discrimination against foreigners, including 
migrant workers and children born from inter-ethnic unions” (FIDH, 2007). 
South Korea’s aspirations to be globally competitive and adhere to global stand-
ards have had the effect of rendering the myth unacceptable in the country (Kim, 
2011:9). However, xenophobia remains intense (Choe, 2009; UN News Centre, 
2014). Unlike in Japan, there have been no policies explicitly termed “eugenic” 
in South Korea. However, according to Kim (2011:9), the South Korean state’s 
“overarching goal is the reproduction of Korean nationals, based on the idea of 
‘purity of blood’ and understood exclusively as the paternal line.”
People’s Republic of China
The People’s Republic of China was established in 1949. In 1986, there were 
guidelines and provisions targeted at preventing people with histories of men-
tal illness, retardation, or hereditary diseases from procreating (Rodgers, 1999). 
The Ministry of Health issued a “Guiding Criteria for Classification of Abnormal 
Cases,” listing groups of people deemed “unfit” to reproduce (Rodgers, 1999). 
The National Eugenics Law in China, enacted in 1995, is also known as the Mater-
nal and Infant Healthcare Law (Sleeboom-Faulkner, 2010:126). Here, I will pay 
particular attention to the history of a law prohibiting the reproduction of the 
intellectually impaired in the Gansu Province to illustrate the operation of “nega-
tive eugenics” and the larger point about the danger of treating a socially deter-
mined category (“the intellectually impaired”) as if it were a biological category. 
Gansu, in northwestern China, is one of the least developed provinces (Chung, 
2011). It was selected as the testing ground for the national eugenics law, and a 
closer look at its history helps us understand how the sterilization law came about.
According to Johnson (1997), the law in Gansu can be translated as “The 
Prohibition of Reproduction by Intellectually Impaired Persons.” It was adopted 
on November 23, 1988, took effect on January 1, 1989, and was suspended on 
January 22, 2002, supposedly due to criticism of its eugenic motives. The main 
aim of the law is to “improve the quality of the population and reduce the bur-
den on society and on the families of the intellectually impaired persons” (John-
son, 1997:221). Under the law, intellectually impaired persons were required to 
undergo sterilization and were defined as having all of the following characteris-
tics (Johnson, 1997):
(1) They are affected congenitally by hereditary causes, marriage of close rela-
tives, or their mothers and/or fathers have been influenced by external fac-
tors; and
(2) They have moderately or severely limited intellectual capacity with an IQ of 
49 or below; and
(3) Their speech, memory, orientation, thinking, etc., are impaired.
In addition, the law stipulated that mentally handicapped individuals were 
not allowed to marry unless they sterilized. The law was greatly supported by 
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the government, with then Prime Minister Li Peng strongly believing that the 
intellectually impaired were incapable of caring for themselves, were a burden to 
their families, and that they would produce more of themselves and, thus, affect 
the quality of the population (Kristof, 1991). The law was praised and further 
adopted in other provinces and, eventually, led to the drafting of the National 
Eugenics Law in 1995.
At the same time, it has been suggested that the majority of intellectual impair-
ment cases in Gansu Province were due to “poor prenatal care and birth pro-
cedures, or of dietary deficiencies like lack of iodine” (Kristof, 1991). As such, 
ensuring adequate resources for care and nutrition could have helped greatly 
reduce such cases (Johnson, 1997). In other words, rather than sterilization, it 
would have been better to bring attention to improving the conditions of the 
destitute and disease-plagued Gansu Province to effectively prevent the births of 
intellectually impaired babies.
Chinese geneticists claimed to have found higher rates of mental and physical 
handicap among the peasantry than the urban population, as well as among eth-
nic minority groups as compared to the majority Han (Qiu and Dikötter, 1999). 
However, Qiu and Dikötter (1999) argue that this is a scientized version of Han 
prejudice against a minority, as the Han “race” is also a socially constructed iden-
tity (Dikötter, 1997).
India
Early eugenic ideas and policies in India grew in the context of national popula-
tion policy during the interwar period in the 1920s, when a discourse linking 
census, population, and progress began among Indian intellectuals (Nair, 2006). 
These ideas grew in the context of famine and deprivation among a growing 
population. India’s large population was no longer seen as a sign of a healthy 
nation; rather, whether the nation was healthy was defined in relation to the 
proportion of nonproductive people (Buckingham, 2006). Census was used pri-
marily as a means to “identify, classify, rank and categorize” society based on 
“religion, caste, sub-caste and profession” (Nair, 2006). International relations 
played an important role, as Indian intellectuals were exposed firsthand to Brit-
ish social, economic, and political movements, including the eugenics movement 
(Nair, 2006). These Indian intellectuals maintained organizational ties with the 
British by holding international conferences. Dr. Gopalji Ahluwalia was a biol-
ogy professor who presented at an international forum on birth in 1922 (Nair, 
2006). It was here that he drew an explicit connection between abject poverty 
and irresponsible and extensive breeding, and asserted that wealth was equated 
with superior racial qualities and that “subaltern populations” (tribal, lower caste, 
and Muslims) should definitely use birth control (Buckingham, 2006). Nonethe-
less, it is important to note that there was little evidence of widespread eugenic 
policies in India in the 1920s.
In the late 1940s, leprosy sufferers became central to biopolitical debates with 
regard to managing the health and welfare of the newly independent Indian 
Appendix C 177
population. Leprosy is a contagious, chronic, and highly stigmatized disease that 
affects one’s nerves and skin, causing physical deformities largely on the limbs 
and face (Buckingham, 2006). It is not, however, a hereditary disease but an 
infectious one, so that patients tend to be isolated from their family members and 
social circle. Given that leprosy sufferers were reluctant to embrace vasectomy, in 
1953, Srimati Lilavati Munshi proposed a bill to the House of People for com-
pulsory sterilization of adults classified as “unfit” to reproduce. This was also the 
period when the discourse on eugenics and the issue of leprosy were both rapidly 
gaining traction internationally. The bill was withdrawn due to strong opposi-
tion from the Health Minister, but resurfaced again in 1968 as a “sterilization of 
the unfit bill” (Buckingham, 2006). This bill was intended not only to limit the 
births of disease sufferers, but also to “eradicate the race of unfit and unhealthy 
people” (Buckingham, 2006). Eventually, the bill failed to pass due to its “unsci-
entific . . . impracticable . . . unethical” basis.
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Japan
In Japan, IRESSA has been approved for the treatment of epidermal growth fac-
tor receptor (EGFR) mutation related cancers since 2002 (AstraZeneca, 2002; 
The Japan Times, 2013), with the drug being used for second-line and third-
line treatment (Frampton and Easthope, 2005). Under Japan’s National Health 
Insurance (NHI), Japanese citizens receive subsidies (co-payments range from 
0 to 30 percent) for medicines that have been placed under the NHI’s list of 
drugs, which is reviewed regularly to add new drugs (Cook and Kim, 2015). The 
Japanese government regulates prices of drugs through the NHI with the aim of 
preventing patients from suffering from crippling drug costs (Wiley Handbook of 
Current and Emerging Drug Therapies., 2007). Narita et al. (2015) conducted a 
cost-effectiveness analysis of IRESSA in Japan, in which the NHI subsidy seemed 
to be factored into the study. In other words, while there is no explicit mention 
of it, the study seems to suggest that IRESSA is on NHI’s drug list, implying that 
it currently qualifies for a subsidy.
Various expensive drugs, such as Zevalin, are currently being subsidized in 
Japan (Okamoto, 2014). However, Japan’s social security system (which encom-
passes the NHI) is being critiqued and labeled as potentially unsustainable (Yoshi-
kawa, 2012), implying that there may come a time when various pricey drugs are 
removed from the NHI list.
South Korea
Like in Japan, IRESSA received approval for the treatment of EGFR mutation 
cancers in 2002 (Pao and Girard, 2009). South Korea also operates under the 
NHI paradigm of universal health care (Kang et al., 2012). As of 2014, 98 per-
cent of the population was covered under NHI (Kim, Kim, and Kim, 2014), a 
proportion that rose to 99 percent in 2015 (Cook and Kim, 2015). Cook and 
Kim (2015) also state that, under the NHI, patients needing oncological drugs 
are only liable for a co-payment of 5 percent of the drug costs. The NHI prior-
itizes drugs that are deemed cost effective to receive subsidies (Williams, 2013). 
This list of subsidized drugs currently includes IRESSA (Ahn, 2012). It should 
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be noted, however, that the introduction of subsidies for treating long-term con-
ditions appears fairly new, and it appears that many expensive drugs have only 
recently been introduced into the NHI (Song, 2009).
Taiwan
As of 2011, IRESSA has been included in the NHI’s list of drugs that receive a 
subsidy (The China Post, 2011; Taipei Times, 2011). As such, IRESSA is both 
available and subsidized in Taiwan.
China
As per the China Food and Drug Administration (CFDA), IRESSA has been 
approved for use to treat EGFR mutation cancers since 2014 (China Food and 
Drug Administration, n.d.)1. It does not seem that a state subsidy is available. 
However, the China Charity Federation (CCF), a Chinese non-governmental 
organization (China Charity Federation, n.d.) appears to be actively involved in 
providing, at the very least, patients in need of financial assistance with free doses 
of IRESSA as long as they have purchased and completed a six-month dosage of 
the drug (Xinhua Net, 2008; Zhu et al., 2013; Zeng et al., 2014). As such, while 
IRESSA does not appear subsidized, there seems to be a nongovernmental effort 
to provide relatively easier access to the drug.
India
IRESSA has been approved to treat EGFR mutation cancers since 2004 (Cen-
tral Drugs Standard Control Organization, n.d.). However, the likelihood of the 
drug being subsidized is low. First, India’s health care system has been criticized 
for its inefficiency, poor infrastructure, and inability to provide basic, primary 
health care to hefty portions of the population (Devadasan et al., 2011; Jayara-
man, 2014), with an estimated 60 percent of the rural population and 40 percent 
of the urban population paying hefty sums out-of-pocket (Joe, 2015). Further-
more, the lack of basic coverage has come under criticism, with the parliament 
indicating to the government that the medicines covered, regulated, and capped 
under the National Pharmaceutical Pricing Authority (NPPA) are paltry, with the 
figure standing at a mere 348 out of thousands of drugs available in the country 
(The Telegraph, 2015).
Indeed, the update to the Gazette of India issued in 2013 and published in the 
NPPA does not include IRESSA in the list of drugs to be given a nationwide price 
cap (Ministry of Chemicals and Fertilizers, 2013).
Singapore
In Singapore, IRESSA was approved to treat and inhibit EGFR mutation related 
cancers in 2003 (Health Sciences Authority, n.d.)2. Furthermore, in response to 
an enquiry in The Straits Times, the Ministry of Health (MOH) mentioned that 
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while the drug is not subsidized per se, individuals needing financial assistance 
can apply for help through the Medication Assistant Fund (MAF) (Au-Yong, 
2013), a fund that physicians can help patients apply for to offset the costs of any 
expensive drugs deemed clinically necessary (Ministry of Health, 2012). Karen 
Au-Yong, then Deputy Director of MOH communications, justifies the MOH’s 
stand by stating that IRESSA could only be given a subsidy if the supplier of the 
drug participated in the centralized purchasing program that allowed the state to 
purchase the drug in bulk (Au-Yong, 2013).
MOH’s “Drug Subsidies” page, which collates a list of all subsidized drugs (i.e. 
not requiring patients to go through the additional step of requesting assistance 
through MAF), does not include IRESSA, indicating that it has not yet received 
state sanctioning for a subsidy (Drug Subsidies, 2015). As such, while IRESSA 
is available in Singapore and is not yet being given a subsidy, patients can still 
request financial assistance with regards to purchasing the drug through the MAF.
Indonesia
In Indonesia, IRESSA has been approved for the treatment of EGFR mutation 
cancers (Frampton and Easthope, 2005). The Indonesian NHI system is fairly 
new and currently operates under the name Asuransi Kesehatan (ASKES) (Thab-
rany, 2008; Wardani, 2010; Holloway, 2011; Husada and Tjandrawinata, 2013). 
ASKES has established a list of medicines that are sold with an enforced price ceil-
ing. This list is known as Daftar Platfon Harga Obat (DPHO), which translates 
to Lowest Level Price Lists for medicines (Husada and Tjandrawinata, 2013). 
The DPHO has included IRESSA in the lists of medicines that require a price cap 
(Daftar Platfon Harga Obat, 2012).3
The Philippines
In the Philippines, IRESSA has been approved for the treatment of EGFR muta-
tion cancers (Frampton and Easthope, 2005). The approval was received in 
2003 after the clinical trials were deemed sufficiently successful (Gridelli et al., 
2011), with the drug now being used for first-line treatment (PhilStar, 2010). 
The state’s Department of Health (DOH) runs the National Center for Pharma-
ceutical Access and Management (NCPAM), an organization that sets the prices 
of drugs with the aim of assuring financial access (Department of Health, n.d.). 
It achieves this through the maintenance of the Philippine National Drug For-
mulary (PNDF), which only appears to list essential medicines as qualifying for 
state subsidies (Paje-Villar, n.d.; Department of Health, 2013). A search on the 
PNDF4 for IRESSA (and gefitinib) yielded no results, suggesting that IRESSA is 
currently not subsidized in the Philippines.
Malaysia
In Malaysia, IRESSA first received approval as a second- or third-line treat-
ment for EGFR mutation cancers in the early 2000 and in 2010, for first-line 
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treatment (The Star, 2010). The drug also appears on the Malaysian govern-
ment’s National Pharmaceutical Control Bureau as an officially registered drug 
(National Pharmaceutical Control Bureau, n.d.). It is also likely that IRESSA is 
currently subsidized in the public health care system. This has been deduced by 
reviewing five sources.
First, the Malaysian public health care system is regarded as heavily subsi-
dized, with the state footing roughly 98 percent of a patient’s bill (The Malay 
Mail, 2015), with co-payments amounting to no more than 3 percent in most 
cases (Jaafar et al., 2013). Furthermore, the drugs available in the public health 
care system are regulated by the drug formulary (Hussain, 2008). One of the 
factors that influences whether or not a drug is listed on the formulary is if the 
suppliers agree to provide public health institutions their drugs at low costs 
(Hassali et al., 2014), hence allowing patients to access them at a low cost. 
Finally, the updated drug formulary lists IRESSA (Pharmaceutical Services 
Division, 2015), implying that it is currently available and subsidized in the 
public health care system.
Thailand
In Thailand, IRESSA was first approved as a second-line treatment of EGFR 
mutation cancers and has more recently been approved as a first-line treat-
ment (Thongprasert, Tinmanee, and Permsuwan, 2012). As it currently stands, 
whether or not IRESSA is subsidized depends on where the individual patient is 
employed. Individuals employed in the public sector, an estimated 8 percent of 
the population, fall under the Civil Servants Medical Benefits Scheme (CSMBS) 
and are entitled to a full reimbursement of drugs regardless of whether or not 
they are listed in the National List of Essential Drugs (NLED) (Holloway, 2012; 
Rousseau, 2014). Non-civil servants, however, are only able to receive reim-
bursements for drugs that are on the NLED (Yoongthong et al., 2012). The 
2012 NLED document, which appears to be the most current available, does not 
include IRESSA (Ministry of Public Health, 2012). Finally, while IRESSA has 
“been put on a special list to help patients” (Sarnsamak, 2012), the article does 
not clearly specify whom these patients are or what this “special list” is. Indeed, 
the same article also mentions that this “special list” has not had the effect of 
increasing access to the drug (Sarnsamak, 2012). As such, IRESSA is currently 
available in Thailand, but the subsidies and reimbursements only appear readily 
accessible to civil servants.
Notes
 1 The China Food and Drug Administration has an e-portal that allows individuals 






 2 The Health Sciences Authority has an e-portal that allows individuals to search 
to see if specific drugs have been registered in Singapore. It is accessible here: 
(http://eservice.hsa.gov.sg/prism/common/enquirepublic/SearchDRBProdct.
do?action=load).
 3 While the list provided is in Bahasa Indonesia, the medicines listed are in English. 
Furthermore, I asked an individual fluent in Bahasa Melayu, a language similar 
to Bahasa Indonesia, to translate the page for me. I was told that the page is the 
DPHO and belongs to ASKES.
 4 The PNDF is accessible at http://ncpam.doh.gov.ph/index.php/pnf1/approved- 
pnf-medicines-samp/category/.
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Of the seven drugs reviewed, the minimum cost per month for usage is $3,300 
and up. Some personalized cancer drugs are indeed subsidized by the Singapore 
Ministry of Health.
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Review of the Singapore Ministry of 









IRESSA/gefitinib Lung cancer $3,300–$6,000 Per month No





$5,000–$7,000 Per dose Yes
Rituximab Lymphoma $4,000–$5,000 Per dose Yes
Herceptin/
trastuzumab
Breast cancer $5,000–$6,000 Per dose Yes




Sutent/sunitinib Kidney,  
stomach 
cancer
$8,000–$10,000 Per month No
  * Please note that all prices are in Singapore dollars.
**  As of April 1, 2014. It is not mentioned whether these prices stated are before or after MOH 
subsidy.
IRESSA/gefitinib
Leong (2006) reported that IRESSA pills cost $110.35 each, which costs 
about $6,000 a month for a patient who has to take two pills daily.
Khalik (2005b) reported that each IRESSA pill costs $115 and has to be taken 
daily, which adds up to a monthly bill of about $3,300 a month. This daily 
prescription may have to be taken for life.
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Glivec/imatinib
Koh (2002) reported that Glivec costs patients about $5,000 to $6,000 a 
month.
Perry (2002b) reported that Glivec costs $4,000 a month or more.
Perry (2002a) also reported that Glivec costs at least $4,500 for a month’s 
supply.
Avastin/bevacizumab
Teo (2014) reported that patients pay between $2,800 and $6,600 for each 
dose of Avastin. This figure is after a subsidy by the Singapore Cancer Soci-
ety and before Medisave and Medishield deductions.
Chew (2012) reported that each dose of Avastin costs between $5,000 and 
$6,000, in addition to each cycle of chemotherapy, which costs between 
$2,000 and $4,000.
Khalik (2005a) reported that Avastin dosage depends on an individual’s height 
and weight and costs about $6,000 to $7,000 a month.
Rituximab
Teo (2013) reported that each dose of rituximab costs about $4,000 to 
$5,000, and a full cycle of treatment usually consists of six to eight doses 
depending on body size.
Herceptin/trastuzumab
Teo (2014) reported that patients pay between $3,600 and $7,000 for each 
dose of Herceptin. This figure is after a subsidy by the Singapore Cancer 
Society and before Medisave and Medishield deductions.
Cheong (2009) reported that each injection of Herceptin costs between 
$5,000 and $6,000.
Nimotuzumab
Liaw (2008) reported that one treatment cycle of nimotuzumab, which lasts 
eight weeks, costs between $15,000 and $20,000.
Sutent/sunitinib
Tay (2007) reported that 30 Sutent pills, or a month’s supply, costs between 
$8,000 and $10,000.
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